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Abstract 
 
Malignant pleural mesothelioma (MPM) is an asbestos-related cancer of the pleural cavities. Since 
the molecular mechanisms of MPM are poorly understood, our main goal was to identify relevant 
genes involved in this neoplasm. Firstly, we performed an extensive literature review focused on the 
MPM transcriptome and a data mining (using Coremine, SNPs3D, and GeneProspector). The 
results from review of transcriptome studies and from data mining were intersected. Then, we 
undertook a validation study to verify whether 77 genes could be confirmed in their de-regulation 
on an independent series of specimens (20 MPM and 20 healthy pleura tissues). The genes resulted 
deregulated in our MPM and healthy pleural tissues, have been further validated on four MPM cell 
lines. The high expression levels of Mesothelin (MSLN), Calretinin (CALB2), and Platelet-derived 
growth factor receptor beta (PDGFRB) captured our interest. PDGFRB is a target for the tyrosine-
kinase inhibitor imatinib. Personal communication (reported by Dr. L. Mutti, Hospital of Vercelli, 
Italy) highlighted that imatinib was assayed for compassionate use in advanced MPM patients in 
combination with gemcitabine. Preliminary observations reported that patients showed a good 
response with the stabilization or partial shrinkage of the tumor mass. However, some patients 
either did not respond or, after an initial response, relapsed. We hypothesized that mutations within 
PDGFRB, occurring during the carcinogenesis or during the therapy, could explain these 
observations but no mutations were found within PDGFRB in 100 surgically resected MPMs. 
Imatinib resistant Mero-14 cell lines did not show mutations within PDGFRB, making difficult to 
understand the resistance to imatinib. In order to prove that MSLN and CALB2 play a role in 
maintaining the malignant phenotype, rather to be simply epiphenomenons, we attempted an 
approach using silencing-RNA. After having switched off these targets, we analyzed the behavior 
of MPM cell lines for their apoptotic ability, invasion capacity, cell cycle, and in culture growth 
parameters. As regard the CALB2 depletion, from our findings we can hypothesize that this gene 
does not seem involved in triggering the disease. For MSLN, its depletion causes the arrest of some 
of the most important characteristics malignant phenotypes. Indeed, the specific gene silencing for 
MSLN decreased the viability, and the invasiveness of MPM cells. Moreover we showed that MSLN 
depletion sensitized Mero-14 cell lines to cisplatin, and that under this treatment, they displayed an 
apoptotic type of cell death, and a substantial arrest of the proliferation rate. 
Finally, the most important result of this work provides evidence for a possible targeting of MSLN, 
alone or in combination with chemotherapy, for the treatment of MPM, highlighting the importance 
of this target gene for novel therapies. 
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1. Introduction 
 
1.1 Background 
Malignant pleural mesothelioma (MPM) is a rare cancer of the pleural cavity triggered by asbestos 
exposure. Besides the clear established role of the asbestos, other risk factors were suggested, such 
as the exposure to ionizing radiations (Zucali and Giaccone 2006; Carbone and Bedrossian 2006), 
the infection to SV40 (Rivera et al., 2008), as well as an enhanced individual genetic susceptibility 
(Carbone et al., 2012; Roushdy-Hammady et al., 2001; Landi et al., 2007). At the present time, the 
overall outcome of this disease remains not encouraging: indeed for the majority of patients, MPM 
is diagnosed at late stages when the tumor remains unresectable, the prognosis is poor, and an 
efficient management strategy for this cancer is still absent.  
It is well known that cancer occurs after a progressive accumulation of mutations in several genes, 
leading to an altered expression of oncogenes and tumor-suppressor genes that are directly involved 
in tumorigenesis. In recent decades, in order to define the molecular aspects of MPM, various 
studies have been conducted. Genome-wide array-based approaches have allowed progress in MPM 
research by identifying changes at the genetic (Ivanov et al., 2009) and epigenetic (Goto et al., 
2009) levels. Transcriptomic studies, classically performed by microarrays, have led to the 
identification of different expression patterns relevant to the biology of several types of cancers 
such as ovarian carcinoma (Chon and Lancaster, 2011), acute myeloid leukemia (Godley et al., 
2011), diffuse large B-cell lymphoma (Alizadeh et al., 2000), and hepatocellular carcinoma (Woo et 
al., 2011). Altered gene expression has been already described for asbestos-induced mice tumors 
(Zhao et al., 2000; Sandhu et al., 2000) and for cell lines reproducing the MPM progression (Rihn et 
al., 2000; Kettunen et al., 2001). Additionally, gene expression profiling has been suggested to 
allow the differential diagnosis between MPM and lung cancer and to monitor the response to 
treatments (Gordon et al., 2003). The identification of specific gene expression changes in cancer 
mesothelial cells may lead to a better understanding of the pathogenesis of MPM and generate new 
candidate biomarkers with potential clinical value. At the moment, indeed, high sensitive and 
specific biomarkers for MPM, useful for clinical practice, are not known except for a few proteins 
like SMRP (serum soluble mesothelin-related peptide) and the osteopontin, which are still under 
investigation (Robinson et al., 2003; Cristaudo et al., 2007; Grigoriu et al., 2007). 
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1.2 The normal mesothelium 
The mesothelium is a membrane, consisting of a monolayer of specialized pavement-like cells that 
line the body’s serous cavities and internal organs. It takes the name of pleura, if it surrounds the 
lung, peritoneum for the abdominal cavity, and pericardium for the heart sac. Mesothelial tissue 
also surrounds the male, and female internal reproductive organs (the tunica vaginalis testis, and the 
tunica serosa uteri, respectively). The visceral mesothelium is the mesothelium that covers the 
internal organs, while the layer that surrounds the body walls is the parietal mesothelium (Mutsaers, 
2002). Mesothelial cells are derived from the embryonic mesoderm cell layer, that lines the coelom 
(body cavity) in the embryo (Tiedemann, 1976). Numerous are their functions. The mesothelium 
forms a barrier against pathogen agents, and injury due to the inflammation, keeping the integrity of 
the serosal space, it surrounds (Mutsaers, 2004). The second important function of the mesothelium 
is the transport of fluid and cells across the serosal cavities.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Functions of mesothelial cells. (Mutsaers, 2004) 
 
1.2.1 The pleura 
The pleura is a thin serous membrane which turns back on itself to form a double layer. The outer 
pleura (parietal pleura) is wrapped around the chest wall. The inner pleura (visceral pleura) covers 
the lungs and adjacent structures, ie. blood vessels, bronchi, and nerves. The pleurae are continuous 
with each other at the hilum. The parietal pleura is divided into three parts: rib, which adheres to the 
coast; mediastinal, which lies medial to the heart; diaphragm, which is located along the diaphragm. 
The visceral pleura starts from the hilum into the lung, along the bronchi and blood vessels, and 
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allows the distinction in the pulmonary lobules. The visceral and parietal pleura delimit a space, 
called "pleural cavity", containing the pleural fluid which, during the respiratory activity, allows the 
two pleurae to slide over each other. Between the two layers there is a negative pressure (vacuum 
Donders), required to keep the lung stretched, within the pleural sac, and to allow the modification 
of volume during breathing movements. Pleural fluid is a serous fluid produced by the normal 
pleurae in order to provide a slippery, non-adhesive, and protective surface to facilitate intra-
coelomic movement (Peek et al., 2000). The parietal layer secretes 2400 ml of fluid daily, which is 
reabsorbed by the visceral layer.  
 
 
 
 
 
 
 
 
 
 
Figure 2: Pleural cavity 
 
1.3 MPM: clinical features 
 
The neoplastic cells are initially localized in the basal pleural segments, then the tumor spreads 
involving the pleural spaces together with a large pleural effusion, as well as with the direct 
invasion of the thoracic structures. The affected lung is permeated and surrounded by a thick layer 
of gelatinous neoplastic tissue. Three main histological subtypes are known: the majority of MPMs 
is of the epithelioid subtype (about 50%), 10% are sarcomatoid and the rest are biphasic/mixed 
(Travis et al., 2004.). These groups show significant differences in their histological and clinical 
features:  
- Epithelioid: characterized by cuboidal, cylindrical or flattened cells, conferring to the structure a 
shape tubular, papillary, or tubulo-papillary. The epithelial cells have an acidophilus cytoplasm, and 
vesicular nuclei with prominent nucleoli.  
- Sarcomatoid: it shows interwoven bundles of spindle cells (fibroblast-like) in a stroma collagen. 
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- Mixed (biphasic): it is the classical histological picture in which the two components, epithelial 
and sarcomatoid, coexist.  
 
 
 
 
 
 
 
 
Figure 3: Haematoxylin-eosin staining to identify the histology of MPM a) Epithelioid MPM b) Sarcomatoid  MPM   
c) Biphasic MPM 
 
According to the TNM staging system, the evolution of the MPM goes through four stages (Moore 
et al., 2008):  
1. Stage I (localized MPM): the cancer interested the right or left pleura and may also spread to the 
lung, pericardium, or diaphragm, on the same side. Lymph nodes are not involved. 
2. Stage II: the cancer spreads from the pleura, on one side, to the lymph nodes next to the lung, on 
the same side. It may also spread to the lung, pericardium, or diaphragm, on the same side. 
3. Stage III: the cancer invaded the chest wall, muscle, ribs, heart, esophagus, or other organs in the 
chest, on the same side, with or without lymph node involvement, on the same side as the primary 
tumor. 
4. Stage IV: the cancer spreads to the lymph nodes in the chest on the side opposite to the primary 
tumor, or extends to the pleura or lung on the opposite side, or directly to the organs of the 
abdominal cavity or neck. At this stage, there are distant metastases. 
 
1.4 Epidemiology of the MPM 
 
Since MPM arises most frequently in workers exposed to asbestos fibres, this neoplasm is 
considered an occupational disease (Mazzoni et al., 2012). Indeed, it is thought that about the 80% 
of cases is caused by asbestos exposure (McDonald and McDonald 1996). 
The first case of MPM has been described in 1947 (Yang et al., 2008). The relationship between 
MPM and asbestos was first documented in a study conducted in South Africa, on a group of 
miners of asbestos in 1960 (Wagner et al., 1960). From then, the scientific community has 
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continued to demonstrate the relationship between exposure to asbestos and development of MPM 
(Selikoff et al., 1968; Spirtas et al., 1994; Hansen et al., 1998; Kurumatani and Kumagai, 2008), and 
the developed countries started to collect epidemiological data on asbestos and MPM to confirm the 
relationship between the incidence of the disease, and the asbestos exposure. 
The latency period for MPM after initial exposure to asbestos is typically longer than 30 years, and 
the median survival time after diagnosis is 9–12 months (Robinson et al., 2005). 
For this reason, although the use of asbestos has been banned in the Western world since the 80s, 
the incidence of MPM is expected to increase in countries such as Italy (Peto et al., 1999), Great 
Britain (Tan et al., 2010), and Australia (Kao et al., 2011). On the contrary, the United States has 
already reached the peak of cases of MPM because asbestos was banned earlier than elsewhere 
(Price and Ware 2004), although it is expected a further increase in incidence in the aftermath of the 
World Trade Center (Ismail-Khan et al., 2006), which was partly built with asbestos (insulation, 
partitions). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Estimations of MPM death in Western Europe countrie 
 
Delgermaa et al., have summarized data on MPM death reported by the World Health Organization 
database since 1994 to 2008 (Delgermaa et al., 2011). However, it should be noticed that, because 
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the MPM is a rare disease, few international data are available. A brief extract of the recorded 
observations are reported below. 
In total, 92.253 MPM deaths were reported by 83 countries. Crude and age-adjusted mortality rates 
were 6.2 and 4.9 per million, respectively. The mean age at death was 70 years, and it has been 
reported that the incidence is much higher in men than women. Regarding the geographical 
distribution of deaths, the United States of America reported the highest number, while over 50% of 
all deaths occurred in Europe. In contrast, less than 12% occurred in middle- and low-income 
countries.  
Although the asbestos was banned or restricted in most of the industrialized world, its use is 
increasing in some parts of Asia, South America, and the former Soviet Union. The asbestos exports 
from Canada, Russia, Brazil to countries such as India, Indonesia, and Philippines, is creating an 
epidemic that may take decades to peak. Moreover, no data were available for China, India, 
Kazakhstan, the Russian Federation or Thailand, which have produced, or consumed asbestos, at 
substantial levels for many years. 
Regarding the Italian background, in 1992 (Law No. 257), each mining, trade, import, export and 
production of asbestos, or products containing asbestos have been banned from the entire Italian 
territory. Epidemiological surveillance of MPM cases is entrusted to the National Register of 
Mesothelioma (ReNaM), established at the National Institute for Occupational Safety and 
Prevention (ISPESL). The third report of the ReNaM, published in 2010, describes the entire series 
of the reported MPMs, until 2004. 9,166 cases of malignant MPM have been counted. The average 
age at diagnosis is 68.3 years. The standardized rate for MPM is equal to 3.42 (per 100,000 
individuals) in men, and 1.09 in women. In all the cases detected by the registry, 69.8% have 
occupational exposure, 4.5% family environment, 19.5% unlikely or unknown exposure. The 
number of cases varies considerably from region to region: Piedmont has the highest number of 
cases, followed by Liguria and Lombardy. Few cases have been reported in Calabria, Sardinia, and 
Abruzzo.  
 
1.5 Aetiology of MPM 
 
1.5.1 Asbestos 
According to the World Health Organization (WHO), “asbestos is one of the most important 
occupational carcinogens causing about half of the deaths from occupational cancer”. 
The term asbestos is a commercial designation which includes a group of mineral silicates fibres of 
the serpentine and amphibole series (Park et al., 2012). The basic forms of asbestos are reported in 
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the Table 1. The chrysotile is also known as white asbestos, the crocidolite as blue asbestos, and the 
amosite as brown asbestos (Straif et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: The basic forms of asbestos 
 
Widely used in the past, the asbestos during the 20th century was known as the "magic mineral". 
Indeed, the physical properties of asbestos - durability, flexibility, high tensile strength and 
resistance to heat, chemicals and electricity, made it suited for a number of commercial 
applications. It has been massively used to produce the Ethernit, a mixture of asbestos with cement 
for the insulation of buildings, roofs, ships, trains, and as a building material (tiles, floors, pipes, 
paint, chimneys), for the car (paint, mechanical parts), for the manufacture of ropes, plastic and 
cardboard. Furthermore, the dust of asbestos has been widely used as an adjuvant in the filtration of 
wine (Virta, 2003). The demand for asbestos peaked around 1977, with a production of almost 5 
million metric tons per year. In the period from 2003 to 2007, the global production of asbestos, 
although it was reduced compared to the first, was fairly stable at 2.1 million metric tons per year. 
The majority of this volume was consumed by industrializing countries. Currently, 90% of asbestos 
is used to manufacture asbestos-cement, and it remains a popular raw material, for construction, in 
the developing world (Park et al., 2012). 
All the mineral silicate fibres can theoretically cause the MPM, but, based on their mineralogical 
series and carcinogenicity, it is possible identify 2 main classes: 
1. The amphibolic asbestos is the most carcinogenic. Their fibres are highly bio-persistent, they can 
stay indefinitely in the tissues, and have a high iron content. Crocidolite, and Amosite are the main 
types of asbestos used commercially, characterized by rigid and straight fibres, with higher physical 
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and chemical stability. Tremolite, Actinolite, and Erionite are not used commercially, and are 
naturally found in different zones (Afghanistan, Turkey, Bulgaria, etc ...).  
2. White asbestos (chrysotile) has minor bio-persistence. Its fibres, spiral and loose over the years, 
are altered by organic liquids. It is generally accepted that chrysotile asbestos is less carcinogenic 
than amphibole types. However, it is nearly always contaminated by a small proportion of tremolite, 
which could confer pathogenicity to the commercial chrysotile (Hodgson and Darnton 2000). 
In general, asbestos fibres appears as microscopic needles, whose carcinogenicity depends on bio-
persistence, surface properties, and dimensions. The fibres have a thickness of less than 1 µM and a 
length varying from 3 to 300 µM. The longer ones (> 4 µM), and thin (<0.25 m in diameter) are 
more dangerous, because of their major capability to passively migrate from the alveoli to the 
pleural interstitium. Asbestos is particularly carcinogenic when its fibres may be dispersed into the 
surrounding environment, as a result of any kind of stress: mechanical, wind, thermal stress or run-
off rain water. 
 
 
 
 
 
 
 
Figure 5: chrysotile (a), and amosite (b) 
 
Asbestos fibres can cause tissue damage trough essentially three mechanisms: ingestion, skin 
contact, and inhalation. It is the inhalation of the fibres, in a dose which exceeds the body's ability 
to defend itself, the mechanism more dangerous. The main diseases associated with inhalation of 
asbestos fibres are asbestosis, pleural plaques, lung cancer, MPM, pleural effusions, and rounded 
atelectasis. 
Normally, the pleura is protected from the inhaled external agents, which are trapped in the alveoli 
or interstitium. The inhaled particles are removed by phagocytosis and transported by the dense 
network of lymphatic vessels to the pulmonary hilum. The amphibolic asbestos fibres are able to 
overcome, exceptionally, the barrier lung-pleura, and the lymphatic drainage of them is difficult.  
The exact mechanism by which asbestos fibres migrate to the pleural surface is not known yet. 
Moreover, it is not possible to explain why the same substance, once in the pleural space, may cause 
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pleural effusions in some individuals, whereas plaques, pleural fibrosis, or MPM in others. The 
explanation probably lies in a delicate combination of mechanical, biological, and genetic events.  
At the present time, the most accredited hypothesis is that the asbestos fibres accumulate within the 
tissue and lead to the activation of a chronic inflammatory status of the mesothelium (Donaldson 
2010). The inflammation, it is thought, induces mesothelial cells to continuously release reactive 
oxygen species (ROS), as well as cytokines and growth factors, such as the hepatocyte growth 
factor (HGF), the epidermal growth factor (EGF), the platelet-derived growth factors (PDGFs) (Lee 
et al., 2007), and the vascular endothelial growth factor (VEGF) (Pasello and Favaretto 2009). An 
elevated expression of PDGF (chains A and B) were observed in the early response to asbestos and 
were found to be mitogens for normal mesothelial cells (Gerwin et al., 1987; Langerak et al., 1996), 
and to act as paracrine stimulators for the proliferation of the MPM (Metheny-Barlow et al., 2001; 
Pass and Mew 1996). However, asbestos may also cause auto-phosphorylation of EGFR (Zanella et 
al., 1996), resulting in activation of mitogen-activated protein (MAP) kinase cascade and 
phosphorylation of extra cellular signal-regulated kinases 1 and 2 (ERK1/ERK2). Studies of 
transforming growth factor (TGF)- in both cell lines and MPM samples have shown the over-
expression of three isoforms, including both active and latent forms of TGF-1 and TGF-2 
(Fitzpatrick et al., 1994).  
On the other hand, the asbestos fibres which interact with the alveolar macrophages, are captured 
and entrapped within lysosomes (Matsuzaki et al., 2012). It seems that this leads to the activation of 
NLRP3 inflammasome, to cleave procaspase 1 to an active form, followed by the activation of pro-
interleukin (IL)-1β, and production of ROS, and reactive nitrogen species (RNS) in the 
macrophages. The consequential apoptotic death of the alveolar macrophages, and the liberation of 
various cytokines/chemokines, such as IL-1β, tumor necrosis factor (TNF)-α, macrophage 
inflammatory protein (MIP)-1/2, monocyte chemo-attractant protein-1, and IL-8, cause chronic 
inflammation and proliferation of collagenic fibres as well. This mechanism is continuously 
repeated: indeed, the released silica particles and asbestos fibres from dead alveolar macrophages 
are recognized by newly nearby macrophages, with the repetition of similar cellular reactions 
described above (Hamilton et al., 2008, Thakur et al., 2008). 
It is current opinion that all these elements push the mesothelium to proliferate (Lee et al., 2007). 
The continuous exposure to ROS and to proliferative stimuli is a stress for the mesothelial cells and 
this may lead to long-term DNA damages (Zucali and Giaccone, 2006). It was also suggested that 
an  increased ROS release could be related to the action of Fe-particles present as contaminant on 
the surface of asbestos fibres, in particular on the amphibolic type (Simeonova and Luster, 1995). 
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As generally acknowledged, the DNA lesions could be converted into permanent mutations and/or 
lead to an epigenetic reorganization of the DNA. These events represent among the most important 
molecular changes for reprogramming cells towards a malignant phenotype.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Mechanisms of action of asbestos fibres. 
 
1.5.2 SV40 infection  
In addition to asbestos exposure, many investigations have found an association of MPM with the 
oncogenic simian virus (SV) 40 (Klein et al., 2002; Cristaudo et al., 2005). Indeed, a transforming 
synergistic action between asbestos fibres and SV40 has been proved in human, hamster, and 
murine mesothelial cells and in animal models (Pietruska et al., 2007; Robinson et al., 2006; 
Kroczynska et al., 2006). However, not all the authors agree with this view (Aoe et al., 2006) and 
the role of SV40 in the aetiology of MPM for humans is still to be ascertained completely. The 
Simian Virus 40 (SV40) is a DNA virus, found in both monkeys, and humans. The virus was firstly 
identified by Dr. Eddy in 1964 in cultures of rhesus monkey kidney cells, employed to produce 
polio vaccine (Eddy, 1964). It has been hypothesized that the virus was transmitted from monkeys 
to humans mainly in the period 1955-1963, through the administration, worldwide, of anti-polio 
vaccines contaminated with SV40 (Strickler et al., 1998). However Carbone et al., have suggested 
also a possible virus transmission directly by person-to-person contact (Powers and Carbone, 2002). 
Once inside the host, the SV40 produces two proteins: the large T antigen (Tag), and the small t 
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antigen (tag). Tag has been shown to bind and inactivate both p53 and pRB in mesothelial cells 
(Carbone et al., 1997; Gazdar et al., 2002), thus stimulating cell proliferation (Testa and Giordano, 
2001). Regarding tag protein, it promotes the MAP signalling pathway, inhibiting the protein 
phosphatase 2A (PP2A), involved in de-phosphorylation of many protein substrates, including 
regulators of the cell cycle (Rundell and Parakati, 2001). Mazzoni E et al., have found that in 97 
MPM serum samples, the prevalence of antibodies against SV40 viral capsid protein antigens is 
significantly higher (26%, P = 0.043) than in the control group (15%, n = 168). Taken with caution, 
this result could suggest that new therapeutic/preventive strategies could be also applied with 
antiviral drugs or vaccines (Mazzoni et al., 2012). 
 
1.5.3 Exposure to Ionizing Radiations 
The exposure to ionizing radiations (IR) is hypothesized playing some role in triggering the disease 
(Zucali and Giaccone 2006; Carbone et al., 2002; Carbone et al., 2006). It was showed that in rats 
exposed to asbestos and IR the probability to develop MPM is increased, compared to rats exposed 
only to asbestos (Warren et al., 1981), suggesting a carcinogenic synergistic effect between 
radiations and asbestos. The MPM is a well-known consequence of radiation therapy used for the 
treatment of primary malignancy, like lymphoma, breast cancer, lung cancer and other 
malignancies. Interestingly, most of the reported cases were not previously exposed to asbestos. 
Teta and collaborators have shown that patients suffering Hodgkin's disease have a 20 times greater 
risk of developing MPM following radiotherapy (Teta et al., 2007). Although at the time, the role of 
radiation in the development of MPM remains still unclear, it is possible that IR exposure could act 
as co-factor with asbestos. 
 
1.5.4 Predisposing Genetic Factors 
The individual genetic factors seem to be important in the development of MPM. This has been 
demonstrated firstly, in a study conducted in three villages of Cappadocia, where erionite, a mineral 
of the zeolite family, was extracted from quarries, and used as building material. In these villages an 
“epidemic” of MPM was recorded, and more than 50% of the inhabitants died for the disease 
(Carbone et al., 2007). Initially, the erionite has been named as the only etiologic factor, but in 2001 
Roushdy-Hammady and colleagues investigated whether some families of the villages were 
genetically predisposed to the development of the malignancy. Through a deep analysis of the 
pedigree, until the sixth generation (526 individuals in total), the authors highlighted the possibility 
that MPM was genetically transmitted, as an autosomal dominant disease (Roushdy-Hammady et 
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al., 2001). The suspicion about a familiarity predisposing to MPM comes also from observations of 
families such as that reported by Musti and collaborators, on a family with a history of 
environmental exposure to asbestos. The entire family (mother, father and 4 children) has lived for 
13 years in Casale Monferrato, very close to the factory where the father worked, the only one with 
a real occupational exposure to asbestos. Two sisters have developed MPM, the other one has 
developed peritoneal mesothelioma, and the brother, pleural plaques, whereas the mother was not 
affected  (Musti et al., 2002). Intriguingly, it is worth to stress that mutations within BAP1 were 
reported to be causative for a rare familial form of MPM (Testa et al., 2011). At the present time, 
this is the only gene identified to confer an increased susceptibility to MPM. Biallelic inactivation 
of BAP1 was found in two US families with high incidence of MPM. In one of theme, Testa et al., 
sequenced BAP1 in germline DNA identifying that six affected members had identical mutations, 
whereas unaffected family members did not. In the second analyzed family, germline DNA from 
three individuals with MPM reported C/G-to-T/A transition in exon 16, creating a stop codon. 
Moreover the authors have identified that in addition to MPM, some BAP1 mutation carriers 
developed uveal melanoma.  
Some studies have also suggested that low-penetrant polymorphisms of genes involved in the 
metabolism of xenobiotics may constitute a risk factor for the development of sporadic MPM.  
Associations between risk of MPM, and polymorphisms in specific genes have been reported. 
Among these, GSTM1 gene encodes for the enzyme "Glutathione S-transferase", which combines 
the glutathione to a wide range of electrophilic substances, such as ROS, easily released from the 
cells and excreted. GSTM1 is a polymorphic gene, and in some studies it has been shown that the 
absence of the gene increases the risk of MPM (Hirvonen et al., 1995; Landi et al., 2007). 
Moreover, for individuals having simultaneously the null genotype for the GSTM1 gene, and the 
slow acetylator alleles for NAT2 gene, the risk of developing MPM doubles, compared to subjects 
with a present genotype for GSTM1,  and rapid acetylator for NAT2 (Hirvonen et al., 1996). 
The NAT2 gene encodes the N-acetyltransferase. The enzyme catalyzes the transfer of the acetyl 
group from acetyl-CoA on the amino groups. Aromatic and heterocyclic amines are some of its 
substrates. The response against oxidative stress induced by asbestos fibres, involves products also 
of other genes, such as manganese superoxide dismutase (MnSOD), one of the most important 
antioxidant enzymes in mammals (Hayes et al., 2005). It has been shown that the activity of 
MnSOD is almost absent in normal mesothelial cells of the pleura, while it is higher in MPM cells 
(Kinnula et al., 1996). The most common polymorphism of MnSOD results in an Alanine (Ala) to 
Valine (Val) amino acid change at codon 16, producing a conformational change in the protein 
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secondary structure that may impair the transport of the protein into the mitochondria. (Sutton et al., 
2003). Ninety cases of MPM and 395 controls were genotyped using the arrayed-primer extension 
technique. The Ala/Ala genotypes at codon 16 within MnSOD was showed to be associated with 
the risk of MPM, and a stronger effect of MnSOD was observed among patients without a clear 
exposure to asbestos fibres (Landi et al., 2007). Other potentially involved polymorphisms are 
within the genes involved in DNA repair. In particular XRCC3 was found associated with MPM. 
This gene encodes a protein involved in homologous recombination and repair of DNA damage. In 
a case-control study in Casale Monferrato, variants of XRCC3 (XRCC3-241T, XRCC1-399Q) were 
associated with an increased risk of MPM (Dianzani et al., 2006). This has been also confirmed by a 
study with a larger sample size, extended to the city of Turin (Betti et al., 2011).  
The studies conducted to date do not clarify in a definitive way what are the susceptibility alleles 
for MPM. This is also due to the rarity of the tumour, and the consequent difficulty in carrying out 
studies of case-control with a sample size sufficient to guarantee the desired statistical significance. 
 
1.6 Molecular alterations in MPM 
 
1.6.1 Somatic genetic alterations in MPM 
Cytogenetic studies have revealed complex karyotypic changes in the MPM, involving all 
chromosomes with chromosomal losses more frequent than chromosomal gains. Frequent losses are 
localized on chromosome arms 1p, 3p, 4q, 6q, 9p, 13q, 14q, and 22q and gains involve chromosome 
arms 1q, 5p, 7p, 8q, and 17q. (Krismann et al., 2002; Lindholm et al., 2007; Taniguchi et al., 2007; 
Ivanov et al., 2009;  Cheung et al., 2010;  Christensen et al., 2010;  Jean et al., 2011). Mutations of 
proto-oncogenes and, deletions, loss of heterozygosity, or inactivation of tumor supressor genes 
occur frequently in basically all human cancers. Interestingly, mutations within p53 and pRb, 
among the most frequently mutated genes in cancer, are rare in the MPM (Lee et al., 2007). 
However, one of the predominant genetic abnormality in the MPM is the homozygous inactivation 
of the gene CDKN2A within the 9p21 region, occurring at a frequency of greater than 70%, (Prins et 
al., 1998; Chiosea et al., 2008). CDKN2A is regulated in order to allow stem cells to proliferate and 
plays a critical role also in the cellular senescence of mature cells, through the regulation of both the 
pathways pRb and p53 (Gil and Peters, 2006). The locus encodes two distinct proteins (overlapping 
genes), p16
INK4a
 and p14
ARF
, originating from different transcription start sites and translated from 
mRNA undergone to alternative splicing p16
INK4a
 exerts its tumour suppressive effect by inhibiting 
the cyclin-D-dependent kinases (CDKs), thus preventing the CDK-mediated hyper-phosphorylation 
and the inactivation of pRB, that normally leads to the cell cycle arrest at the G1-phase (Zucali and 
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Giaccone, 2006). p14
ARF
 inactivates the human homolog of mouse double minute 2 (MDM2), which 
is an upstream regulator of p53 (Sekido, 2008).  
The TSG neurofibromin 2 (NF2), a gene mutated in the type 2 neurofibromatosis (an autosomal 
dominant hereditary disease characterized by tumours of the nervous system) is a tumour 
suppressor gene mapped to 22q12.2, a region frequently involved as cytogenetic abnormality in the 
MPM (Flejter et al., 1989; Hansteen et al., 1993; Taguchi et al., 1993). Interestingly, mutations in 
NF2 occur in approximately half of MPM cases (Bianchi et al., 1995; Schipper et al., 2003). 
Although NF2 disease does not usually occur with MPM (Deguen et al., 1998), the risk of 
developing MPM may increase if an NF2 patient is exposed to asbestos (Baser et al., 2002), likely 
because of a potential link between asbestos exposure and the NF2 inactivation (Fleury-Feith et al., 
2003). The loss of NF2 function has been proposed to be an early event in the MPM (Metcalf et al., 
1992).  
Another chromosomal alteration involved in MPM is the deletion of 3p21 band. This deleted region 
carries nine genes including BAP1, PHF7, SEMA3G, TNNC1, NISCH, STAB1, NT5DC2, C3orf78, 
and PBRM1. Given the role of BAP1 in the rare familial form of MPM, it is conceivable that an 
altered activity of BAP1 could provide a reasonable explanation for the frequent loss of 3p21 in 
MPM. BAP1 encodes a nuclear ubiquitin carboxy-terminal hydrolase (UCH), called “BRCA1 
associated protein-1”, belonging to one of several classes of de-ubiquitinating enzymes. This gene 
contains binding domains for BRCA1 (113705) and BARD1 (601593), that form a tumor 
suppressor heterodimeric complex. Ventii KH et al., have shown that BAP1 exerts its tumor 
suppressor functions by affecting the cell cycle, speeding the progression through the G1-S 
checkpoint, and inducing cell death via a process that has characteristics of both apoptosis and 
necrosis (Ventii et al., 2008). Bott et al., have analyzed 53 samples of MPM patients, looking for 
additional genes crucial for MPM pathology, and have found that 12 (23%) of theme showed 
somatic mutations inactivating the gene BAP1 (Bott et al., 2011). Yoshikawa and collaborators have 
analyzed the genomic alterations of BAP1 in 23 samples of MPM (16 epithelioid and 7 non-
epithelioid), finding biallelic alterations of BAP1 in 14 samples (61%). Seven of these showed 
homozygous deletions of the BAP1 (partial or total), five had point mutations (including small 
deletions), while the other two had homozygous mutations without deletions. Of the 14 samples 
with mutations in BAP1, 13 were epithelioid and only one biphasic. These results reveal that the 
inactivation of BAP1 occurs at a very high frequency in patients with epithelioid MPM, and this 
could be useful for diagnosis of epithelioid type MPM (Yoshikawa et al., 2012).  
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Recently, the new techniques of micro-arrays and deep-sequencing made possible to detect the 
somatic mutations occurring in the MPM, and to identify new genes involved in driving the 
carcinogenetic process. Ivanov et al. (Ivanov et al., 2009), performed Representative 
Oligonucleotide Microarray Analysis (ROMA) on DNA isolated from tumors of 22 patients, 
confirming the most frequent gains and deletions in the MPM samples, already detected trough the 
classical CGH analysis. Moreover, analysis of the minimal common areas of frequent gains and 
losses identified candidate genes that may be involved in different stages of MPM: OSM (22q12.2), 
FUS1 and PL6 (3p21.3), DNAJA1 (9p21.1) and CDH2 (18q11.2-q12.3).  
Sugarbaker et al., used shotgun pyrosequencing to characterize mutations within transcribed 
sequences unique to MPMs and not present in control tissues (Sugarbaker et al., 2008). Thus, new 
genes - plausibly related to oncogenesis - were identified, including XRCC6 (involved in mediating 
the repair of DNA double-strand breaks via non-homologous end-joining), PDZK1IP1 (over-
expressed in human carcinomas of diverse origin), ACTR1A (associated with transport of p53 to the 
nucleus, its disruption via mutations could potentially result in p53 inactivation,), and AVEN 
(involved in the apoptotic process). Dong et al. (Dong et al., 2009), demonstrated that the whole-
transcriptome shotgun sequencing can be a powerful high-throughput tool for the identification of 
differentially expressed exon junctions resulting from alternative splicing variants. With this study, 
they suggested two differentially expressed exon junctions (ACTG2.aAug05 and CDK4.aAug05) to 
be used to classify MPM and normal tissue samples using the median value as a cut-off.  
However, we should be aware that the MPM, as many human cancers, is a biologically 
heterogeneous disease and the studies carried out at genome level are, likely, too few, and often 
carried out with insufficient number of samples, in order to provide a clear picture of the molecular 
events. In summary, the complete pattern of molecular changes will need further confirmation and 
more studies, integrating knowledge from different type of information in a more systematic 
approach. 
 
1.6.2 Main molecular pathways involved in the MPM 
Numerous molecular pathways involved in the MPM have been studied and identified, including 
the regulation of cell cycle, apoptosis, cell proliferation, and angiogenesis. 
1.6.2.1 Apoptosis and Cell cycle 
Apoptosis is a form of cell death essential for development, deletion of damaged cells and the 
turnover of the cells (Danial and Korsmeyer, 2004). Since 1998 it has been reported that the MPM 
cell lines are more resistant to apoptosis, than the normal mesothelial cells (Narasimhan et al., 
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1998). This may be a possible explanation of why the MPM does not respond to the conventional 
chemotherapy, usually able to induce the apoptotic process. In MPM, several mechanisms of natural 
inhibition of apoptosis have been described, including the stabilization of the mitochondrial 
membrane and the inhibition of caspases, through the IAP activity, a family of “proteins inhibiting 
the apoptosis” (Gordon et al., 2002; Kleinberg et al., 2007). It has been hypothesized that apoptosis 
can be induced or inhibited by altering the ratio of expression between pro-apoptotic and anti-
apoptotic genes, belonging to the Bcl-2 family (Chresta et al., 1996). Inhibitors of Bcl-xL/Bcl-2 
emerge as a new class of compounds for disrupting the balance between pro-apoptotic and the anti-
apoptotic stimuli. The exposure of tumor cells to inhibitors of Bcl-2/xL, alone or in combination 
with other chemotherapeutic, has shown a synergistic inhibition of tumor growth, inducing 
apoptosis and increasing the chemo-sensitivity both in vitro and in vivo, and it may represent a new 
therapeutic strategy in the treatment of MPM (Cao et al., 2007).  
An important factor involved in the immortality of cancer cells is also the transcription factor NF-
kB. Once activated, its p65 subunit translocates to the nucleus to activate IAP. The deriving effect is 
the promotion of the cells growth and differentiation and, moreover, the induction of the angiogenic 
factors synthesis. After the activation of TNF-α induced by asbestos, NF-kB increases cell survival, 
allowing cells with DNA damage, asbestos caused, to proliferate, rather than die. The therapeutic 
targeting toward the signaling TNF-α/NF-κB may decrease drug resistance and increase 
cytotoxicity in MPM cells (Carbone and Bedrossian, 2006).  
1.6.2.2 Proliferation and angiogenesis 
The particular growth factors that affect MPM cell growth are under investigation.  
The hepatocyte growth factor / scatter factor (HGF / SF) is a multifunctional growth factor that can 
induce many biological functions, critical for the malignant phenotype, including invasion, 
proliferation and morphogenesis. The receptor c-Met is the only known receptor for HGF / SF. 
Downstream of c-Met, more signalling pathways are activated, including Ras / Erk, PI3K/Akt, and 
c-Src kinase pathways. It has been demonstrated an autocrine loop of HGF / SF / c-Met in both cell 
lines and MPM tissue samples, and the over-expression of HGF and c-Met has been associated with 
increased microvascular density and an increased expression of matrix metalloproteinases (Tolnay 
et al., 1998).  
It has been noticed that the small molecule SU11274, through the inhibition of c-Met, is able to 
induce the suppression of cell growth in some MPM cell lines, but not in non-malignant mesothelial 
cells. In particular, SU11274 inhibits cell migration, and the signal transduction induced by HGF 
(Jagadeeswaran et al., 2006).  
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The cytoplasmic tyrosine kinase Src is often expressed and activated in MPM. The activity of SRC 
kinases family is associated with an advanced stage of MPM, and it may contribute to invasiveness 
and metastatic spread. In preclinical models, the dasatinib, a potent inhibitor of SRC kinases family, 
prevents the migration and the invasion of MPM (Tsao et al., 2007). In MPM it was also observed 
the over-expression of EGFR (epidermal growth factor receptor), especially in the epithelioid 
subtype. An important molecule, involved in EGFR downstream signalling is the phosphoinositide-
3-kinase (PI3K), whose pathway appears to be active in MPM cell lines (Cacciotti et al., 2001). The 
PI3K/AKT pathway is involved in the regulation of cell size, proliferation and survival, as well as 
in the formation of cancer metastasis, angiogenesis and invasiveness. The PI3K/AKT pathway can 
be tested as a target for inhibiting the growth of MPM cells, although it has been observed that cell 
lines of human MPM with high constitutive activity of AKT are more resistant to drugs (Ramos-
Nino et al., 2005).  
The MPM patients have the highest levels of VEGF (vascular endothelial growth factor) compared 
to patients suffering of any other solid tumor. Indeed, VEGF, VEGF-C and their receptors are over-
expressed in the tissue of MPM, in cell lines and in pleural effusions (Strizzi et al., 2001). In 
addition, elevated levels of VEGF have been observed in the sera of MPM patients, compared to the 
serum of normal subjects. In particular, MPM cell lines express high levels of VEGF and its 
receptors (VEGFR-1 and VEGFR-2), compared with normal mesothelial cells. Neutralizing 
antibodies against VEGF and VEGFR 1-2 reduce significantly the viability and the proliferation of 
the MPM cells in vitro, while the pre-treatment in vivo with an antibody anti-VEGFR reduces the 
malignant pleural effusion in a murine model. VEGF may also act in an functional autocrine loop 
that directly stimulates the growth of cells of MPM. In fact, the production of VEGF can have an 
impact on patients survival, not only promoting tumor angiogenesis, but also by directly stimulating 
tumor growth (Zucali et al., 2011). High levels of VEGF in the pleural were associated with 
reduced survival in patients with MPM (Strizzi et al., 2001). Similarly, the over-expression of 
VEGF, as detected by immunohistochemical analysis, predicts a shorter survival in patients with 
MPM (Demirag et al., 2005). To conclude, the expression of VEGF and VEGF-C in MPM is 
correlated with microvessel density, and high density of microvessels is associated with poor 
survival.  
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Figure 7: Signaling pathways of EGF, VEGF, and HGF 
 
In recent years it has become clear that the MPM is characterized by activation of survival pathway 
and inhibition of tumor suppressor (Fennell, 2011). Other molecules have been identified (Fox and 
Dharmarajan, 2006). Among them, WNT (that seems to play an important role in homeostasis and 
development), mesothelin (regulatingd apoptosis and cancer cell growth) (Wang et al., 2012), and 
calretinin, whose up-regulation seems to increase resistance to asbestos cytotoxicity and thereby 
contributing to fibrers carcinogenicity (Henzi et al., 2009). 
 
1.7 Diagnosis of MPM 
1.7.1 The importance of an early detection 
The MPM is characterized by non-specific clinical signs and symptoms, i.e. pleural effusions, short-
breathing, chest pain, lack of appetite, weight loss, and night sweat. For this reason, early diagnosis 
results very difficult (Melaiu et al., 2012). At the present time, improved detection methods for 
diagnosis of asymptomatic MPM are lacking, but needed for an early and reliable detection and 
treatment of this disease. A definitive and early diagnosis on effusion samples could be important, 
because advances in therapy for patients with MPM may result in an improved outcome if they are 
applied to stage I disease (Pomjanski et al., 2008). The International Association for the Study of 
Lung Cancer Staging Committee developed an international database, focusing on patients managed 
surgically. It has been reported that because of the absence of valid methods with which recognize 
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promptly the MPM, no significant difference on median survivals (by clinical TNM and 
pathological TNM) are present: stage I, 21 months; stage II, 19 months; stage III, 16 months; and 
stage IV, 12 months (Rusch et al., 2012). The need to detect the MPM at the early stages led several 
authors to investigate whether tumor-related biomarkers can contribute towards the evaluation of 
the carcinogenic risk in populations exposed to asbestos. 
Amati M et al., analyzed 94 asbestos-exposed subjects, 22 patients with MPM, and 54 healthy 
subjects. They evaluated levels of 8-hydroxy-2'-deoxy-guanosine(80HdG) in white blood cells, and 
plasma concentrations of soluble mesothelin-related peptides (SMRPs), angiogenic factors, and 
matrix proteases for potential early detection of MPM. The combination of 80HdG, VEGF and 
SMRPs best distinguished the individual groups (asbestos-exposed subjects, controls and MPM 
patients), suggesting a potential indicator of early and advanced MPM cancers (Amati et al., 2012). 
Recently, Ostroff et al., conducyed a case-controls study, using SOMAmer proteomic technology, 
which simultaneously measures over 1000 proteins in unfractionated biologic samples, identifying a 
promising biomarker panel for surveillance and diagnosis of MPM (Ostroff et al., 2012). 
To date, specific tests, currently employed in case of suspected MPM are following (Moore et al., 
2008): 
-  Chest X-ray allows to show abnormalities of the pleura or lung. 
- Computer Assisted Tomography or Computerized Tomography (CT) is useful to determine the 
presence of cancer, its exact location, and its possible spread to other organs, thanks to the 
visualization of the whole pleura surface, and diaphragm, but also of the livers and adrenal glands 
(Armato et al., 2008). The most significant evidences, allowing the discrimination between MPM 
and benign pleural disease are: pleural thickening, mediastinal pleural involvement, and 
circumferential pleural rind. However, the absence of this picture does not exclude the MPM 
diagnosis (Leung et al., 1990).  
- Positron Emission Tomography (PET) allows to measure the metabolic activity of a lesion: the 
value obtained in case of MPM is significantly higher, compared with that from other benign 
disease (Wang et al., 2004; Bénard et al., 1998).  
- Magnetic Resonance Imaging (MRI) is not so often employed to assess a MPM case. However it 
can provide additional information above CT, with a more precise identification of the staging of 
the tumor, and of its extension into the diaphragm (Wang et al., 2004). 
- Biopsy: the pleural sample can be excised from the chest (thoracentesis), abdomen (paracentesis) 
or the cavity around the heart (pericardiocentesis), to verify, under a microscope, the presence of 
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tumor cells. The analysis of pleural biopsies allows the diagnosis in 98% of patients (Boutin and 
Rey, 1993). For this reason it is considered the gold standard for the diagnosis of MPM. 
To further ascertain the MPM diagnosis, a useful tool routinely employed is the immune-
histochemical analysis, easily reproducible and reliable. The histological investigation is important 
to distinguish MPM from other types of lung diseases. Positive staining for calretinin, WT-1 
(Wilms Tumor antigen 1), cytokeratin 5/6, podoplanina, mesothelin, and thrombomodulin; and 
negative staining for carcinoembryonic antigen (CAE), and for other epithelial antigens, generally 
expressed by lung adenocarcinoma, such as TTF-1 (Thyroid Trascription Factor 1) (Scherpereel et 
al., 2010), can address for the MPM diagnosis. 
If the MPM is of sarcomatoid or mixed type, the histologic diagnosis is complicated by the 
combination of epithelioid cells and spindle-shaped. To distinguish the sarcomatoid subtype, from 
the squamous cell lung carcinoma, antibodies anti-cytokeratins as positive markers, and anti-p63 
and anti-desmin, as a negative marker (Scherpereel et al., 2010) are used. However, there is 
currently no marker that provide 100% specificity and high sensitivity for the diagnosis of MPM. 
 
1.7.2 Calretinin as potential biomarker for MPM 
A promising immuno-histochemical marker, which seems highly specific, compared with the others 
commonly employed, is the calretinin (CALB2). It has been found positive in 97% of the MPM 
cases, with the majority of them showing both cytoplasmic and nuclear staining (Shield and 
Koivurinne, 2008). This data has been confirmed also recently by Dinu M et al., (Dinu et al., 2012). 
CALB2 is a calcium binding protein belonging to the large EF-hand family, involved in the control 
of the calcium signal function, needed for numerous cellular functions as gene expression, synaptic 
transmission, cell cycle progression and apoptosis. CALB2 is a 29KDa protein, whose structure is 
highly conserved. The sequence of 261-271 amino acids is organized into six EF-hand domains. 
The EF-hand motif is formed from a conserved sequence of amino acids (29–30 residues): an alpha 
helix, a highly conserved 12 residue sequence that functions as the calcium-binding domain, 
followed by a second alpha helix oriented perpendicular to the first. Of the six EF-hand motifs 
present in calretinin, only five are active. Of the active domains, four display high affinity calcium-
binding sites with positive cooperativity (Schwaller et al., 1997), while the remaining domain 
displays lower affinity binding (Stevens and Rogers, 1997). 
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Figure 8: (A) Schematic representation of calretinin. The yellow blocks indicate the E-helix-loop-Fhelix- hand (EF) 
hand regions. (B) The three-dimensional structure of the EF-hand calcium-binding domain can be visualized using the 
right hand: the index finger represents residues 1–10 (the E-helix), the middle finger represents residues 10–21 (the 
calcium-binding loop), and the thumb represents residues 19–29. Modified by Camp and Wijesinghe, 2009. 
 
 
CALB2 is expressed in distinct neuronal populations including the retina, granule cells of the 
cerebellum, and brainstem auditory neurons. It is also expressed under pathological conditions, 
particularly in colon adenocarcinoma and epithelial MPM cells. In addition to playing a role in 
modulating neuronal excitability, CALB2 has been proposed as target in gene therapeutic 
approaches. Inase et al., explored the 5-flanking region (2.2 kb) of the calretinin gene as a tumor-
specific promoter, showing that 2 MPM cell lines transfected with the pCAL-TK expression vector 
became about 100 times more sensitive to ganciclovir than the parental cells, and suggesting the 
calretinin promoter a promising candidate as a specific and efficient promoter in MPM (Inase et al., 
2001). 
 
However, an early diagnosis with the described techniques is extremely difficult. The characteristics 
of the samples themselves do not facilitate the differential diagnosis of pleural diseases: pleural 
effusion and thoracoscopic biopsies could have several problems such as small size, compression 
artifacts, and poor fixation. For this reason, the search for tumor markers useful to detect the tumor 
from the earliest stages of its development is needed. 
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1.7.3 Mesothelin: diagnostic and prognostic marker in the MPM? 
The mesothelin is one of the most promising biomarkers for the surveillance of asbestos-exposed 
people, as well as for the prognosis and clinical course of MPM (Cristaudo et al., 2011). 
Mesothelin (MSLN), a 40 KDa glycosylphosphatidylinositol (GPI) anchored cell surface protein, is 
normally expressed at low levels in mesothelial cells and over-expressed in several human tumors, 
including MPM, ovarian and pancreatic adenocarcinoma. Recent studies have shown the expression 
of mesothelin gene (MSLN) also in lung adenocarcinomas (Ho et al., 2007), uterine serous 
carcinoma (Dainty et al., 2007), acute myeloid leukemia (Steinbach et al., 2007) and 
cholangiocarcinoma (Ordóñez, 2003; Yu et al., 2010). MSLN maps to chromosome 16p13,3, 
consists of 17 exons, its cDNA is of 2130 bp, and contains an open reading frame of 1884 bp. 
Human MSLN encodes a ~71kDa precursor protein of 622 amino acids, having a hydrophobic 
sequence at the C-terminal, removed and replaced by a phosphatidylinositol, and with four potential 
glycosylation sites. Following glycosylation, the precursor is proteolytically cut by a furin-like 
protein at Arg295 into two products, a ~31kDa mature megakaryocyte potentiating factor (MPF 
residues Ser34 – Arg286) (Yamaguchi et al., 1994) and a ~40kDa GPI-anchored membrane-bound 
mature mesothelin starting from Glu296 (Chang and Pastan, 1996;  Hassan et al., 2004;  Hassan and 
Ho, 2008).  
 
 
 
 
 
 
 
 
 
 
Figure 9: Structure of mesothelin (Tang et al., 2013) 
 
Hassan et al., have reported 2 protein variants of MSLN (Hassan et al., 2004). The variant 1 presents 
an insertion of 8 amino acids, after the glutamine 408 and arises a protein still able to bind to the 
plasma membrane. The variant 2 maintains the intron between exons 16-17, giving rise to a protein 
missing the C-terminal, because of an alternative splicing mechanism. This protein isoform is 
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released from the cell and defined “soluble mesothelin related protein” (SMRP). 
Immunohistochemical investigations revealed that the main form of MSLN anchored to the 
membrane is the 40 kDa ones. However it has been found also a glycosylated form of 71 kDa 
(Hassan et al., 2006). It is not clear which is the variant of MSLN / MPF detected by ELISA in 
different human tumors. 
A full understanding of biological functions of MSLN is lacking. It seems that MSLN pays a role in 
cancer progression, cell-adhesion, metastasis, and chemoresistance (Tang et al., 2013).  
The link between adhesion molecules and MSLN was suggested early, following studies on the 
ovarian carcinoma. It was suggested that MSLN might be involved in the adhesion and spread of 
ovarian cancer cells throughout the mesothelial lining of the peritoneal cavity (Chang and Pastan, 
1996). Moreover, recently, it was clearly shown that deficiency of MSLN in Tsc2-KO mice was 
associated with a decreased number and size of renal tumors, reduced cell proliferation, increased 
apoptosis, inhibited cell adhesion to collagen-coated plates, and suppressed tumor formation in nude 
mice. In that study, it was shown that MSLN affected the expression of mature integrin b1, thereby 
affecting also the phosphorylation of several downstream proteins, such as FAK, Akt, rpS6, and 
Stat3 (Chang and Pastan, 1996). In addition, in pancreatic cancer cells, the over-expression of 
MSLN determines the up-regulation of growth factors such as IL-6, known to be involved in cancer 
survival/proliferation and tumor progression (Bharadwaj et al., 2011). Conversely, the MSLN 
silencing reduced the IL-6 levels. MSLN also induces an increase in NF-κB activation which leads 
to resistance to TNFα induced apoptosis (Bharadwaj et al., 2011), indicating a mechanism through 
which MSLN may help increase survival of tumour cells in the highly inflammatory milieu, evident 
in pancreatic cancer through Akt/PI3K/NF-κB activation and IL-6 over-expression. In breast cancer 
cells it has been shown that the over-expression of MSLN promoted anchorage-independent growth 
in soft agar. Moreover, cells expressing high levels of MSLN exhibited resistance to anoikis, a type 
of apoptosis induced by detachment from substratum, as indicated by decreased DNA 
fragmentation and down-regulation of the proapoptotic protein Bim (Uehara et al., 2008). Elliot L. 
Servais et al., have shown that MSLN expression promotes MPM cell invasion and 
metalloproteinases secretion in both human and murine MPM cells. In a tissue microarray from 
epithelioid MPM patients, MSLN over-expression correlated with higher MMP-9 expression at 
individual core level. According to the authors, this evidence elucidated a biologic role for MSLN as 
a factor promoting tumor invasion and MMP-9 expression in MSLN-expressing MPM (Servais et 
al., 2012). Furthermore, it has been proposed that serum mesothelin (SMRP) could be a sensitive 
and highly specific biomarker for MPM. Indeed, concentrations of mesothelin in serum of MPM 
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patients are significantly higher than those of healthy individuals (Beyer et al., 2007). Robinson was 
the first to understand the potential of mesothelin in the early diagnosis. When the concentration of 
SMRP was measured in 40 healthy controls previously exposed to asbestos and monitored for 5 
years, seven showed high levels of SMRP and 3 of them developed MPM, and one lung cancer. 
None of the remaining 33 with low levels of mesothelin developed any disease (Robinson et al., 
2003). Other research groups have reported elevated levels of SMRP in patients with MPM, 
compared to subjects previously exposed to asbestos (Scherpereel et al., 2006; Cristaudo et al., 
2007; Grigoriu et al., 2007; Creaney et al., 2007; Creaney et al., 2008;  Pass et al., 2008; Schneider 
et al., 2008; Azim et al., 2008; Iwahori et al., 2008; Rodríguez Portal et al., 2009; Davies et al., 
2009; Hollevoet et al., 2010; Cristaudo et al., 2011). Furthermore, it has been demonstrated that the 
SMRP results much higher not only when compared with the levels of mesothelin in healthy pleural 
controls, but also when compared with other cancers (including lung cancer) or other inflammatory 
lung or pleural disease (Cristaudo et al., 2007; Creaney et al., 2008; Pass et al., 2008;  Schneider et 
al., 2008; Rodríguez Portal et al., 2009;  Hollevoet et al., 2010). Overall, according to various 
authors, the mesothelin is nowadays considered a promising marker for the epitheliod MPM, but it 
is less attractive as biomarker for the sarcomatoid type (Beyer et al., 2007; Hollevoet et al., 2010; 
Grigoriu et al., 2007). 
In other studies SMRP has been proposed as marker useful for prognostication and monitoring of 
treatment response in MPM. Grigoriu BD et al., (Grigoriu et al., 2009) measured the SMRP levels 
in 40 patients diagnosed with MPM and subjected to gene-transfer therapy or conventional 
treatment. They have found that in patients, with baseline SMRP levels greater than 1 nM, and 
disease progression after therapy, the SMRP increased (by 2.1 nM at two, 5.2 nM at four and 1.3 
nM at 6 months), whereas patients, who responded to treatment, had an initial small decrease of 
mesothelin, followed by a return to baseline values after 6 months of follow-up. Wheatley-Price P 
(Wheatley-Price et al., 2010) collected serial plasma samples from 41 patients with MPM, and 
observed that seven patients who underwent surgical resection with negative margins had elevated 
preoperative SMRP levels that fell to normal postoperatively. Moreover, rising SMRP was 
observed in all patients with radiologic disease progression. In a study in which 91 MPM patients 
have been enrolled, and SMRP levels measured, it has been observed that changes in mesothelin 
level were correlated to objective response to chemotherapy, as assessed radiologically and by PET 
imaging, and with patient survival. In 55 patients who received chemotherapy, change in mesothelin 
correlated with radiological response (χ(2) = 11.32; P = 0.023) and change in metabolically active 
tumor volume (r = 0.58; P < 0.01). Median survival for patients with a reduction in mesothelin 
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following chemotherapy (19 months) was significantly longer than for patients with increased 
mesothelin [5 months; P < 0.001 (Creaney et al., 2011)].   
 
In summary, more studies are needed in order to detect novel deregulated genes and altered 
molecular pathways in the MPM, useful as biomarkers for a more effective early diagnosis and of 
prognostic value.  
Nowadays, novel methods of investigation are available in order to better ascertain whether a given 
gene is involved in specific biological process. 
 
1.8 Novel methods for the functional study of individual genes 
 
Among the available methods, the use of siRNAs has been considered a powerful strategy allowing 
to study the function of any gene. For this reason, nowadays, the use of “RNA-interference” (RNAi) 
is of increasing interest. This term designs an endogenous mechanism allowing the degradation of 
specific mRNA. siRNAs are small RNA of about 21-23 nucleotides, that bind their mRNAs target 
with a perfect complementarity and trigger their destruction (Baselga, 2006; Carthew and 
Sontheimer, 2009). They could derive from the cleavage mediated by Dicer (an endoribonuclease 
belonging to the RNaseIII family) of a long non-coding double-stranded RNAs either produced in 
the cell, introduced by viruses, or also by transfection (Sashital and Doudna, 2010). The RNAi is an 
evolutionary conserved mechanism and the great interest resides in the fact that, with a simple 
transfection of a siRNA, it is possible to knock-down the expression of a specific gene. For this 
reason, this tool has a wide application in basic research (Lindbo et al., 1993; Tamura et al., 2006). 
Moreover, siRNA have potentially unlimited therapeutic applications and preliminary studies are 
ongoing (Dykxhoorn, 2009; Lindbo et al., 1993). Indeed, siRNAs have some distinct advantages 
over conventional drug therapies: they have high specificity, a potentially enormous number of 
targets, and a fast and common method of synthesis as respect to small molecules (Vaishnaw et al., 
2010), as shown in table 2. 
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Table 2: A comparison of various drug discovery attributes of siRNAs and small molecules (Vaishnaw et al., 2010) 
 
Algorithms have been developed for screening and selection of siRNAs. These are necessary to 
identify segments of double-stranded 19-23 bp that have the minimal complementarities with the 
no-target molecules, for the synthesis of siRNA with small size, for in vitro assays in order to assess 
the power and non-specific cytotoxicity, and for pharmacological evaluating in vivo (Vaishnaw et 
al., 2010). 
In order to better understand the role of genes/pathways in the development of the MPM, in the past 
few years, gene silencing strategy has been attempted, alone or in combination with the 
conventional chemotherapy. Several target genes have been proposed to stop the progression of the 
pleural malignancy. Here some examples: (1) REV3 is the catalytic subunit of DNA polymerase ζ. 
Inhibition of REV3 expression increases the sensitivity of human MPM cells to a variety of DNA-
damaging agents and reduces the formation of resistant cells. (Knobel et al., 2011). (2) ZDHHC8 is 
a putative palmitoyl-transferase enzyme containing a DHHC domain, proposed as a novel 
molecular-targeted radiosensitizing agent. Thanks to immunohistochemical analysis, decreased cell 
proliferation and induction of apoptosis have been observed in tumors treated with ZDHHC8 
siRNA and X-irradiation, but not with ZDHHC8 siRNA alone (Sudo et al., 2012). (3) Since it has 
been suggested that Mcl-1 cooperates with Bcl-x(L) for protection against cell death, Varin E et al., 
investigated the response of MPM cell lines to the down-regulation of Bcl-x(L) (alone or in 
combination with cisplatin) and the potential interest of its concomitant inhibition of Mcl-1. Bcl-
x(L) depletion sensitized two highly chemoresistant MPM cell lines to cisplatin: one cell line 
displayed an apoptotic type of cell death, whereas the other evidenced mainly necrotic-type cell 
death. Moreover, the simultaneous inhibition of Bcl-x(L) and Mcl-1 induced a massive cell death in 
the absence of chemotherapy (Varin et al., 2010). (4) Data from Mohammed research group 
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suggested EphA2 as potential target in the MPM therapy. This gene belongs to the ephrin receptor 
subfamily of the protein-tyrosine kinase family, and it has been shown that silencing of EphA2 
cause the induction of both extrinsic and intrinsic apoptotic pathways in MPM cells. Its targeting 
may thus be an effective approach for inhibiting MPM growth (Mohammed et al., 2011).  
In summary, the combination of the attractive mechanism of action, and of the relative ease of 
manufacturing explain why both biotechnology and pharmaceutical companies have shown great 
enthusiasm for RNAi therapeutics (Haussecker, 2008). However, these experimental approaches 
were also very useful in order to determine whether a gene could play an important role for 
sustaining the malignant phenotype.  
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2. Aim 
 
Given the difficulty of an early diagnosis, the limited therapeutic approaches now available, and the 
rapid progression of the MPM, there is the need to understand the molecular mechanisms involved 
in carcinogenesis and in chemo-resistance. So, in this study we investigated genes potentially 
deregulated in MPM, as candidate genes involved in the initiation, sustainment and evolution of 
MPM, with the following purposes: 
1) Identification of early diagnostic markers 
2) Identification of putative therapeutic markers 
3) Gain novel insights into mechanisms related to responses to chemotherapeutic drugs 
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3. Materials and Methods 
 
3.1 Review of literature data 
 
3.1.1 Data collection 
In order to identify a MPM-gene (MG), i.e. a gene crucial for any process leading to the disease 
(e.g. initiation, maintenance, or clonal evolution), we made an extensive review of the literature. 
Specifically, assuming that most of the MGs could be differentially expressed in MPM as compared 
to normal mesothelial cells, we focused on microarray studies of cell transcriptome. In this kind of 
studies a great number of transcripts are analyzed without formulating any a priori hypothesis. This 
approach should prevent any bias coming from previously established knowledge leading to an 
over-representation of specific genes. To systematically collect MPM microarray studies published 
until 2011, PubMed (URL: http://www.ncbi.nlm.nih.gov/pubmed/) was searched with keywords 
related to the study background. The search was limited to English-language publications. Only 
studies where the expression profiles of MPM cells were compared to normal mesothelial cells were 
included, thus excluding papers with different types of control samples (i.e. different histotypes of 
MPM). Microarray studies using both MPM derived cell lines and MPM tissue samples were 
included. Studies carried out on animal models of MPM and studies where MPM cells have been 
exposed to drugs were excluded. Only a few microarray studies compiled the mentioned criteria. 
This probably depends on the difficulty of acquiring a large number of tissue samples, due to the 
low incidence of MPM. Thus, we selected a total of nine papers (listed in Table 3), out of which 
only four had complete information about microarray experiments and results retrievable from 
ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) or GEO (http://www.ncbi.nlm.nih.gov/geo/). 
Due to the small number of selected studies, and the non-availability of raw data for half of them, 
performing a meta-analysis was not feasible. Each selected study was then thoroughly analyzed, 
paying particular attention to: (i) the employed microarray platform, (ii) the number and type of 
samples, (iii) the fold-change, and (iv) the statistical significance of deregulated genes. In gathering 
this information, we noticed that no uniform criteria exist in describing the used materials and 
methods or in presenting the microarray results. In fact, some papers disclosed only the number or a 
reduced list of differentially expressed genes considered interesting by the authors (Crispi et al., 
2009), in other cases the information concerning the used microarray platform was only 
approximate (Gordon et al., 2005) and not all the studies make the raw data available by public 
repositories. In order to retrieve missing or unclear data, specific information was requested to the 
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corresponding authors of the manuscripts or to the microarray suppliers. Thus, for each study we 
recorded the complete platform information (i.e. microarray supplier, design version, the list of 
genes or ESTs probed on the microarray, etc.) except for one, which used a no longer commercially 
available platform (MicroMax Human cDNA Microarray System II-TSA; Perkin Elmer Life 
Sciences; Boston, MA). We finally collected the lists of differentially expressed genes produced by 
the authors’ analysis with the relative fold-changes and statistical significance values. Gene names 
were uniformed according to the HUGO nomenclature. All this body of information was resumed in 
the supplementary table S3 of the review (Melaiu et al., 2012), where each gene was identified as 
up-regulated or down-regulated in the MPM, simply according to what reported by the papers’ 
authors, without any re-interpretation of the results. We only applied a selection threshold, by 
excluding genes too weakly deregulated, that means with fold changes ranging between 0.7 and 1.3. 
 
References 
Microarray 
platform 
Tot. 
Genes 
MPM cell 
lines  
MPM tissue 
samples  
Control cell 
lines  
Control 
tissue 
samples  
Rihn et al. 2000.   A 3962 1  1  
Kettunen et al. 2001.   B 588 4   2   
Singhal et al. 2003.  C 4132   16   4 
Hoang et al. 2004.  D 4800 10 4 1   
 Mohr et al.2004.  E 9984 1 2 1   
Gordon et al. 2005.  F 14500 4 40 1 9 
Crispi et al. 2009.  G 38500   9   4 
Røe et al. 2009.  G 38500   5   6 
Røe et al. 2010.  G 38500   6   7 
 
Table 3. Schematic representation of the transcriptome studies evaluated in the present RTS 
Legend:  A= Incyte Pharmaceuticals arrays (UnigemV, Genome system Inc., St Louis, USA) 
  B= Atlas Human Cancer gene filters (Clontech) 
  C= GF211 GeneFilters Microarrays (Research Genetics, Inc., Carlsbad, CA) 
  D= MicroMax Human cDNA Microarray System II-TSA; Perkin Elmer LifeSciences; Boston, MA 
  E= Human UnigemV from IncyteGenomics (Palo Alto, CA, USA) 
  F= Affymetrix Human U133A (Affymetrix, Santa Clara, CA, USA) 
  G= Affymetrix Human Genome U133 Plus 2.0 GeneChip (Affymetrix, Santa Clara, CA, USA) 
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3.1.2 Finding a consensus among RTS genes 
A first requirement for a gene to be considered a true MG was to appear reproducibly deregulated in 
independent studies. However, the absolute number of positive calls alone is not exhaustive by 
itself, unless adjusted to the total number of analyses carried out by different studies. For example, 
two independent studies showed that SOD1 and JUNB were up-regulated in the MPM (Appendix 1, 
Melaiu et al., 2012), but while SOD1 was analyzed in eight different studies, only two studies (both 
positive) analyzed JUNB. Table 10 in the text and Appendix 1 (Melaiu et al., 2012) report the ‘‘total 
number of studies’’ that analyzed a particular gene and the number of ‘‘positive studies’’ where that 
gene was found statistically deregulated. Findings from literature were then summarized by writing 
a U (up-regulated) or D (down-regulated) for each publication, and by specifying the tumor 
histology when possible. Most of the studies, in fact, either did not mention the tumor histology or 
merged all the MPMs into a unique histotype. These studies were reported as ‘‘MPM unspecified’’ 
in the fourth column of Table 10 in the text (and Appendix 1, Melaiu et al., 2012). Because in one 
study (Hoang et al., 2004) different histotypes were analyzed, the sum of the Us (or Ds) is greater 
than the total number of positive studies, such as the case of JUNB. Genes described as U and D for 
the same histotype in different studies, were classified as ‘‘contradictory’’ and no further analyzed. 
Genes resulted as U in a sub-type of MPM, but D in another were classified as ‘‘inconsistent among 
histotypes’’ and no further analyzed. Both these classifications, together with the full dataset, are 
reported in the second-last column of Appendix 1. In order to reduce any publication bias due to 
similar findings from different studies by the same authors, we considered just one paper for 
authors’ group. Results, corrected by authors, are reported in Table 10 and Appendix 1. In order to 
rank RTS data, for each gene a score based on the probability values from the binomial distribution 
was calculated, given by the probability mass function: 
 
P-value 
 
This function returns the probability of getting exactly k successes in n trials. Specifically, for each 
gene the probability to observe k positive studies (i.e. successes), in n independent studies (i.e. the 
total number of independent studies) was calculated. The a priori probability (p) for an event to 
occur corresponds to the total number of positive events, divided by the total number of the 
analyses. 
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3.2 Data mining 
 
To confirm results obtained by RTS, an automated search in literature by using the following data 
mining (DM) tools: SNPs3D (URL: http://www.snps3d.org/), GeneProspector (URL: 
http://hugenavigator.-net/HuGENavigator/geneProspectorStartPage.do), and Coremine (URL: 
http://www.coremine.com/medical/) was performed. Each of the selected tools adopts a different 
algorithm to mine information from a text or a database and connect gene or protein names to 
keywords of interest. Furthermore, the level of confidence that each tool expresses on the achieved 
results is based on different scoring or statistical methods. In order to find a group of as exhaustive 
as possible keywords, both the Coremine ability to connect each other Medical Subject Heading 
subcategories relating to MPM, and SNPs3D filter of MPM aliases were used. The lists of 
keywords were inspected for consistency with MPM by using Medical Subject Heading Terms and 
the information from the studies’ background. The following list of keywords was used to 
interrogate the tools: Pleural Neoplasms, Malignant Pleural Mesothelioma, Pleural Mesothelioma, 
Asbestos Exposure, Cisplatin, Cisplatin Treatment, Cisplatin Resistence, mpm, malignant pleural, 
mpm cells, mpms, mpm cell, mpm patients, mpm cell lines, pleural mesotheliomas, pleural 
malignant, malignant pleural mesothelioma mpm, asbestos-exposed, cisplatin, cisplatin treatment, 
cisplatin resistance, asbestos. A binomial distribution was applied to associate a statistically 
significant value to each gene correlated to MPM, based on the total number of retrieved genes and 
the number of tools which found each gene. The gene lists from RTS and DM were compared to 
look for the degree of overlap. 
 
3.3 Gene expression analysis 
 
 
3.3.1 Tissues collection 
Twenty fresh-frozen MPM and 20 non-MPM pleural tissues were collected, thanks to the 
collaboration with the surgeons of the Cardio-thoracic Department of the hospital “Cisanello” of 
Pisa (Italy) and with the Occupational Medicine Unit of the Hospital “Santa Chiara” of Pisa. MPM 
were surgically resected during the pleurectomy/decortication procedures and the specimens were 
eye-inspected by pathologists to minimize the collection of non-cancerous tissues. Control tissues 
were normal pleura from patients diagnosed for lung cancer undergone to surgery (6 diagnosed for 
lung adenocarcinoma and 14 for lung squamous cell carcinoma). Similarly as before, the specimens 
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were eye-inspected, in order to collect a small portion of pleura not containing signs of lung cancer 
spread. All samples were immediately placed in 50mL Falcon tubes containing ice-cold RNAlater 
(Qiagen, S.p.A, Milano, Italy), a RNA preservation solution, and stored at −80◦C until use. The 
collection of MPM resulted in 14 MPM of epithelioid type, 3 sarcomatoid, and 3 biphasic. 
Diagnoses were all confirmed by the Pathological Anatomy unit of the hospital, following the 
standard clinical routine. All patients gave informed consent for the research and the local ethical 
committee approved the study, according to the Helsinki declaration. 
 
3.3.2 Cell cultures 
Four mesothelioma cell lines (Mero-14, Mero-25, IstMes2, and NCI-H28) and one mesothelial non-
MPM immortalized cell line (MeT-5A) were used. Mero-14, Mero-25, and IstMes2 MPM cells 
have been kindly donated by the Istituto Tumori of Genova (National Research Council, Genova, 
Italy). The MeT-5A mesothelial cells, and the NCI-H28 MPM cells were purchased from the ATCC 
(American Type Culture Collection) and kindly donated by collaborators of the Pharmaceutical 
Department of the University of Pisa. Met-5A, Mero-14, Mero-25, and NCI-H28 cell lines were 
verified for their identity, by analysing the genetic markers reported in the certification. IstMes2is a 
cell line established locally and no certification is available. Mero-14, Mero-25, and IstMes2 were 
cultured in DMEM medium (Lonza, Basel, Switzerland), supplemented with 10% fetal bovine 
serum (Sigma Aldrich Corp. St Louis, MO, USA) and 1% Pen-Strep (Lonza, Basel, Switzerland). 
The NCI-H28 cell line was grown in RPMI 1640 medium (Gibco, Life Technologies, Monza, Italy), 
supplemented with 10% fetal bovine serum (Sigma Aldrich Corp. St Louis, MO, USA) and 1% 
Pen-Strep (Lonza, Basel, Switzerland. The MeT-5A cell line was grown in Medium199 with 
HEPES (Life Technologies, Monza, Italy) supplemented with 3.3 nM epidermal growth factor 
(EGF, Life Technologies, Monza, Italy), 400 nM hydrocortisone (Sigma Aldrich Corp. St Louis, 
MO, USA), 870 nM insulin (Life Technologies, Monza, Italy), 10% fetal bovine serum (Sigma 
Aldrich Corp. St Louis, MO, USA), and 1% Pen-Strep (Lonza, Basel, Switzerland). All of them 
were maintained at 37°C in a 5% CO2–humidified atmosphere (Forma* 311 Direct Heat CO2 
Incubator, Thermo Scientific, Waltham, MA, USA). 
 
3.3.3 RNA isolation and cDNA synthesis 
Total RNA was isolated from individual tissue samples by using Tri-Reagent (Sigma Aldrich Corp. 
St Louis, MO, USA) according to the standard protocol. Sample was first grinded in a mortar, then 
mixed and homogenized with 0.7 ml Tri-Reagent using the electric homogenizer TissueRuptor 
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(Qiagen, S.p.A, Milano, Italy). To ensure complete dissociation of nucleoprotein complexes, the 
sample was allowed to stand for 5 minutes at room temperature before adding 0.2 ml of chloroform. 
The mixture was shaken and left at room temperature for 10 min and centrifuged at 12,000 x g for 
15 min at 4
o
C. The chloroform completes the denaturation of proteins and, thanks to its high 
density, facilitates the separation of the aqueous phase colorless, containing the RNA, from the 
organic phase, containing DNA, lipids and proteins. At the interface between the two phases, there 
are the denatured proteins. The upper aqueous phase was transferred to another fresh centrifuge 
tube and RNA was precipitated with 0.5 ml of isopropanol. After being incubated at room 
temperature for 10 min, the sample was centrifuged at 12,000 x g for 10 min at 4
o
C to get the RNA 
pellet, which was subsequently washed by 75% (v/v) ethanol. Centrifugation was then performed 
and the RNA pellet was air-dried and resuspended in 25 μl of RNAse free water. In order to remove 
possible contaminating genomic DNA, the extracted RNA was treated with DNase buffer (Sigma 
Aldrich Corp. St Louis, MO, USA). Concentration of clean-up RNA was determined 
spectrophotometrically (SmartSpec 3000, Bio-Rad Laboratories, Hercules, CA) at 260nm. The ratio 
of readings at 260 and 280 nm (A260/A280) provided an estimate of the purity of RNA with respect 
to contaminants that absorb in the UV spectrum, such as proteins and DNA. The integrity and purity 
of total RNA was further verified by electrophoresis on ethidium bromide agarose gel, inspecting 
the 18 and 28S ribosomal RNA bands. Whether the absorption ratio was outside the window 
encompassing 1.9 - 2.1, or any other quality control criterion was not met, the extraction was 
repeated. The reverse transcription (RT) of mRNA to cDNA was performed using the iSCRIPT 
cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA). cDNA synthesis was carried out from 1 
g of total RNA in a final reaction volume of 20 μl. The reaction is catalyzed by the Moloney 
Murine Leukemia Virus (MMuLV) reverse transcriptase, an RNA/DNA-dependent DNA 
polymerase modified and optimized for the synthesis of cDNA, in presence of an mRNA-polyA 
template and a single-stranded oligo-dT. 
 
3.3.4 Selection of candidate genes 
From the previously elaboration of data published on the MPM (described above), we selected for 
validation 77 genes, on the basis of a probability value taking into account, for each gene, the 
number of studies with positive findings (i.e. deregulated in a statistically significant way) as well 
as the number of negative studies. These genes were either well-known markers of cell 
transformation, or involved in cell proliferation, cell cycle checkpoints, immortalization, cell 
adhesion, or known to play role in cancer progression. 
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3.3.5 Primer design and quantitative Real-Time PCR (QPCR) 
For each gene, primer pairs were designed using the publicly available web-based tool Primer3 
(http://frodo.wi.mit.edu/), and the software “Beacon Designer” (PREMIER Biosoft), whereas the 
analysis of the oligonucleotides was performed with the online tool “Netprimer” (PREMIER 
Biosoft) available at the URL: www.netprimer.com. Primer pairs were designed to allow a specific 
amplification of the spliced mRNA, avoiding any possible amplification of the genomic DNA. To 
this aim, most of the primers were designed on the exon-exon boundaries or on exons spaced by 
long intronic sequences (i.e. >2000 base pairs). Primers were tested for their specificity to have 
unique hits within the whole genome, with “Primer-BLAST” algorithm within BLAST webpage, 
available at the URL: www.ncbi.nlm.nih.gov/tools/primer-blast. Each PCR was tested using 
melting curve analysis to verify the presence of gene-specific peaks and the low abundance of 
primer-dimers. The PCR products were also run on agarose gel electrophoresis in order to test 
further the specificity of the amplicons, following eye-inspection.  
To assess the efficiency of each primer pair, five serial dilutions were prepared from a pool of 
cDNAs and used as template for the generation of the standard curves. QPCR was set up using 2 μl 
first-strand cDNA template, 16 μl deionized H2O, 0.3 μM of upstream and downstream primers and 
5 μl 5× Eva Green master mix with ROX as reference dye (Solis, Tartu, Estonia). The thermal 
cycling conditions were 15 min at 95°C followed by 15 s at 95 °C, 30 s 60°C (40 cycles) and 30 s at 
65 °C.  Based on the Ct values for all dilution points in a series, a standard curve was generated 
using linear regression analysis. The PCR amplification efficiency of each primer pair is calculated 
from the slope of a standard curve. To ensure reproducibility of the experiments, all the reactions 
were executed in triplicate and the average was used for the statistical analyses. 
When the primer pair did not meet the required criteria of specificity or showed a low efficiency 
(thresholds: r
2
>0.96, 3.11<slope<3.58), TaqMan probes (Life Technologies, Monza, Italy) were 
employed. For the TaqMan assay, the reaction mixture consisted of 2 μl of cDNA template, 7 μl of 
deionized H2O, 1 μl of specific TaqMan Assay probe and primers mixture, and 10 μl of TaqMan® 
Gene Expression Master Mix (Life Technologies, Monza, Italy). The thermal cycling conditions 
were: 15 min at 95°C followed by 15 s at 95 °C, (40 cycles) and 60 s at 60 °C. Primers and TaqMan 
assays are reported in tables 4 and 5 respectively. 
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Gene 
Symbol 
(HUGO) 
NM Primers sequences (foward/reverse) 
Tm 
(°C) 
Amplicon 
lenght 
CCND2 NM_001759 
gCT ggC TAA gAT CAC CAA CAC A 
60 62 bp 
CCT CAA TCT gCT CCT ggC AA 
ITGA6 NM_000210 
gCT ggT TAT AAT CCT TCA ATA TCA ATT gT 
60 113 bp 
TTg ggC TCA gAA CCT Tgg TTT 
TIMP3 NM_000362 
CCA ggA CgC CTT CTg CAA C 
60 71 bp 
CCT CCT TTA CCA gCT TCT TCC C 
AKR1C1 NM_001353 
ggA TTA TgT TgA CCT CTA CCT TAT T 
60 86 bp 
TTT TTC CAT TTT CAT CTT TTg ggA T 
CDKN1A NM_001220778 
ggC AgA CCA gCA TgA CAg ATT 
60 73 bp 
gCg gAT TAg ggC TTC CTC TT 
IGFBP4 NM_001552 
CCC ACT CCC AAA gCT CAg ACT 
60 89 bp 
CCA AgC AgA Tgg TgC AAC AA 
ASS1 NM_000050 
ATT gAC ATC gTg gAg AAC Cg 
60 101 bp 
gCC TCg ATg TCT AAA TgA gCA 
BUB1B NM_001211 
gTg CTT CCC AgT TTC ACT CC 
60 110 bp 
CCA ggC TTT CTg gTg CTT Ag 
ITGA4 NM_000885 
AgA TgC Agg ATC ggA AAg AA 
60 117 bp 
CCC CAA CCA CTg ATT gTC TC 
NUSAP1 NM_016359 
gCC AAg AgT CTg ggT CTC C 
60 95 bp 
TCA TTT CCT TTT CTT gCC TCA 
CFB NM_001710 
Tgg AAA ACC Tgg AAg ATg TTT 
60 109 bp 
ggT TgC TTg Tgg TAA TCg gT 
BLMH NM_000386 
AAT TCA Tgg ggT gAA gAC CA 
60 92 bp 
CTg TCC ACC ACC ACT TCg TA 
CDK2AP1 NM_004642 
TCT TAC AAA CCg AAC TTg gC 
60 106 bp 
ggC ggT ACT gTg AAg ACg TT 
COL6A1 NM_001848 
AgA ggA gAC CCT ggT gAA gC 
60 110 bp 
Cgg TAg CCT TTA ggT CCg AT 
CRIP1 NM_001311 
ATg CCC AAg TgT CCC AAg T 
60 114 bp 
CAg CgT CTT CCC ACA TTT CT 
VCAN NM_004385 
TCT CCC CAG GAA ACT TAC GA 
60 110 bp 
CAC TCT TTT GCA GCC TCC TC 
DAB2 NM_001343 
AAg TCA TgC TCg CTT CAC g 
60 108 bp 
CCA gTg gAC ACT Tgg TgA CA 
EEF2 NM_001961 
CTg gAg ATC TgC CTg AAg gA 
60 109 bp 
gCA CgT TCg ACT CTT CAC Tg 
IARS NM_013417 
TCA CCA gAg gAT CTT CCC TT 
60 111 bp 
CAC CTT TTg gAT TTT CCA gg 
NME2 NM_001018137 
AAA gAC CgA CCA TTC TTC CC 
60 104 bp 
ATC ACT Cgg CCT gTC TTC AC 
PDGFRB NM_002609 
AAC TgT gCC CAC ACC AgA Ag 
60 106 bp 
CAg gAg AgA CAg CAA CAg CA 
RAN NM_006325 
CAg gAg AAA TTC ggT ggA CT 
60 111 bp 
ATg CCA gTT Agg CAC ATT CTT 
RCN2 NM_002902 
Tgg ATg ATg CAg AAg Agg Ag 
60 101 bp 
TTC AAg ACT CAA ACC ggg AC 
THBS1 NM_003246 
CAA TgC CAC AgT TCC TgA Tg 
60 110 bp 
CAC AgC TCg TAg AAC Agg Agg 
THBS2 NM_003247 
TCA ggg gTT TgC TTC AgA AC 
60 116 bp 
gTT CTC ACT gAT ggC gTT gA 
TNPO2 NM_001136195 
gAg Tgg gTg gTC AAg gAg TC 
60 94 bp 
ggA TCA gCT CAg gCA ggT Ag 
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Table 4. Selected candidate target genes, primers, and amplicon length.
CXADR NM_001338 
ATT TCg CCA gAA gTT TgA gTA TCA 
60 81 bp 
TgC ATg gCA gAT Agg CAg TTT 
PCNA NM_002592 
Agg CAC TCA Agg ACC TCA TCA 
60 76 bp 
gAg TCC ATg CTC TgC Agg TTT 
RAD21 NM_006265 
ggA AAg AgA CAg gAg gAg TA 
60 86 bp 
gCg TgT AAA gAg CTT CAg TA 
SOD1 NM_000454 
Agg CCC CTT AAC TCA TCT 
60 122 bp 
CTA CAg gTA CTT TAA AgC AAC TCT 
SPINT2 NM_021102 
CAA gTg CTC CCA gAA ggC 
60 78 bp 
CgT Tgg Cgg TgC AgT ATT C 
CALB2 NM_001740 
TAT GGA AGC ACT TTG ACG CA 
60 106 bp 
GAC ATC ATG CCA GAG CCT TT 
ALDOA NM_000034 
Cgg gAA gAA ggA gAA CCT g 
60 98 bp 
gAC CgC TCg gAg TgT ACT TT 
DSP NM_004415 
CTC AAT CAg CAT CCA gCT TC 
60 100 bp 
gAA CAT CAA TgC ACT Tgg Tg 
PGK1 NM_000291 
CAA gCT ggA CgT TAA Agg gA 
60 108 bp 
CTT ggg ACA gCA gCC TTA AT 
PGM1 NM_001172818 
CCg ACT gAA gAT CCg TAT TgA T 
60 110 bp 
gAA CgC AgT TAA CTg CCg Ag 
VEGFA NM_001025366 
CTA CCT CCA CCA TgC CAA gT 
60 104 bp 
AgC TgC gCT gAT AgA CAT CC 
SFRP2 NM_003013 
CAA CgA CAT AAT ggA AAC gC 
60 116 bp 
Tgg TCT TgC TCT Tgg TCT CC 
NR3C1 NM_001018077 
TTC CCT ggT CgA ACA gTT TT 
60 96 bp 
TgT TgT TgC TgT TgA ggA gC 
LGALS3BP NM_005567 
CAT gAg TgT ggA TgC TgA gT 
60 109 bp 
CAg CTT gTg gAA gCA CTT g 
SSBP1 NM_ 001256510 
ATA ATg TgA ggC gAC AAg CA 
60 103 bp 
Tgg CCA AAg AAg AAT CAT CC 
SYNE1 NM_ 182961 
ggg ATA TCg CCA ATg TgA Tg 
60 92 bp 
ggC CAg ATg AgA gTT gAT CC 
UPK1B NM_006952 
CTA CCg TgT gCg CAg AAA 
60 92 bp 
Tgg AAg CAA CgA ACA gTT gA 
FGF2 NM_002006 
ggA gAA gAg CgA CCC TCA C 
60 94 bp 
AgC CAg gTA ACg gTT AgC AC 
CCNH NM_ 001199189 
TCT gTT gTg ggT ACg gCT Tg 
60 90 bp 
AgT gAg CAT TAT TAT CCT ggg g 
PTGS2 NM_000963 
CAT gAT gTT TgC ATT CTT TgC 
60 111 bp 
TgA TTT AAg TCC ACC CCA Tg 
COL1A1 NM_000088 
AAg Agg AAg gCC AAg TCg Ag 
61.4 91 bp 
CAC ACg TCT Cgg TCA Tgg TA 
FEN1 NM_004111 
Agg gAg AgC gAg CTT Agg AC 
60 104 bp 
ggC AAC ACA gAg gAg ggA T 
HEG1 NM_020733 
CAg CgT TAC CTA gTT ACA TC 
60 109 bp 
AAT AgC gTC ACA TTg gAg 
FGF9 NM_002010 
gTg gAC TCT ACC TCg ggA Tg 
60 98 bp 
CCA gTT TTC TTC gAA CTg TTC TC 
MCM4 NM_005914 
ggC AgA CAC CAC ACA CAg TT 
60 108 bp 
CgA ATA ggC ACA gCT CgA TA 
GALNT7 NM_017423 
AgT ggT CCT CTg gTC TTC CC 
60 92 bp 
gCA Tgg ggT CAT TgA CAT CT 
TMEM176A NM_018487 
ggA TTT TTC TAC ATC CgC gA 
60 119 bp 
gTA CCA CCC CgT TTC TCg TA 
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Table 5. Selected candidate target genes, TaqMan assay, and amplicon lenght. 
 
 
3.3.6 GeNorm software and Selection of RT-qPCR reference genes 
For a precise comparison of mRNA transcription in different samples or tissues it is crucial to 
choose the appropriate reference genes. The optimal reference gene should be constantly 
transcribed in all types of cells at any time of the cell cycle and of the ontogenesis. To identify the 
ideal group of RT-qPCR reference genes, geNorm (URL: http:// medgen.ugent.be/genorm/), a 
software that ranks the candidate reference genes based on their stability parameter M, has been 
employed, according to the MIQE guidelines (Bustin et al., 2009). After a literature search to 
identify the housekeeping genes commonly used in MPM studies, the departing list of reference 
genes has been analyze in RT-qPCR: GAPDH, HPRT1, B2M, RPLP0, TBP, GUSB and PPIA 
(Tables 6, 7). 
 
Gene Name 
(HUGO) 
NM Assay ID 
Tm 
(°C) 
Amplicon 
lenght 
SULF1 NM_001128205 Hs00290918_m1 60 65 bp 
TOP2A NM_001067 Hs03063307_m1 60 72 bp 
CCNO NM_021147 Hs00221731_m1 60 79 bp 
FANCI NM_001113378 Hs00383049_m1 60 66 bp 
CHEK1 NM_001114122 Hs00967506_m1 60 79 bp 
PECAM1 NM_000442 Hs00169777_m1 60 65 bp 
SMARCA4 NM_003072 Hs00231324_m1 60 106 bp 
KRT5 NM_000424 Hs00361185_m1 60 133 bp 
KRT18 NM_000224 Hs01653110_s1 60 81 bp 
ASPA NM_000049 Hs00163703_m1 60 63 bp 
C10orf116 NM_006829 Hs00428992_m1 60 89 bp 
DAP NM_004394 Hs00234397_m1 60 102 bp 
EID1 NM_014335 Hs00534885_s1 60 58 bp 
FAS NM_000043 Hs00236330_m1 60 125 bp 
METAP1 NM_015143 Hs00299385_m1 60 61 bp 
PDGFRA NM_006206 Hs00998018_m1 60 84 bp 
RHOB NM_004040 Hs03676562_s1 60 82 bp 
CENPF NM_016343 Hs01118845_m1 60 77 bp 
MSLN NM_005823 Hs00245879_m1 60 65 bp 
ANXA4 NM_001153 Hs00984874_m1 60 94 bp 
MCM2 NM_004526 Hs01091564_m1 60 67 bp 
PLK2 NM_006622 Hs00198320_m1 60 75 bp 
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Gene 
Symbol 
(HUGO) 
NM Primers sequences (foward/reverse) 
Tm 
(°C) 
Amplicon 
lenght 
PPIA NM_021130 
ACT gAg Tgg TTg gAT ggC AAg 
60 378 bp 
TCA ACA CTC TTA ACT CAA ACg Agg A 
GAPDH NM_002046 
CCA CTC CTC CAC CTT TgA Cg 
60 252 bp 
TgT gAg gAg ggg AgA TTC AgT g 
B2M NM_004048 
CTC CgT ggC CTT AgC TgT g 
60 69 bp 
TTT ggA gTA CgC Tgg ATA gCC T 
GUSB NM_000181 
CCT gCC TAT CTg TAT TCA TTg 
60 80 bp 
ggg AgT gTg TAg AAg TCA 
TBP NM_003194 
gCg gTT TgC TgC ggT AAT C 
57 109 bp 
TCT ggA CTg TTC TTC ACT CTT gg 
HPRT NM_000194 
TTC Agg Cgg CTg CgA CgA g 
62 110 bp 
Tgg Cgg AgC AgA ggA ggA g 
RPLP0 NM_053275 
CCT CAT ATC Cgg ggg AAT gTg 
60 95 bp 
gCA gCA gCT ggC ACC TTA TTg 
 
Table 6. Selected candidate reference genes, primers, and amplicon length. 
 
Gene Name 
(HUGO) 
NM Assay ID 
Tm 
(°C) 
Amplicon 
lenght 
PPIA NM_021130 Hs99999904_m1 60 98 bp 
GAPDH NM_002046 Hs99999905_m1 60 122 bp 
B2M NM_004048 Hs00984230_m1 60 81 bp 
GUSB NM_000181 Hs00939627_m1 60 96 bp 
TBP NM_003194 Hs00427620_m1 60 91 bp 
HPRT NM_000194 Hs01003267_m1 60 72 bp 
RPLP0 NM_053275 Hs99999902_m1 60 105 bp 
 
Table 7. Selected candidate reference genes, TaqMan assay, and amplicon lenght. 
 
Each of them has been analyzed by using qPCR. In order to analyze the gene expression stability 
(Vandesompele et al., 2002), Ct values of all samples were exported to Excel, ordered for use in 
geNorm software and transformed to relative quantities using the gene-specific PCR amplification 
efficiency (Hellemans et al., 2007), according to the formula: 
 
Q = E
Ct
 = E
(minCt-sampleCt) 
 
where E is the amplification efficiency (2 = 100%; 1.95 = 95%); minCt is the lowest average of the 
Ct, which corresponds to the highest level of expression; sampleCt is the average of the Ct of each 
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sample. Once the relative quantities have been inserted in geNorm software, the program calculates 
the M value, and based on that, we can establish the most stable reference genes. Based on the 
principle that the expression ratio of two ideal reference genes should be identical in all samples, 
independent of the treatment, condition, or tissue type, increasing variations in the expression ratio 
between two genes correspond to lower expression stability across samples. geNorm calculates the 
stability using a pairwise comparison model (Vandesompele et al., 2002) and determines the level 
of pairwise variation for each reference gene with all other reference genes as the standard deviation 
of the logarithmically transformed expression ratios. In this way, the reference gene expression 
stability measure (M value) was calculated as the average pairwise variation of a particular gene 
with all other control genes included in the analysis (Vandesompele et al., 2002; Maroufi et al., 
2010). Lower M values represent higher expression stabilities, and vice versa. geNorm was also 
used to estimate the normalization factor (NFn) by calculating the geometric mean of the expression 
levels of the n best reference genes (Vandesompele et al., 2002). Thanks to geNorm, it is also 
possible to determine the optimal number of reference genes: the optimization of the number of 
reference genes starts with the inclusion of the two genes with the lowest M value, and continues by 
sequentially adding genes with increasing values of M. Thus, geNorm calculates the pairwise 
variation Vn/Vn+1 between two sequential normalization factors NFn and NFn+1 containing an 
increasing number of reference genes (Vandesompele et al., 2002). A large variation means that the 
added gene has a significant effect on the normalization and should preferably be included for 
calculation of a reliable normalization factor. According to the geNorm, if Vn/Vn+1 <0.15 the 
inclusion of an additional reference gene is not required and the recommended number of reference 
genes is given by n (Vandesompele et al., 2002).  
 
3.3.7 Normalization and Statistical analysis methods 
With the relative quantification, after having transformed into quantities the mean-Ct of the various 
target genes, it is needed to normalize these values compared to those of reference genes. For each 
sample the normalization factor has been calculated, according to the formula:  
 
 
 
where n is the number of selected reference genes, while REF indicates the Quantity of each 
reference gene obtained for each sample. The following passage is to divide the quantity of the 
target gene (for each sample), for the NF of each sample: 
 46 
 
QsampleX/NFsampleX 
 
The statistical test employed for the comparison of the normalized results is the One-tailed 
Wilcoxon test. One-tailed Wilcoxon signed rank test was applied to evaluate the statistical 
significance of the results adopting a threshold of 0.05. The a priori hypothesis tested for each gene 
was derived from the up- or down-regulation identified in the literature review (Melaiu et al., 2012), 
reported in Appendix 1 (Table S2, Melaiu et al., 2012). The q-value (Storey JD, 2002) was used to 
correct for multiple testing. 
 
3.4 Mutation screening of PDGFRB 
 
3.4.1 Samples collection 
Paraffined embedded MPM tissues from 100 surgical resection were available thanks to the 
collaboration with Prof. Gabriella Fontanini (Pathologic anatomy, Hospital of Pisa, Italy). Informed 
consent was obtained from all individuals analyzed. 
 
3.4.2 DNA sequencing 
To measure the frequency of activating mutations within PDGFRB in MPM at the presentation, 
exons 12 and 18 have been screened. Genomic DNAs were prepared from each sample according to 
the standard procedure, using the QIAamp DNA FFPE Tissue Kit (Qiagen S.p.A. Milan Italy). The 
whole exons 12 and 18 of PDGFRB were PCR-amplified from genomic DNA using the specific 
primer pairs reported in Table 8, and sequenced using either PCR oligonucleotide as sequencing 
primer. The mutation screening was performed with automatic sequencing (Sanger reaction), thanks 
to the collaboration with Prof. Gabriella Fontanini (Pathologic anatomy, Hospital of Pisa, Italy). 
With this method, we could detect all the occurring somatic mutations within exons 12 and 18, 
namely the classical D850 mutation (PDGFRB) as well as other eventual mutations in the neighbor 
sequence encoding for the kinase activation loop domain. Moreover, we could detect the eventual 
presence of the “gatekeeper” mutation or any other mutations in the neighbor sequence. 
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Gene 
Symbol 
(HUGO) 
Exon Primers sequences (foward/reverse) 
Amplicon 
lenght 
PDGFRB Exon 12 
TgT CCT AgA Cgg ACg AAC CT 
258 bp 
CCA ACT TgA gTC CCC ACA CT 
PDGFRB Exon 18 
gAA ggg TCT TTC CCC ACA AT 
259 bp 
CAC ACT ggT CAg gAg ggA AT 
 
Table 8. PDGFRB, exons, primers, and amplicon length. 
 
3.4.3 Cell viability for chemoresistance 
In order to ascertain whether PDGFRB plays a role in the secondary resistance to imatinib, Mero-14 
over-expressing PDGFRB cells were employed, after having checked the absence of mutations 
within the target gene, before the treatment with imatinib. Mero-14 cells were seeded onto 96-well 
plates and allowed to attach 24 h before drug treatment. To assess the IC50, the cells were treated 
for 48h with different concentrations of imatinib. At the end of the experiment, the [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium], inner salt 
(MTS) assay was performed using a commercial kit (CellTiter Aqueous Solution, Promega), 
according to the manufacturer’s instructions;. The absorbance values were recorded at 490/620 nm 
by a spectrophotometric plate reader (Sirio S, SEAC, Florence, Italy) and corrected by subtraction 
of the absorbance of MTS alone. 
 
3.4.4 Selection of imatinib-resistant MPM cells 
Selection of resistant cells was achieved by treating Mero-14 cells to a scaling concentrations of 
imatinib, starting with a concentration of 25M and increasing gradually, by 25%, until the 
concentration of 100 M, that revealed to be the IC50. Viable cells were grown in the presence of 
imatinib, replacing the medium twice a week, for about 6 months. Once reached the concentration 
of 100 M, viable cells stopped to replicate. At the end of this selection period, genomic DNA was  
extracted according to the standard protocol, with QIAamp DNA Mini Kit (Qiagen S.p.A. Milan 
Italy) and processed for next-generation sequencing (NGS). 
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3.4.5 Samples preparation and NGS 
We screened the resistant clones for mutations in exons 12, 14, and 18 of PDGFRB by using NGS. 
The whole exons 12, 14 and 18 of PDGFRB were PCR-amplified from genomic DNA using 
specific primer pair showed in Table 9. 
  
Gene Exon Primers sequences (foward/reverse) Amplicon lenght 
PDGFRB Exon 12 
CGTATCGCCTCCCTCGCGCCATCAGTgT CCT AgA Cgg ACg AAC CT 
308 bp 
CTATGCGCCTTGCCAGCCCGCTCAGCCA ACT TgA gTC CCC ACA CT 
PDGFRB Exon 14 
CGTATCGCCTCCCTCGCGCCATCAGgAg gCC TCC ATA ggg ACT gT 
309 bp 
CTATGCGCCTTGCCAGCCCGCTCAGgCT CCT CAg gTA TCC CAA AgA 
PDGFRB Exon 18 
CGTATCGCCTCCCTCGCGCCATCAGgAA ggg TCT TTC CCC ACA AT 
310 bp 
CTATGCGCCTTGCCAGCCCGCTCAGCAC ACT ggT CAg gAg ggA AT 
 
Table 9. PDGGRB, exons, primers, and amplicon lenght. 
 
The 5’-portion is a 25-mer whose sequence is dictated by the requirements of the 454 Sequencing 
System for hybridizing to the DNA Capture Beads (Lib-A), and for annealing the emPCR 
Amplification Primers and the Sequencing Primer; in addition, this 5’-part must always end with 
the sequencing key “TCAG” used for Amplicon sequencing. The 3’-portion of each primer is 
designed to anneal with a specific sequence on either side of the target of interest on the DNA 
sample, delineating the margins of the amplicon that will be produced. This requires detailed 
knowledge of the target sequence, in particular the sites targeted by the primers. 
We prepared 3 different mixes for each primer pairs in order to amplify the three target exons. The 
protocol employed was: 
 
Primers (10 μM): 0.5 μl F + 0.5 μl R 
Buffer BD (10X): 2 μl 
MgCl2 (25mM): 1.2 μl 
dNTPs (2mM): 2 μl 
H2O: 10,6 μl 
Hotfire® Taq polimerasi: 0,2 μl 
DNA: 3 μl (30 ng/ μl) 
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The thermal cycle program used included: 
 
95 °C for 8 min (to active the Hotfire® Taq polimerasi) 
 
20 cycles    95°C for 30 sec (to denature the DNA) 
                  68°C for 30 sec, -1°C/cycles (hybridization of primers) 
                  72°C for 1 min and 30 sec (the stage of extension) 
 
20 cycles    95°C for 30 sec (to denature the DNA) 
                  51°C for 30 sec (hybridization of primers) 
                  72°C for 1 min and 30 sec (the stage of extension ) 
 
72°C for 10 min (to complete the synthesis) 
4°C forever 
 
The visualization of the PCR products was carried out through electrophoresis in 2% agarose gel, 
obtained through the polymerization of 5 g of agar in 250 ml TBE 0,5X (TRIS borat-EDTA buffer), 
with the addition of 8 μl of Ethidium Bromide (10mg/ml), at 180V for 20 minutes. 
The purified PCR products have been sent to the BMR centre (Bio Molecular Research, CRIBI, 
Padova, Italy), to perform sequencing through the 454 Sequencing System and the subsequently 
data analysis.  
 
3.5 Functional studies on MSLN and CALB2 genes 
 
3.5.1 Chemicals 
Imatinib was purchased from Cayman Chemical (Michigan, USA); Gemcitabine was obtained from 
Sigma Aldrich Corp. (St Louis, MO, USA); Cisplatin has been kindly donated by Prof. Justin 
Stebbing (Imperial college, London). The drugs were dissolved in DMSO at the final concentration 
of 10 mM. The antibodies used are the following: MSLN mouse monoclonal (Santa Cruz); CALB2 
mouse monoclonal (Santa Cruz); β-actin mouse monoclonal (Abcam), p53 mouse monoclonal 
(Santa Cruz); pERK, mouse polyclonal (Abcam); PARP rabbit polyclonal (Cell Signaling); pAKT 
rabbit polyclonal (Abcam); ERK1-2 rabbit polyclonal (Abcam); Secondary HRP (horseradish 
peroxidase)-conjugated goat anti-rabbit IgG and goat antimouse IgG antibodies were from GE 
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Healthcare. The expression plasmid pcDNA3.1 encoding for MSLN (aa 360-2230) was kindly 
donated by Dr. Chen (Taiwan); the empty vector pcDNA3.1, employed as control, was donated by 
Dr. Giamas (Imperial college, London). 
 
3.5.2 siRNA transfection 
siRNAs were purchased from Qiagen (Qiagen, S.p.A, Milano, Italy). The target sequence for Hs-
MSLN-1 (SI0081704) was: CTGGACGTCCTAAAGCATAAA. The target sequence for 
Hs_CALB2_5 (SI02660980) was: GACGGAAATGGGTATATTGAA. AllStars Negative Control 
siRNA (SI03650318) was used as non-targeting control. siRNA oligo was re-suspended in the 
provided buffer at final stock concentration of 20 M. siRNA transfection was performed with the 
HiPerfect transfection reagent (Qiagen, S.p.A, Milano, Italy), according to the manufacturer’s 
instruction. In brief, the appropriate number of cells was seeded in different plates. The day after, 
siRNA was diluted in culture medium without serum, and x μl of HiPerFect Transfection Reagent 
was added. After an incubation of 10 min at room temperature, allowing the formation of 
transfection complexes, the mixture was added drop-wise onto the cells. The cells were incubated 
with the transfection complexes under their normal growth conditions for 6–72 h, depending on 
experimental setup. Following siRNA transfection experiment, the efficiency of the knock-down of 
the targeted mRNA was checked.  
 
3.5.3 Plasmid transfection 
NCI-H28 cells were employed for the transient over-expression of MSLN. Transfections were 
performed using the FuGENE® Transfection Reagent (Promega Corp. Madison, Wisc., USA) in 
penicillin/streptomicine-free RPMI for 24 h according to manufacturer instructions. The amounts of 
FuGENE® Transfection Reagent used were 6 μL for 2 μg plasmid in 95% confluent cells plated 
onto 6 cm dish (approximately 8 x 10
5
 cells/well). pcDNA3 and pcDNA3-MSLN were used, as 
previously mentioned. 
 
3.5.4 Proteins extraction and Western Blotting 
Cell pellets were re-suspended in ice-cold RIPA buffer containing proteases and phosphatases 
inhibitors. The extracts were then clarified by centrifugation at 15000 rpm for 15 min at 4 °C, and 
the proteins concentration was determined. Lysates were incubated in 5x sodium dodecyl sulfate 
(SDS) sample buffer (5 min, 95 °C). 10-30 g of proteins for each sample was loaded onto 8–15% 
SDS polyacrylamide gel. Proteins were then transferred onto a nitrocellulose membrane. The 
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membrane was blocked for 1 hour with non-fat dry milk in TBS containing 0.05% Tween 20, 
washed, and successively incubated with different primary antibodies for 12 h at 4 °C. The 
membranes were then washed three times for 10 min and incubated with the HRP-conjugated 
secondary antibody for 1 h at room temperature (RT). After a thorough washing, the blot was 
exposed to ECL (GE Healthcare, NJ) and autoradiography. The intensity of the bands was 
quantified using Image J software (NIH, Bethesda, MD). 
 
3.5.5 Sulphorhodamine (SRB) assay 
The SRB assay was performed to test the proliferation of the cells after the depletion of MSLN and 
CALB2 with and without the combination with 3 different drugs (Imatinib 25 uM; Cisplatin 5 uM; 
Gemcitabine 1 uM; Imatinib 5 uM + Gemcitabine 1 uM). 3 x 10
3
 cells were seeded in a 96 well 
plate. The day after, one plate was assessed at this time (day 0) and further plates were tested at 
intervals of 2-d for a total of 6-8 days. Cells were fixed with 100 μL per well of ice-cold 40% 
(vol/vol) TCA (Sigma Aldrich Corp. St Louis, MO, USA), by gently adding on top of the medium 
overlaying the cells. The plates were then incubated for 60 min at 4°C. Wells were rinsed five times 
with tap water and then they were stained with 0.4% SRB solution (100 µl stain/well; Sigma 
Aldrich Corp. St Louis, MO, USA) for 30 min at room temperature. After staining, SRB solution 
was poured off, unbound dye was removed by washing five times with 1% acetic acid solution and 
left to air dry. The bound SRB dye was then solubilized by adding unbuffered Tris-base solution 
(100 µl/well), and plates were placed on a plate shaker for 10 min at room temperature. Plates were 
then read at OD 492 nm, using a microplate reader. Every condition was done in quadruplicate. 
Mean and SEM of independent experiments were calculated. Statistical analysis was performed 
using a two-tailed Student’s t-test to determine the statistical significance of the differences 
observed. A P-value below 0.05 was considered significant. 
 
3.5.6 3D Overlay Culture on Matrigel 
Thawed Matrigel (BD Bioscience) in a volume of 70 μL/well was added into each of the wells of 
the eight-well glass slide chambers (Thermo Scientific), and spread to form a 1-mm thick bed. 
Matrigel was left to solidify at 37 °C for 15 min. Then, cells (1 × 10
3
/well) were plated in medium 
containing 2% Matrigel and allowed to grow in a 5% CO2 humidified incubator at 37 °C. Each 
condition was represented in triplicate. 
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3.5.7 Flow cytometry (FACS) 
To evaluate the effect of the silencing of MSLN and CALB2 on cell cycle progression, Mero-14 
cells (subject to the depletion of MSLN) and IstMes2 cells (subject to the depletion of CALB2) were 
treated with CT siRNA or MSLN/CALB2 siRNA for 72 h, with and without the combination with 
the drugs (Imatinib 25 uM; Cisplatin 5 uM; Gemcitabine 1 uM; Imatinib 5 uM + Gemcitabine 1 
uM). After the treatment, cells were collected by trypsinization, washed in phosphate-buffered 
saline (PBS), pelleted by centrifugation and fixed in 70% ethanol. Immediately prior to staining, 
cells were washed twice in PBS and resuspended in PBS containing 50 μg/ml of RNAse A (Qiagen, 
S.p.A, Milano, Italy). Cells were stained with propidium iodide (final concentration 100 μg/ml) for 
at least 1hr at 4°C and were analyzed using a LSR II flow cytometer (BD Biosciences). The 
percentage of cells in subG1 G0/G1, S and G2/M phases were determined from >10,000 cells using 
the FACSDiva 6.0 software (BD Biosciences). Three independent experiments were performed for 
each condition. 
 
3.5.8 Caspase - Glo® 3/7 assay 
Caspase-3/7 activation was measured using the Caspase-Glo 3/7 Luminescence Assay (Promega 
Corp. Madison, Wisc., USA) according to the manufacturer’s instructions. Briefly, 3 x 105 cells 
were incubated in a 6 well plate and allowed to adhere overnight. The day after, cells were treated 
with 40 nM of MSLN siRNA, or 50 nM of CALB2 siRNA (and the CT siRNA), with and without 
the combination with the drugs (Imatinib 25 uM; Cisplatin 5 uM; Gemcitabine 1 uM; Imatinib 5 
uM + Gemcitabine 1 uM), for 48 hr. Afterwards, cells were collected by trypsinization, and 
approximately 15 x 10
3
 cells were transferred in a 96-well white plate. Caspase-3/7-Glo reagent was 
added, and the samples were incubated at 37°C for 1 h. The luminescence that is proportional to the 
caspase 3/7 activities was determined by luminometer (Tecan Sunrise, Austria GMBH). Three 
independent experiments were performed for each condition. 
 
3.5.9 Transwell Cell Invasion Assay 
To assess the cell invasion capacity after depletion of MSLN and CALB2, 5 × 10
4
 cells in 200 μL of 
α-MEM (Gibco, Life Technologies, Monza, Italy) were plated in the Matrigel-coated upper 
chambers of the 24-well Transwell invasion assay plate (Corning, NY 14831 USA). Each condition 
was represented in triplicate. Plates were incubated at 37 °C for 48 h for Mero-14 and IstMes2 cells. 
Cells in the lower chamber (including those attached to the under surface of the membrane) were 
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fixed in 4% paraformaldehyde (VWR, Milan Italy), stained with DAPI (Lonza, Basel, Switzerland), 
and counted with fluorescence microscope (Metamorph – Axiovert microscope). 
 
3.5.10 Wound-Healing Assay 
Mero-14 and IstMes2 cells were seeded in a 12-well plate at 25 X 10
3
 cells per well. The following 
day, they were respectively transfected with MSLN (40 nM) and CALB2 (50 nM) siRNAs. After 52 
hr, a linear scratch in the confluent cell monolayer was made with a sterile pipette tip. Cells were 
rinsed and then incubated in full medium 20 hr prior to fixation followed by staining with crystal 
violet solution to enhance contrast. For each well, pictures were taken at 10× magnification along 
the scratch area with a phase-contrast microscope. 
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4. Results 
 
 
4.1 Review of literature data 
  
4.1.1 RTS 
Our main requirement for a gene to be an MG is to be reproducibly deregulated among independent 
studies. To get this information, and rank RTS data, a binomial distribution has been applied. Since 
the a priori probability (p) for an event to occur corresponds to the total number of positive events, 
divided by the total number of the analyses, we have calculated respectively the sum of all the 
positive findings, corresponding to 1081, and the sum of all the genes on all the platforms used for 
all the studies, corresponding to 153,383. Thus, 7.05 x10
-3
 was the a priori probability to observe 
one positive event (a success), that means the probability for each gene to appear as deregulated in a 
single trial. The P-values are reported in ascending order in the last column of Table 10 in the text 
and Appendix 1 (Melaiu et al., 2012). Nine hundreds and thirty-one out of a total of 968 identified 
genes were statistically significant (P-value < 0.05) (see Appendix 1). 
 
4.1.2 Data mining 
The DM analysis collected a total of 3236 genes (Melaiu et al., 2012). Coremine detected 3149 
genes (CM genes), out of which 657 showed a P-value < 0.05 (CM-significant, CMS), whereas 
SNPs3D (S3D) and GeneProspector (GP) retrieved 186 and 242 genes, respectively. Based on 
binomial distribution, 56 (reported in Table 11) out of the 3236 genes were found by all the three 
tools (P-value = 0.000512), 230 by only two tools (P-value = 0.017664), and 2950 by only one tool 
(P-value = 0.203136). 
 
4.1.3 Comparison between RTS and DM 
RTS and DM results shared the following numbers of genes: RTS vs CM = 387 genes, RTS vs 
CMS = 84, RTS vs GP = 42, RTS vs S3D = 39, RTS vs (CM + GP + S3D) = 397, and RTS vs 
(CMS + GP + S3D) = 131, as the Venn Diagram shows (Figure 10). 
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Figure 10: Venn Diagram showing the intersection between RTS and (CMS + GP + S3D), highlighting 131 potential 
MGs. 
 
DM retrieved about 43% of genes collected by RTS. Genes detected by RTS and not by DM are 
genes differentially expressed in MPM but never discussed among the sources inspected by DM. In 
fact, only the most relevant findings of microarray studies are usually reported in literature. RTS 
was focused specifically on genes detected by microarrays not taking into account genes associated 
to MPM via different mechanisms (including promoters’ methylation, somatic mutations, chromo-
somal translocations, gene deletions, miRNA regulations and so on). It is not therefore surprising 
that DM was able to highlight a greater number of genes. However, comparing information from 
RTS and DM was useful to highlight RTS genes supported by other scientific evidence.  
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Gene name Rank 
Total 
number 
of 
studies 
Total number 
of studies 
with a 
statistically 
significant 
deregulation  
MPM 
unspecified 
MPM 
epithelioid 
MPM 
sarcomatoid 
MPM 
biphasic 
Total number 
of studies 
corrected by 
authors 
Total number of 
studies with a 
statistically 
significant 
deregulation, 
corrected by 
authors 
Final judgment P-value 
ANXA4 1 6 3 UUU    6 3 Up-regulated 6.85E-06 
ASS1 2 7 3 UUU    7 3 Up-regulated 1.19E-05 
JUNB 3 2 2 U U U  2 2 Up-regulated 4.97E-05 
S100A11 3 2 2 UU    2 2 Up-regulated 4.97E-05 
PTGS2 3 2 2 DD    2 2 Down-regulated 4.97E-05 
TMEM176A 3 2 2 UU    2 2 Up-regulated 4.97E-05 
HEG1 3 2 2 UU    2 2 Up-regulated 4.97E-05 
RCN2 3 2 2 UU    2 2 Up-regulated 4.97E-05 
KIF23 3 3 3 UUU    2 2 Up-regulated 4.97E-05 
PLK2 10 3 2 UU    3 2 Up-regulated 1.48E-04 
UBXN4 10 3 2 U U U  3 2 Up-regulated 1.48E-04 
DSP 10 3 2 UU    3 2 Up-regulated 1.48E-04 
EEF2 10 3 2 UU    3 2 Up-regulated 1.48E-04 
FGF9 10 3 2 UU    3 2 Up-regulated 1.48E-04 
HELLS 10 3 2 UU    3 2 Up-regulated 1.48E-04 
SULF1 10 3 2 UU    3 2 Up-regulated 1.48E-04 
KIF14 10 3 2 UU    3 2 Up-regulated 1.48E-04 
NMU 10 3 2 UU    3 2 Up-regulated 1.48E-04 
CENPF 10 4 3 UUU    3 2 Up-regulated 1.48E-04 
TOP2A 10 4 3 UUU    3 2 Up-regulated 1.48E-04 
BUB1 10 4 3 UUU    3 2 Up-regulated 1.48E-04 
CDK2AP1 10 4 3 UUU    3 2 Up-regulated 1.48E-04 
RAD21 10 4 3 UUU    3 2 Up-regulated 1.48E-04 
SSBP1 10 4 3 UUU    3 2 Up-regulated 1.48E-04 
MCM2 10 4 3 UUU    3 2 Up-regulated 1.48E-04 
FGF2 26 4 2 U U U  4 2 Up-regulated 2.94E-04 
SMC4 26 4 2 UU    4 2 Up-regulated 2.94E-04 
CDC2 26 5 3 UUU    4 2 Up-regulated 2.94E-04 
ACSL1 26 4 2 DD    4 2 Down-regulated 2.94E-04 
AURKA 26 5 3 UUU    4 2 Up-regulated 2.94E-04 
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BIRC5 26 5 3 UUU    4 2 Up-regulated 2.94E-04 
MKI67 26 4 2 UU    4 2 Up-regulated 2.94E-04 
AOC3 26 4 2 DD    4 2 Down-regulated 2.94E-04 
PPARA 26 4 2 DD    4 2 Down-regulated 2.94E-04 
TGFBR2 26 4 2 DD    4 2 Down-regulated 2.94E-04 
TSPAN7 26 4 2 DD    4 2 Down-regulated 2.94E-04 
CCNO 26 4 2 UU    4 2 Up-regulated 2.94E-04 
FANCI 26 4 2 UU    4 2 Up-regulated 2.94E-04 
RAN 26 5 3 UUU    4 2 Up-regulated 2.94E-04 
CCNB2 26 5 3 UUU    4 2 Up-regulated 2.94E-04 
SMARCA4 41 5 2 UU    5 2 Up-regulated 4.86E-04 
PTMS 41 6 3 UUU    5 2 Up-regulated 4.86E-04 
CHEK1 41 5 2 UU    5 2 Up-regulated 4.86E-04 
CAV1 41 5 2 DD    5 2 Down-regulated 4.86E-04 
NR4A2 41 5 2 DD    5 2 Down-regulated 4.86E-04 
PECAM1 41 5 2 DD    5 2 Down-regulated 4.86E-04 
SFRP1 41 5 2 DD    5 2 Down-regulated 4.86E-04 
TACC1 41 5 2 DD    5 2 Down-regulated 4.86E-04 
VWF 41 5 2 DD    5 2 Down-regulated 4.86E-04 
IFITM1 41 5 2 UU    5 2 Up-regulated 4.86E-04 
LGALS3BP 41 5 2 UU    5 2 Up-regulated 4.86E-04 
PTGIS 41 5 2 UU    5 2 Up-regulated 4.86E-04 
S100A10 41 5 2 UU    5 2 Up-regulated 4.86E-04 
XPOT 41 5 2 UU    5 2 Up-regulated 4.86E-04 
NME2 41 6 3 UUU    5 2 Up-regulated 4.86E-04 
COL1A1 56 6 2 UU    6 2 Up-regulated 7.24E-04 
CDK4 56 6 2 UU    6 2 Up-regulated 7.24E-04 
CCNB1 56 7 3 UUU    6 2 Up-regulated 7.24E-04 
EGR2 56 6 2 DD    6 2 Down-regulated 7.24E-04 
EGR3 56 6 2 DD    6 2 Down-regulated 7.24E-04 
EPAS1 56 6 2 DD    6 2 Down-regulated 7.24E-04 
ALDOA 56 6 2 UU    6 2 Up-regulated 7.24E-04 
CFB  56 6 2 UU    6 2 Up-regulated 7.24E-04 
CCT2 56 6 2 UU    6 2 Up-regulated 7.24E-04 
CDH11 56 6 2 UU    6 2 Up-regulated 7.24E-04 
COL6A1 56 6 2 UU    6 2 Up-regulated 7.24E-04 
CRIP1 56 6 2 UU    6 2 Up-regulated 7.24E-04 
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EIF4G1 56 6 2 UU    6 2 Up-regulated 7.24E-04 
FHL1 56 6 2 UU    6 2 Up-regulated 7.24E-04 
KIF5B 56 6 2 UU    6 2 Up-regulated 7.24E-04 
MSLN 56 6 2 UU    6 2 Up-regulated 7.24E-04 
PGM1 56 6 2 UU    6 2 Up-regulated 7.24E-04 
PKM2 56 6 2 UU    6 2 Up-regulated 7.24E-04 
PSMD11 56 6 2 UU    6 2 Up-regulated 7.24E-04 
VCAN 56 6 2 UU    6 2 Up-regulated 7.24E-04 
CDK7 56 7 3 UUU    6 2 Up-regulated 7.24E-04 
PCNA 56 7 3 UUU    6 2 Up-regulated 7.24E-04 
GAPDH 56 6 2 UU    6 2 Up-regulated 7.24E-04 
 
Table 10. Genes showing repeated citations in independent studies (ranked by increasing P-values). U= up-regulated; D=down-regulated.                                                                                 
 
 
 
 
 
Table 11. Genes detected by all the three employed DM tools (Coremine, SNPs3D, GeneProspector). All the listed genes show 
a P-value of 5.12x10
-4
 from Coremine. 
 
 
 
 
 
 
Gene Names 
ABCB1 BRCA1 FAS                                 PTGS2
ABCC1 CASP3 FASLG RRM1 
ABCC2 CASP7 GCLM SERPINA1 
ABCC3 CASP9 GPX1 SLC28A1 
ABCC4 CAT  GSTM1 SOD2 
ABCC5 CDKN1A GSTP1 TNF 
ABCG2 CDKN2A IFNG TP53 
AKT1 CYP1A1 IL10 TP73 
AKT2 EPO KRAS VEGFA 
ATM ERBB2 MGMT XPA 
ATP7B ERCC1 MLH1 XPC 
BID  ERCC2 MSH2 XRCC1 
BIRC5 ERCC4 NAT2 XRCC2 
BRAF ESR1 NR1I2 XRCC3 
 59 
 
4.2 Gene expression analysis 
4.2.1 Specificity and efficiency of primers pairs 
The agarose gel electrophoresis (example shown in figure 11) revealed that all primer pairs 
amplified a single PCR product with expected size, ranging between 90 and 110 bp, as small size 
amplicons guarantee the best reaction efficiency. 
 
 
 
 
Figure 11: Analysis of primers pairs specificity 
 
The results of the averaged amplification efficiencies for the candidate target and reference genes 
are shown in table 12 and 13, respectively. The amplification efficiencies ranged between 90.1% 
and 110%, in agreement with the MIQE guidelines. 
  
Gene Symbol 
(HUGO) 
Amplification 
efficiency (%) 
r2 
Gene Symbol 
(HUGO) 
Amplification 
efficiency (%) 
r2 
Gene Symbol 
(HUGO) 
Amplification 
efficiency (%) 
r2 
COL1A1 99.4 0.97 NME2 94.9 0.98 LGALS3BP 104.8 0.97 
HEG1 102.7 0.99 CFB 90.1 0.99 PGK1 95.4 0.97 
FEN1 110 0.99 SOD1 98 0.99 CCNH 110 0.99 
SPINT2 110 0.96 CXADR 96.5 0.98 CDK2AP1 106.2 0.97 
NUSAP1 110 0.99 UPK1B 96.8 0.99 RCN2 98.6 0.98 
CALB2 99.6 0.98 PCNA 90.8 0.98 PTGS2 92.5 0.99 
ASS1 91.1 0.98 ALDOA 97.9 0.98 SYNE1 96.8 0.99 
MCM4 105.9 0.99 THBS1 99.4 0.99 NR3C1 104.3 0.98 
TIMP3 108.8 0.99 BUB1B 94.7 0.97 FGF2 106.4 0.99 
DSP 110 0.97 SSBP1 94.5 0.99 CCND2 98.9 0.99 
TNPO2 107.3 0.99 COL6A1 110 0.99 SARP1 96.2 0.99 
GALNT7 110 0.96 EEF2 94.3 0.99 DAB2 98 0.99 
TMEM176A 110 0.99 RAD21 97.4 0.96 IARS 101.9 0.99 
THBS2 103.1 0.99 CRIP1 93 0.99 CDKN1A 92.4 0.97 
ITGA4 107.3 0.98 FGF9 104.1 0.97 IGFBP4 98.7 0.99 
AKR1C1 105.2 0.98 VCAN 108 0.98 ITGA6 99.3 0.99 
RAN 94.3 0.99 VEGFA 110 0.99 BLMH 107.5 0.99 
PDGFRB 110 0.99 PGM1 90.4 0.99    
 
Table 12: Efficiency of target genes and corresponding correlation coefficient (r
2
) 
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Table 13: Efficiency of reference genes and corresponding r
2 
 
4.2.2 Identification of optimal reference genes 
For a precise comparison of mRNA transcription in different samples or tissues it is crucial to 
choose the appropriate reference genes. In our study, geNorm software showed that RPLP0, HPRT, 
and TBP were the most stable genes in MPM tissues with M value equal to 1.62, 1.62, and 1.66 
respectively (Figure 12).  
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Average expression stability M for the 7 reference genes analyzed 
 
 
4.2.3 Expression levels of selected genes target 
Since we observed heterogeneity among studies and also a biological heterogeneity among tumors, 
in order to ascertain the reproducibility of the findings obtained from different publications, we 
have undertaken a validation study to verify the up- and down-regulation of genes that, from our 
research, are potentially involved in the development and progression of the disease. We analyzed a 
total of 77 genes. Among them, 53 RT-qPCR showed a correct PCR efficiency (90-110%). The 
Gene Symbol  
(HUGO) 
Amplification  
efficiency (%) 
r2 
PPIA 104.3 0.996 
GAPDH 99.8 0.999 
B2M 104.4 0.997 
GUSB 103.7 0.992 
TBP 110 0.992 
HPRT 109.7 0.997 
RPLP0 96.3 0.993 
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remaining 24 genes, whose amplification efficiency was not acceptable with the Eva Green RT-
qPCR, have been analyzed through the TaqMan® assay, whose efficiency is guaranteed to be 
100%. We have analyzed 33 genes detected in both RTS and DM, with high statistical significant 
level for DM (Table 14), 15 genes with low significant level in DM (Table 15), whereas 29 only 
found with the RTS (Table 16). 
Among the total analyzed genes, 36 were found differentially expressed (DE) in a statistically 
significant way (q-value <0.05) in tissues: 34 up-regulated, and 2 down-regulated. All the 
statistically significant DE genes were concordant with the literature reports. Among the remaining 
39 non-statistically significant DE genes, 9 showed an opposite direction of their expression as 
compared to what reported previously in literature. AURKA and BIRC5, although very promising 
(considering that survivin is a novel therapeutic target for lung cancer), did not show any evaluable 
fluorescence signal using both techniques based on Evagreen® and TaqMan® probes. 
 
Gene Symbol Up/Down regulation (see Appendix1) log2(FC) One tail-WT BH qvalue 
TOP2A U 3.073 4.84x10-4 1.33x10-2 6.24x10-3 
CHEK1 U 1.49 5.33x10-4 1.33x10-2 6.24x10-3 
FEN1 U 1.78 1.24x10-3 1.86x10-2 8.74x10-3 
FANCI U 2.53 1.84x10-3 1.97x10-2 9.25x10-3 
CALB2 U 5.67 3.95x10-3 2.96x10-2 1.39x10-2 
SULF1 U 1.47 6.42x10-3 3.79x10-2 1.78x10-2 
CCNO U 3.17 7.99x10-3 3.79x10-2 1.78x10-2 
KRT5 U 1.49 8.45x10-3 3.79x10-2 1.78x10-2 
C10orf116 D -2.13 1.02x10-2 4.02x10-2 1.88x10-2 
SMARCA4 U 0.61 1.10x10-2 4.02x10-2 1.88x10-2 
MSLN U 1.84 1.35x10-2 4.60x10-2 2.16x10-2 
THBS2 U 4.99 2.15x10-2 6.71x10-2 3.15x10-2 
AKR1C1 D -0.22 2.87x10-2 7.69x10-2 3.61x10-2 
PDGFRB U 2.79 2.98x10-2 7.69x10-2 3.61x10-2 
KRT18 U 0.86 4.63x10-2 9.70x10-2 4.55x10-2 
VEGFA U 2.14 8.87x10-2 1.42x10-1 6.63x10-2 
PGK1 U 2.47 1.12x10-1 1.64x10-1 7.69x10-2 
CCNH U 3.054 1.30x10-1 1.88x10-1 8.80x10-2 
EID1 U 0.53 1.74x10-1 2.37x10-1 1.11x10-1 
PECAM1 D -0.34 1.86x10-1 2.50x10-1 1.17x10-1 
FAS U 0.31 2.06x10-1 2.72x10-1 1.27x10-1 
PTGS2 U 0.13 2.48x10-1 3.21x10-1 1.51x10-1 
RHOB U 0.28 2.74x10-1 3.37x10-1 1.58x10-1 
PDGFRA D 0.0027 2.87x10-1 3.47x10-1 1.63x10-1 
DAP U 0.027 3.07x10-1 3.66x10-1 1.71x10-1 
FGF2 U 1.61 4.27x10-1 5.00x10-1 2.34x10-1 
CCND2 D 1.41 5.60x10-1 6.46x10-1 3.03x10-1 
CDKN1A D 1.40 8.48x10-1 9.08x10-1 4.26x10-1 
METAP1 U -0.36 8.59x10-1 9.08x10-1 4.26x10-1 
ASPA U -1.54 9.99x10
-1 1 4.69x10-1 
BLMH U 0.092 1 1 4.69x10-1 
AURKA U Not detected 
BIRC5 U Not detected 
 
Table 14: Analyzed genes detected by both a statistically significant RTS and DM (all listed genes had a P-value 
of 1.77x10
-2 
from DM). In bold, statistically significant results at P-value<0.05. In italics, genes showing an opposite 
trend between what reported in literature and tissue expression verified in our study. log2 (FC)= logarithm in base 2 of  
Fold-Change. One tail-WT = p-value following Wilcoxon test at 1 tail. BH= p-value corrected with Benjamini & 
Hochberg method  (1995). qvalue= p-value corrected with False Discovery Rate, (Storey, 2002). 
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Gene Symbol Up/Down regulation (see Appendix1) log2(FC) One tail-WT BH qvalue 
CENPF U 1.97 1.82x10-3 1.97x10-2 9.25x10-2 
ASS1 U 2.28 6.44x10-3 3.80x10-2 1.78x10-2 
DSP U 4.69 8.61x10-3 3.80x10-2 1.78x10-2 
ITGA4 U 1.04 2.57x10-2 7.68x10-2 3.60x10-2 
NME2 U 1.94 2.98x10-2 7.69x10-2 3.60x10-2 
SOD1 U 2.42 3.26x10-2 7.88x10-2 3.70x10-2 
CXADR U 3.51 3.44x10-2 8.06x10-2 3.78x10-2 
PCNA U 2.52 3.96x10-2 8.74x10-2 4.10x10-2 
PLK2 U 0.81 5.69x10-2 1.10x10-1 5.16x10-2 
BUB1B U -0.10 5.72x10-2 1.10x10-1 5.16x10-2 
EEF2 U 1.87 6.52x10-2 1.16x10-1 5.46x10-2 
RAD21 U 4.81 6.68x10-2 1.16x10-1 5.46x10-2 
MCM2 U 0.82 9.66x10-2 1.51x10-1 7.07x10-2 
LGALS3BP U 1.89 1.01x10-1 1.52x10-1 7.14x10-2 
NR3C1 U 1.083 2.73x10-1 3.37x10-1 1.56x10-1 
 
Table 15: Analyzed genes detected by a statistically significant RTS and with a low significant level in the DM 
(all  listed genes had a P-value of 2.03x10
-1 
from DM). In bold, statistically significant resulst at P-value<0.05. In 
italics, genes showing an opposite trend between what reported in literature and tissutal expression verified in our study. 
log2 (FC)= logarithm in base 2 of  Fold-Change. One tail-WT = p-value following Wilcoxon test at 1 tail. BH= p-value 
corrected with Benjamini & Hochberg method  (1995). qvalue= p-value corrected with False Discovery Rate, (Storey, 
2002). 
 
Gene Symbol Up/Down regulation (see Appendix1) log2(FC) One tail-WT BH qvalue 
COL1A1 U 4.68 2.76x10-4 1.33x10-2 6.24x10-3 
HEG1 U 1.94 9.02x10-4 1.70x10-2 7.93x10-3 
SPINT2 U 4.64 2.81x10-3 2.64x10-2 1.24x10-2 
NUSAP1 U 1.46 3.24x10-3 2.70x10-2 1.26x10-2 
MCM4 U 0.87 7.36x10-3 3.80x10-2 1.78x10-2 
TIMP3 U 1.039 7.80x10-3 3.80x10-2 1.78x10-2 
TNPO2 U 3.80 1.13x10-2 4.02x10-2 1.88x10-2 
GALNT7 U 2.28 1.13x10-2 4.02x10-2 1.88x10-2 
HCA112 U 2.89 2.00x10-2 6.52x10-2 3.06x10-2 
RAN U 3.72 2.96x10-2 7.69x10-2 3.61x10-2 
CFB U 1.0541 3.15x10-2 7.87x10-2 3.69x10-2 
UPK1B U 5.20 3.95x10-2 8.74x10-2 4.10x10-2 
ALDOA U 1.75 4.65x10-2 9.70x10-2 4.55x10-2 
THBS1 U 2.99 5.60x10-2 1.10x10-1 5.16x10-2 
SSBP1 U 2.61 5.90x10-2 1.11x10-1 5.18x10-2 
COL6A1 U 0.85 6.10x10-2 1.12x10-1 5.23x10-2 
CRIP1 U 1.45 7.01x10-2 1.20x10-1 5.60x10-2 
FGF9 U 2.94 8.21x10-2 1.36x10-1 6.40x10-2 
VCAN U 1.48 8.37x10-2 1.36x10-1 6.40x10-2 
PGM1 U 0.90 9.86x10-2 1.51x10-1 7.07x10-2 
CDK2AP1 U 1.48 1.57x10-1 2.22x10-1 1.04x10-1 
RCN2 U 3.54 1.74x10-1 2.37x10-1 1.11x10-1 
SYNE1 U 6.51 2.56x10-1 3.25x10-1 1.52x10-1 
SARP1 U 1.34 6.23x10-1 7.07x10-1 3.31x10-1 
DAB2 U -0.158 6.55x10-1 7.33x10-1 3.44x10-1 
IARS U -0.63 7.53x10-1 8.23x10-1 3.86x10-1 
ANXA4 U -0.36 7.57x10-1 8.23x10-1 3.86x10-1 
IGFBP4 D 1.76 9.66x10-1 1 4.69x10-1 
ITGA6 U 0.016 9.85x10-1 1 4.69x10-1 
       
Table 16: Analyzed genes detected by (statistically significant) RTS only. In bold, statistically significant result at P-
value<0.05. In italics, genes showing an opposite trend between what reported in literature and tissutal expression 
verified in our study. log2 (FC)= logarithm in base 2 of  Fold-Change. One tail-WT = p-value following Wilcoxon test 
at 1 tail. BH= p-value corrected with Benjamini & Hochberg method  (1995). qvalue= p-value corrected with False 
Discovery Rate, (Storey, 2002). 
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In order to validate further the results obtained in the tissues, we performed QPCR measurements of 
the 36 positive genes on two MPM cell lines (Mero-14 and Mero-25; MeT-5A were used as 
reference). The results are reported in table 17. 
 
    
 
Tissue 
samples 
RTS Mero-14 cell line Mero-25 cell line 
 log2(FC) q-value 
Up/ 
Down 
Up/Down-
Table S2 
log2(FC) q-value 
Up/ 
Down 
log2(FC) q-value Up/ Down 
AKR1C1 -0.22 3.61x10-2 D D 13.3 <10-3 U 7.27 <10-3 U 
ALDOA 1.75 4.55x10-2 U U -0.87 4.01x10-1 D 0.35 5.03x10-1 U 
ASS1 2.28 1.78x10-2 U U 0.92 1.73x10-1 U 2.44 <10-3 U 
CALB2 5.67 1.39x10-2 U U -4.77 <10-3 D -0.088 3.69x10-1 D 
CCNO 3.17 1.78x10-2 U U 0.93 7.79x10-3 U 1.51 <10-3 U 
CENPF 1.97 9.25x10-2 U U -1.65 <10-3 D 0.56 1.26x10-2 U 
CFB 1.054 3.69x10-2 U U 5.74 <10-3 U 4.43 <10-3 U 
CHEK1 1.49 6.24x10-3 U U -2.21 <10-3 D -0.0018 6.05x10-1 D 
COL1A1 4.68 6.24x10-3 U U 1.86 4.96x10-1 U 5.50 <10-3 U 
CXADR 3.51 3.78x10-2 U U 0.74 4.96x10-1 U 6.040 <10-3 U 
DSP 4.69 1.78x10-2 U U 0.25 4.96x10-1 U 1.23 5.03x10-1 U 
FANCI 2.53 9.25x10-3 U U -3.10 <10-3 D -2.42 <10-3 D 
FEN1 1.78 8.74x10-3 U U -2.36 <10-3 D -0.73 5.03x10-1 D 
GALNT7 2.28 1.88x10-2 U U 5.69 <10-3 U 4.78 5.13x10-1 U 
HEG1 1.94 7.93x10-3 U U 3.39 3.09x10-1 U 3.740 2.13x10-1 U 
ITGA4 1.042 3.60x10-2 U U 3.71 <10-3 U -0.53 4.89x10-1 D 
KRT18 0.86 4.55x10-2 U U -0.88 7.79x10-3 D 0.15 6.05x10-1 U 
KRT5 1.49 1.78x10-2 U U       1.69 1.98x10-2 U 
MCM4 0.87 1.78x10-2 U U 0.42 4.96x10-1 U 2.024 5.03x10-1 U 
MSLN 1.84 2.16x10-2 U U 1.086 9.31x10-2 U 0.53 5.69x10-1 U 
NME2 1.94 3.60x10-2 U U 2.25 6.39x10-1 U 3.48 5.62x10-1 U 
NUSAP1 1.46 1.26x10-2 U U -2.59 <10-3 D 0.016 5.03x10-1 U 
PCNA 2.52 4.10x10-2 U U -0.020 4.96x10-1 D 1.20 5.03x10-1 U 
PDGFRB 2.79 3.61x10-2 U U 9.83 <10-3 U 8.82 <10-3 U 
RAN 3.72 3.61x10-2 U U 3.27 9.31x10-2 U 5.025 4.65x10-2 U 
SMARCA4 0.61 1.88x10-2 U U -1.70 <10-3 D -0.90 <10-3 D 
SOD1 2.42 3.70x10-2 U U 1.61 6.39x10-1 U 3.93 5.07x10-2 U 
SULF1 1.47 1.78x10-2 U U 9.76 <10-3 U 14.19 <10-3 U 
THBS2 4.99 3.15x10-2 U U 9.65 <10-3 U 7.70 <10-3 U 
TIMP3 1.039 1.78x10-2 U U 0.98 7.79x10-3 U 4.18 <10-3 U 
TNPO2 3.80 1.88x10-2 U U 2.94 6.39x10-1 U 1.017 5.03x10-1 U 
TOP2A 3.073 6.24x10-3 U U -1.98 <10-3 D -0.92 <10-3 D 
 
Table 17: Comparison between results from RTS, measurements in tissue samples, and measurements 
performed in Mero-14 and Mero-25 cell lines. Only genes positive in tissues were measured in cell lines. In bold, 
statistically significant result at P-value<0.05. In italics, genes showing an opposite trend between what reported in 
literature and tissutal expression verified in our study. log2 (FC)= logarithm in base 2 of  Fold-Change. qvalue= p-value 
corrected with False Discovery Rate, (Storey, 2002). 
 
 
Comparing the results obtained on the tissues with those on cell lines, it should be noticed that: 
• 6 genes (CCNO, CFB, PDGFRB, SULF1, THBS2, TIMP3) confirmed the same direction (all up-
regulated) in tissues and both cell lines, in a statistically significant way; 
 • 2 genes (GALNT7 and ITGA4) confirmed the same direction (both up-regulated) in tissues and in 
Mero-14 cell line in a statistically significant way (GALNT7 shows also the same direction in Mero-
25, although in a not-statistically significant way); 
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 • 6 genes (ASS1, CENPF, COL1A1, CXADR, KRT5, and RAN) showed the same trend (all up-
regulated) in tissues and in Mero-25 cell line in a statistically significant way (COL1A1 and RAN 
showed the same direction also in Mero-14, although in a not-statistically significant way); 
 • 4 genes (AKR1C1, FANCI, SMARCA4, and TOP2A) showed the same trend both in Mero-14 and 
Mero-25, but they were in the opposite direction as compared to the tissues; 
The remaining 14 genes were found up-regulated in a statistically significant way only in tissues. 
However, among these genes, HEG1, NME2, and SOD1 showed the same direction also in both the 
cell lines. Moreover, TNPO2, PCNA, and MCM4 showed the same trend in Mero-25, while MSLN 
showed a trend of up-regulation in Mero-14 cell line, close to the statistical significance. 
In summary, ASS1, CCNO, CENPF, CFB, COL1A1, CXADR, GALNT7, ITGA4, KRT5, PDGFRB, 
RAN, SULF1, THBS2, and TIMP3 were genes deregulated in tissues confirmed in at least one cell 
line. Moreover, at least one cell line showed the same trend found in tissues (close to a statistical 
significance) for MSLN, TNPO2, NME2, HEG1, PCNA, SOD1, and MCM4. 
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4.3 Mutation screening of PDGFRB 
 
Among the analyzed genes, an interesting result is the up-regulation of PDGFRB (NM_002609). It 
encodes for a tyrosine-kinase receptor, member of the platelet-derived growth factor (PDGF) 
family. PDGF is composed of homo-dimers or hetero-dimers of two polypeptide chains, denoted A 
and B. These polypeptides are encoded by two distinct genes, showing a high degree of similarity 
(Betsholtz et al., 1986). All three dimeric combinations (AA, AB and BB) were identified 
(Stroobant and Waterfield, 1984; Heldin et al., 1986; Hammacher et al., 1986). Based on ligand-
binding and cross-competition analysis, two different PDGF receptors, alpha and beta, have been 
described (Hart et al., 1988; Heldin et al., 1986). The PDGF-alpha receptor binds all three forms 
with high affinity, whereas the beta-receptor subtype only binds PDGF-BB with high affinity 
(Claesson-Welsh et al., 1988; Hammacher et al., 1988; Seifert et al., 1989). Early, it was observed 
that a panel of human MPM cell lines express PDGF beta-chain and PDGF beta-receptor 
transcripts, whereas normal mesothelial cell lines express no PDGF B-chain mRNA and little or no 
PDGF beta-receptor mRNA (Gerwin et al., 1987; Versnel et al., 1991). It has been suggested that 
normal mesothelium may be responsive to PDGF by the predominant expression of PDGFR-alpha, 
whereas MPM is subjected to a growth self-stimulation loop through PDGF/PDGFR-beta 
interaction (Ascoli et al., 1995). More recent experiments seemed to elucidate a different 
mechanism of tumorigenesis, not involving the autocrine stimulation via PDGF, rather suggesting a 
mechanism of paracrine growth stimulation in MPM (Metheny-Barlow et al., 2001). However, all 
these findings indicated that PDGFRB could be an interesting therapeutic target for MPM, at least 
for those patients expressing PDGFRB in the tumour cells. Following this hypothesis, tyrosine 
kinase inhibitors were assayed as potential new drugs against MPM. One of the most promising 
drug for targeted therapy is Imatinib (imatinib mesylate, STI571; Gleevec or Glivec). Imatinib is an 
ATP-competitive inhibitor that has revolutionized drug therapy of chronic myeloid leukemia. It 
induced cytotoxicity and apoptosis selectively on PDGFRB positive MPM cells via blockade of 
receptor phosphorylation and interference with the Akt pathway (Druker, 2006). Personal 
communication (reported by Dr. L. Mutti, Hospital of Vercelli, Italy) highlighted that PDGFRB was 
assayed for compassionate use in advanced MPM patients in a pre-clinical trial where imatinib was 
administered with gemcitabine, in a combined targeted therapy protocol. Preliminary observations 
reported that patients showed a good response with the stabilization or partial shrinkage of the 
tumor mass. However, some patients either did not respond or, after an initial response, relapsed.  
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In other tumour types, the causes for the resistance to imatinib were, at least in part, ascertained. 
Some specific mutations, the gatekeeper mutations (like T670 and T681) within PDGFRB, make 
cells insensitive to imatinib. Therefore, gastro-intestinal stromal tumor (GIST) patients with these 
mutations respond poorly to imatinib (Corless et al., 2005; Heinrich et al., 2006). The resistance to 
imatinib usually results from the emergence of tumour clones with mutations that prevent drug 
binding (Blencke et al., 2004; Böhmer et al., 2003; Heinrich et al., 2006). The question arises 
whether the mechanisms of lack of response to imatinib in MPM patients are similar to those 
observed in GIST. The frequency of mutations within PDGFRB at the presentation in MPM is 
unknown. Moreover, it is also unknown whether in the MPM the resistance to Imatinib could be 
ascribed to specific mutations within PDGFRB, similarly to what observed in GlST. 
To measure the frequency of these events, we performed a mutation screening of exons 12 and 18 
of PDGFRB, the two exons that commonly show activating somatic mutations in human cancers 
(e.g. in the GIST), in 100 surgically resected MPMs, and we did not found any mutation, as 
reported in table 18. 
 
Number of MPM Exon 12 Exon 18 
92 wt wt 
4 NA NA 
2 NA wt 
1 wt NA 
1 wt 
  c.2523G>A 
                      p.K841K 
 
 
Table 18: Results of the mutation screening of PDGFRB (wt: wild type; NA: no-amplification). 
This led to conclude that the malignancy is not driven by somatic mutations of this gene, but an 
increased expression could be functionally equivalent to a constitutive activation of the receptor. 
Thus, imatinib could be helpful in patients where PDGFRB is over-expressed. In any case, the lack 
of response to imatinib should not be ascribed to mutant PDGFRB, at the presentation. Concerning 
the relapse, we studied an in vitro model. To ascertain whether PDGFRB plays a role in the 
secondary resistance to imatinib, we induced a long-term resistance to imatinib in the over-
expressing PDGFRB Mero-14 cells, and we screened the resistant clones for mutations in exons 12, 
14, and 18 by using Next Generation Sequencing. Again, we could not detect any mutation. 
Moreover, resistant cells were sequenced for c-KIT, and c-MET, two tyrosine kinase receptors, 
frequently mutated in neoplastic diseases, without finding any mutation 
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4.4 Functional study on Mesothelin and Calretinin 
 
4.4.1 Phenotypic tests after knockdown of target genes 
Out of the 77 genes analyzed, also the high levels of MSLN, and CALB2 in MPM samples captured 
our interest, given that these genes are both biomarkers useful for diagnosis and prognosis. 
Unfortunately, few is known about their biological functions. For this reason, in order to ascertain 
whether these genes play some role in maintaining the malignant phenotype, rather to be simply 
epiphenomenons, we used a gene silencing-RNA approach (this part of the work was carried out at 
the laboratories of Prof. Justin Stebbing, and Dr. Georgious Giamas at the Imperial College of 
London, UK).  
The first step was to verify the expression of MSLN and CALB2 in MPM cell lines at protein level. 
Thus, we screened MeT-5A (as reference), and Mero-14 and Mero-25 MPM cell lines for MSLN 
and CALB2 with western blot. We found that Mero-14 over-expressed MSLN as compared to 
MeT-5A  and Mero-25: the difference appeared proportionally more relevant in comparison to the 
increase of mRNA. Mero-14 and Mero-25 were also not expressing CALB2, thus we screened more 
cell lines. Thanks to the collaboration with  Antonio Daga (Istituto Tumori, Genova) we could 
obtain one cell line (IstMes2), over-expressing CALB2 at protein level. Moreover, in order to 
perform more experiments on mesothelin, we included also the cell line NCI-H28, one MPM cell 
line not expressing MSLN. Thus, for all these cell lines we repeated the measurements both of the 
mRNA and the protein levels and the results, confirming our expectations, are reported in figure 13.
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Fig. 13: Basal expression level of MSLN and CALB2 in four MPM cell lines. On the left, RTqPCR showing 
fold change of quantitative mRNA levels of MSLN (on the top), and CALB2 (on the bottom) measured on MPM cell 
lines versus MeT-5A cells. Mean of RPLP0, HPRT, and TBP was used for normalization. Errors bars are SEM of the 
fold change from three independent experiments, each in triplicate. Mero-14 cells showed the highest expression levels 
of MSLN (p =0.02). IstMes2 cells showed the highest expression level of CALB2 (p = 0.017). On the right, the protein 
levels of MSLN and CALB2 on MeT-5A, Mero-14, Mero 25, IstMes2, and NCI-H28 cells. β-Actin was used as loading 
control. The protein levels were confirmed with two independent experiments. 
 
We tested two different siRNAs to get an optimal depletion of MSLN, and other 2 for the depletion 
of CALB2. The knockdown of MSLN was about 90% with both the siRNAs, so we have arbitrarily 
chosen the MSLN siRNA 1 at a concentration of 40 nM. Regarding CALB2, even if at mRNA level, 
the siRNA 6 shows to be more effective, at protein level siRNA 5 seemed more efficient. For this 
reason we have chosen the latter siRNA, at a concentration of 50 nM (Figure 14). However, it 
should be observed that the silencing of CALB2 was not optimal (it was observed only a reduction 
of about 50% of the protein), and not better results could be obtained. 
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Fig. 14: Silencing of MSLN and CALB2 genes. On the left, RTqPCR showing fold change of quantitative mRNA 
levels of MSLN in Mero-14 cells (on the top), and CALB2 in IstMes2 cells (on the bottom) measured to detect the best 
siRNA to be used. Mean of RPLP0, HPRT, and TBP was used for normalization. Errors bars are SEM of the fold 
change from three independent experiments, each in triplicate. The siRNAs chosen for the analysis are MSLN siRNA 1 
(40 nmol; *P=0.002) on Mero-14 cells, and CALB2 siRNA 5 (50 nmol; *P =0.013) on IstMes2 cells. On the right, the 
protein levels of MSLN after its depletion with MSLN siRNA 1 and 2 (40 nmol) versus the control, and of CALB2 after 
its depletion with CALB2 siRNA 5 and 6 (50 nmol) versus the control. β-Actin was used as loading control. The protein 
levels were confirmed with three independent experiments. 
 
After having confirmed the depletion of the target genes in the relevant cell lines, we studied the 
behavior of Mero-14 and IstMes2 cell lines for their culture growth parameters, cell cycle, 
migration, invasion, and apoptosis. 
 
 
 
 
 
 70 
 
siRNA and Growth 
As shown in fig. 15, we observed a significant reduction (p < 0.05) in the proliferation rate of Mero-
14 cells starting from the third day of treatment with MSLN siRNA, and increasing until the 6
th
 day, 
end of the experimental procedure. To elucidate the molecular mechanism underlying this 
phenotypic effect, we evaluated the expression of some of the most important proteins involved in 
the signaling pathways of metastasis and cell proliferation, as pAKT and pERK, and we have 
noticed that following MSLN silencing, we get a reduction of protein expression levels of pAKT 
and pERK. As further step, we induced a transient over-expression of MSLN in the NCI-H28 cells 
that do not express endogen levels of MSLN at RNA and protein levels. Reassuringly, we measured 
increased levels of pAKT and pERK, confirming the link between MSLN expression, proliferation 
and phosphorylation status of AKT and ERK.  
Then, we tested the proliferation rate of IstMes2 cells following the CALB2 knockdown, but we did 
not observe any change for this parameter.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 15: Effect of MSLN on the proliferation. On the left, proliferation assay in Mero-14 cells treated with 40 nmol of 
the Control siRNA (siCt), and MSLN siRNA (siMsln). *P = 0.04. Error bars represent SEM of three separate 
experiments, each done in quadruplicate. On the right, Western blotting analysis of Mero-14-control, Mero-14-MSLN 
siRNA, NCI-H28-empty vector, and NCI-H28-overexpressing MSLN vector with indicated antibodies. β-Actin was 
used as loading control. The protein levels were confirmed with three independent experiments. 
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We studied further the growth by employing the 3D Matrigel-overlay model, where the conditions 
have more similarities with the physiological growth conditions, allowing the integration of crucial 
extracellular matrix signaling. In the tridimensional contest, after having silenced MSLN, Mero-14 
cells formed spheres smaller and more uniform, acquiring a shape closely resembling that of 
nonmalignant cells, compared to the control. With the depletion of CALB2, the spheres were bigger 
and they lost morphological uniformity. The cells formed grape-like complexes, characterized by 
the absence of functional cell-cell adhesion and increased invasive behavior (Fig. 16). We have also 
measured the dimension of the single spheres created by Mero-14 cells. We got 72.5% of the 
spheres bigger than 40 µm in the control group, and 22.5% in the group treated with MSLN siRNA. 
The measure of grape-like structures formed by IstMes2, and the consequential comparing with the 
control group were not possible because of the characteristic unusual jagged shape obtained 
following the depletion of CALB2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 16: Effect of gene silencing on the growth on 3D-matrigel. MSLN and CALB2 knock-down affect morphological 
features of Mero-14 and IstMes2 cell lines respectively. The picture represents the phase contrast microscopy of         
Mero-14 (a), and IstMes2 (b) cells cultured in 3D Matrigel-overlay chambers after silencing of MSLN 40nM (a), and 
CALB2 50nM (b). Magnification 10X. Two different experiments, each in triplicate. On the right, the percentage of 
Mero-14 cells, having different dimension in the group treated with MSLN siRNA, versus the control.  
 
 
(a) 
(b) 
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siRNA and Cell cycle 
To examine the effect of MSLN and CALB2 silencing on cell cycle progression, Mero-14 and 
IstMes2 cells were treated with CT siRNA or MSLN and CALB2 siRNA for 72 h and analyzed with 
FACS Diva Software, allowing measuring the share of cells in each stage of the cell cycle.  
We observed a decreased share of cells in S/G2M-phases following the treatment with the MSLN 
siRNA (although the difference with controls was not statistically significant) (Figure 17). No 
significant differences were noticed after depletion of CALB2 (not showed). 
 
 
 
Fig. 17: Progression of cell cycle. The graph shows the percentage of cells in phase S/G2M in Mero-14 treated with 
with 40 nmol of the Control siRNA, and MSLN siRNA. Error bars represent SEM of four separate experiments.  
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siRNA and Migration/Invasion 
With the Wound-Healing Assay we have monitored the migration of cells into a scratch made in a 
confluent monolayer, after the knockdown of MSLN and CALB2 within 72h. We could not detect 
any statistically significant difference for both the treatments (figure 18). On the contrary, the 
invasion, performed with the trans-well assay, showed a reduction (indicative of a reduced 
metastatic capability) of the Mero-14 cells (p < 0.05), after 48h of treatment with MSLN siRNA. On 
the other hand, even if in not statistical significant way, the depletion of CALB2 increased 
invasiveness, according with the findings obtained with the 3D Matrigel-overlay model (Fig. 19).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 18: Scratch assay of gene silenced cells. Confluent monolayers of Mero-14 cells on the top, and IstMes2 cells on 
the bottom, were pretreated for 72 hr with 40 nmol of the Control siRNA, and MSLN siRNA, and 50 nmol of the 
Control siRNA, and CALB2 siRNA respectively. After introducing a scratch, cells were incubated in full medium and 
visualized 36 hr later the Mero-14 cells, and 20 hr later the IstMes2 cells. Two different experiments were performed, 
each in triplicate.  
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Fig. 19: Transwell assay of gene silenced cells. On the top, transwell invasion assay of Mero-14 cells treated with 40 
nmol of the Control siRNA, and MSLN siRNA (*P = 0.0044). Error bars represent SEM of two separate experiments, 
each done in triplicate. On the bottom, the picture of the transwell invasion assay of IstMes2 cells treated with 50 nmol 
of the Control siRNA, and CALB2 siRNA.  
 
siRNA and Apoptosis 
Subsequently, we measured the apoptotic level of MPM cells after the knockdown of MSLN and 
CALB2. We observed that the depletion of the target genes did not affect the degree of caspases 
released (data not showed). 
 
4.4.2 Combination between MSLN/CALB2 siRNA and drugs 
We tested the effect of the gene silencing (either MSLN or CALB2), and the administration of 
chemotherapeutics drugs including cisplatin, commonly used in MPM patients, gemcitabine, and 
imatinib, promising drugs next to be assayed in clinical trials, alone, or in various combinations. 
Following these treatments, we studied the proliferation rates, the cell cycle, and the apoptosis of 
Mero-14 and IstMes2. 
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siRNA+chemotherapeutic drugs and proliferation 
Regarding the proliferation assay, we observed an additive effect when Mero-14 cells were treated 
with MSLN siRNA alone, cisplatin 5 µM alone, or the combination between the two agents (Figure 
20) (p < 0.05). For CALB2 siRNA on IstMes2, or the use of gemcitabine/imatinib (alone or in 
combination with or without siRNAs, in both the cell lines) we did not observe any effect and, for 
brevity, data were not showed.  
 
 
 
Fig. 20: Proliferation assay in Mero-14 cells treated with 40 nmol of the Control siRNA (siCt), plus 5 µM of Cisplatin, 
and MSLN siRNA, plus 5 µM of Cisplatin. The graph shows an additive effect between MSLN siRNA, and 5 µM of 
Cisplatin, compared with the single reagents (*P=0.009). Error bars represent SEM of three separate experiments, each 
done in quadruplicate. 
 
 
siRNA+ chemotherapeutic drugs and Cell cycle 
We did not observe any significant difference on the cell cycle progression after the treatment with 
MSLN/CALB2 siRNA and different concentrations (5-10-20 µM) of cisplatin, gemcitabine, 
imatinib, and the combination between gemcitabine, and imatinib. However, a slight reduction of 
the share of cells in the S+G2+M phase of the cell cycle was also observed in MSLN siRNA treated 
cells, as compared to Control-siRNA, in presence of cisplatin, confirming the same trend found in 
previous experiments when cisplatin was not added to the cultures. 
Intriguingly, combining the experiments (those with and without cisplatin), a statistically significant 
difference could be observed where the share of cells in the S+G2+M phase of the cell cycle was 
slightly reduced following the treatment with MSLN siRNA (Fig. 21).  
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Fig. 21: Progression of cell cycle. The graph shows the percentage of cells in phase S/G2M in Mero-14 treated with 40 
nmol of the Control siRNA, and MSLN siRNA for the individual experiments (Exp.1–Exp.6) with and without cisplatin 
5 µM. The S+G2+M phase of the cell cycle was slightly reduced following the treatment with MSLN-siRNA                   
(*P= 0.022).  
  
siRNA+chemotherapeutic drugs and apoptosis 
The combined effect detected between MSLN siRNA and cisplatin 5 µM in the proliferation assay 
could be explained by results obtained when apoptosis was measured in Mero-14 cells. The 
Caspase - Glo® 3/7 assay employed measures the amount of caspase 3 and 7, involved in the 
intrinsic apoptotic pathway, where high absorbance values correspond to a high amount of caspases 
released (i.e. increased apoptosis). Interestingly, we found a synergistic effect of the treatment with 
MSLN siRNA and cisplatin. MSLN siRNA or cisplatin alone, do not seem to be able to induce 
apoptosis on Mero-14 cells. However, combined together, the cells show a statistically significant 
increased apoptosis, as it can be seen in Figure 22. In order to further investigate this finding, we 
tested some of the most important proteins involved in the apoptotic process, such as p53, and 
PARP. As shown in Figure 22, the combination between MSLN siRNA, and cisplatin 5-10-20 µM 
led to a stronger expression of the pro-apoptotic signals (i.e. up-regulation of p53 and PARP 
cleavage), compared with the treatments performed with MSLN siRNA or cisplatin alone. The 
effect on apoptosis is visible already from 5 µM of cisplatin, and it is more evident when 10µM is 
used.  
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Fig. 22: Interaction between cisplatin and MSLN-siRNA on the apoptosis of Mero-14 cells. On the left, apoptosis 
assay performed on Mero-14 cells treated with 40 nmol of the Control siRNA, plus 5 µM of Cisplatin, and MSLN 
siRNA, plus 5 µM of Cisplatin. The graph shows a synergistic effect between MSLN siRNA, and 5 µM of Cisplatin, 
compared with the single reagents (*P=0,018). Error bars represent SEM of three independent experiments, each done 
in triplicate. On the right, Western blotting analysis of Mero-14-control plus 5 µM of Cisplatin, Mero-14-MSLN siRNA 
plus 5 µM of Cisplatin, Mero-14-control plus 10 µM of Cisplatin, Mero-14-MSLN siRNA plus 10 µM of Cisplatin, and 
Mero-14-control plus 20 µM of Cisplatin, Mero-14-MSLN siRNA plus 20 µM of Cisplatin, with indicated antibodies. β-
Actin was used as loading control. The protein levels were confirmed with three independent experiments.  
 78 
 
5. Discussion 
 
 
The high lethality of MPM results from the aggressive phenotype, the difficulty of an early 
diagnosis, and the inability of current treatments to cure the disease. MPM is a tumor poorly  
studied (mainly due to its low incidence), and there is the need to identify the role of 
genes/pathways in the development of the MPM and to obtain new therapeutic targets for a 
development of a specific targeted therapy. 
In the present study, starting from a huge panel of genes analyzed through microarrays in different 
publications, we focused our attention on a group of RNA markers that more redundantly 
appeared as de-regulated in the MPM, and that could be potentially involved in the carcinogenesis 
of this neoplasm. The screening we made could help to identify a set of genes useful for diagnosis 
and, potentially, for personalized therapies. Indeed, it is well known that every tumor is extremely 
heterogeneous, and it is likely that, in addition to the distinction between the known subtypes of 
MPM, differences between individuals with the same histotype of tumor are present.  
We found that the deregulated genes are mainly involved in processes as DNA replication, and 
cell-cell, and cell-matrix interaction. Genes such as FEN1, MCM4, CCNO, AKR1C1 and PCNA 
are markers of proliferation, and their over-expression at the RNA level is in agreement with other 
experimental evidence. Indeed, FEN1 was found up-regulated in metastatic prostate cancer cells 
(Latulippe et al., 2002), gastric cancer cells (Kim et al., 2005), neuroblastomas (Krause et al. 
2005) and in lung cancer cell lines (Sato et al., 2003). The elevated expression of MCM4 in lung 
cancer, compared to the adjacent bronchial epithelial cells or various normal tissues, is consistent 
with the fact that MCM proteins are highly expressed in cancer cells and in human pre-cancerous 
cells, while they are not expressed in differentiated somatic cells and in quiescent cells (Freeman 
et al., 1999). AKR1C1, a member of the aldo-keto reductase superfamily, is associated with 
decreased levels of progesterone, and it is involved in proliferation, and differentiation of 
endometrial cells. Inhibitors of AKR1C1 have been suggested as potential agents for treatment of 
endometrial cancer and endometriosis (Brozic et al., 2009). In some human cancers, such as 
gastric cancer, an increased immunoreactivity of PCNA has been related to a worse prognosis 
(Jain et al., 1991). Concerning the interaction cell-cell and cell-matrix, among the genes 
significantly up-regulated in our cases of MPM, we can find components of the cellular matrix (as 
COL1A1 and TIMP3), cell adhesion molecules (CAM integrins, as ITGA4), receptors of growth 
factors, and glycoproteins (as THBS2, and MSLN). Cell adhesion allows and promotes biological 
processes such as growth, survival, migration and metastasis. In addition, it is one of the causes 
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for the drug resistance in blood cancers as well as in neuroblastoma, MPM, pancreatic, lung and 
breast cancer. Finally, it protects against cell death due to radiation, genotoxic chemotherapy, or 
targeted inhibitors (Schmidmaier and Baumann, 2008). Worthy of note is also the over-expression 
of TOP2A, and SULF1: TOP2A encodes a DNA topoisomerase, proposed as a negative prognostic 
marker of the breast cancer and it has also been associated with a positive response to 
anthracycline-based therapy (Brase et al., 2010). Roe et al., (Roe et al., 2010) were the first to 
detect the over-expression of TOP2A in cases of MPM, confirmed by our work. The protein 
encoded by the gene SULF1 modulates the activity of many growth factors and signaling 
molecules. This gene is clearly over-expressed in brain cancer, breast cancer, colon 
adenocarcinoma, skin carcinoma, esophageal and gastric cancer, tumors of the head and neck, 
lung cancer, MPM, pancreatic cancer, and sarcoma (Rosen et al., 2010).  
However, out of the analyzed genes, the high levels of MSLN, and CALB2 in the MPM group 
captured our interest, appearing as the most promising MGs from which to start functional studies, 
by using RNA interference, and pharmacological approach.  
The properties of calretinin and its role in carcinogenesis of the MPM are not known, but 
experimental evidences (Kinoshita et al., 2013; Kao et al., 2011) show that this marker is up-
regulated in malignant pleural tissues, with immuno-histochemical analysis, and that, at 
diagnostics level, it is a marker commonly employed for discriminating the MPM especially of 
epithelial type, from other forms of cancer, such as the lung adenocarcinoma (Hyun et al., 2012; 
Mohammad et al., 2012). Up to now, only a scientific paper reported the increase of mRNA 
expression of CALB2 (Melotti et al., 2010). In the colorectal cancer cells (CRC),  Stevenson et al., 
have investigated the role of CALB2, in regulating the response to 5-Fluorouracil (5-FU). They 
have reported that 5-FU-induced apoptosis was significantly reduced in CRC cell lines in which 
CALB2 expression had been silenced, suggesting that following 5-FU treatment in CRC cell lines, 
CALB2 is involved in apoptosis induction through the intrinsic mitochondrial pathway. Moreover, 
down-regulation of CALB2 in response to 5-FU may represent an intrinsic mechanism of 
resistance to this anti-cancer drugs (Stevenson et al., 2011). Gander et al., have observed that after 
the depletion of CALB2 in the colon adenocarcinoma cell line WiDr, the morphology of these 
epithelial cells changed from a polygonal to a spherical shape and they formed dense cell clusters, 
displaying morphological alterations typical for apoptotic cells. Moreover, they have reported also 
an accumulation of cells in phase G1, highlighting that CALB2 may have an impact on the 
progression of the cell cycle of  WiDr cells (Gander et al., 1996). On the contrary, the silencing of 
CALB2 did not produce significant effects in our experimental system. The only effect obtained 
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did not promote tumor regression, but increased the motility and the invasion capabilities of 
cancer cells, indicating a probable involvement of this protein in a feed-back mechanism. An 
observation worthy of note, in the IstMes2 cells, and that could explain the lack of positive 
phenotypic effects, following CALB2 depletion is that the decrease in the levels of the target gene 
was not optimal, despite many trials setting, made by varying the concentrations of siRNA, times 
of treatment, and types of siRNA. The decrease of calretinin that we obtained was in fact around 
50%, perhaps not sufficient to get evidences on the malignant phenotype. It is plausible indeed, 
that the 50% of calretinin, still active was sufficient for the cells to maintain their characteristic 
picture of malignancy. On the other hand, however, it should be noticed that the other MPM cell 
lines, that we have previously screened for CALB2, did not express high levels of this target. So, it 
is not clear whether the results we have achieved depend on the extreme variability, and 
heterogeneity of MPM, or by the fact that the calretinin is not a gene closely linked to 
tumorigenesis, but only an epiphenomenon. 
The present study highlighted the important role of MSLN in the carcinogenesis of the MPM. 
Indeed, the MSLN transient genetic silencing in Mero-14 cells compromised their proliferation 
rate, their invasion capacity, and their ability to form big spheroids. From this experimental 
evidences, it seems that the depletion of MSLN causes the arrest of some of the most important 
characteristics malignant phenotypes. For this reason, MSLN could be considered not only a 
promising diagnostic marker, but also a molecular target for the cure of the MPM. With this work 
we have confirmed findings already revealed by Wang et al. They have reported that specific gene 
silencing for MSLN by distinct methods (siRNA and microRNA) decreased viability of cancer 
cells from different origins, such as MPM (H2373), ovarian cancer (Skov3 and Ovcar-5) and 
pancreatic cancer (Miapaca2 and Panc-1). Additionally, the invasiveness of cancer cells was also 
significantly decreased upon such treatment, suggesting that the molecular mechanism of reduced 
invasiveness was connected to the reduced expression of b-Catenin, an important marker of EMT 
(epithelial-mesenchymal transition). Ero1, a protein involved in clearing unfolded proteins and a 
member of the ER-Stress (endoplasmic reticulum-stress) pathway was also markedly reduced. 
Furthermore, they have found that the MSLN knock-down caused a significant increase in fraction 
of cancer cells in S-phase (Wang et al. 2012). On the contrary, for the Mero-14 cells we have 
observed an increase in fraction of cells in G0-G1 phase, in agreement with the significant stop of 
cell proliferation, that paralleled with the decreased expression of the PI3K/AKT survival 
pathway. Reassuringly MSLN over-expression in NCI-H28 cells showed opposite activity of 
PI3K/AKT pathway. In addition, to earlier described findings, this study did reveal changes not 
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previously described, as the morphological changes in a tridimensional contest of the spheroid 
cultured in the matrigel. An important and innovative result is that using RNA interference, we 
showed that MSLN depletion sensitized Mero-14 cell lines to cisplatin, and that under this 
treatment, they displayed an apoptotic type of cell death, and a substantial arrest of the 
proliferation rate. Moreover, the combination of MSLN siRNA (depletion) with cisplatin enhanced 
the apoptotic rate measured as the activation of Caspases 3 and 7 (that paralleled with the high 
expression of p53, and the cleavage of PARP, at protein level). Taken together these findings 
reveal that the inhibition of MSLN, as a potential novel strategy for targeting MPM, could be a 
very promising approach, especially in combination with standard chemotherapies. 
In this regard, monoclonal antibodies against mesothelin are being evaluated for the treatment of 
MPM and multiple forms of cancers (Macura et al., 2012; Al-Taei et al., 2012; Kelly et al., 2012), 
and show great promise for clinical development for solid cancers. Antibodies against mesothelin 
have been shown to act via immunotoxin-based inhibition of tumor growth and induction of 
antibody-dependent cellular cytotoxicity (ADCC). Very recently, Tang et al., used phage display 
antibody engineering technology and synthetic peptide screening to identify SD1, a human single-
domain antibody to mesothelin. And they have generated a recombinant human Fc (SD1-hFc) 
fusion protein. Interestingly, the SD1-hFc protein exhibits strong complement-dependent 
cytotoxicity (CDC) activity, in addition to ADCC, against mesothelin-expressing tumor cells. 
Furthermore, it causes growth inhibition of human tumor xenografts in nude mice as a single agent 
(Tang et al., 2013). Some of the therapeutic agents that target cell surface mesothelin have been 
evaluated in preclinical and clinical studies. Recombinant immunotoxin SS1P is composed of a 
variable fragment (Fv) of SS1 and a truncated form of Pseudomonas exotoxin A (PE) (Chowdhury 
et al., 1998; Chowdhury et al., 1999). Two phase I clinical trials of SS1P were completed at the 
U.S. National Cancer Institute (NCI) (Hassan et al., 2007; Kreitman et al., 2009). MORAb-009 
(amatuximab), a chimeric (mouse/human) antibody containing murine SS1 Fv and human IgGγ1 
and k constant regions, was developed (Hassan et al., 2007). A phase I clinical trial of MORAb-
009 for MPM, pancreatic cancer and ovarian cancer patients was recently completed (Hassan et 
al., 2010). A total of 24 subjects were treated, including 13 MPM, 7 pancreatic cancer, and 4 
ovarian cancer patients. Eleven subjects had stable disease. Phase II studies of MORAb-009 in 
different mesothelin-expressing cancers are ongoing. 
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6. Conclusions and future perspectives 
 
The results prompt the conclusion that, keeping with the screening of RNA markers in MPM 
samples, we can identify a panel of MGs specific for the analyzed disease. Regarding the negative 
outcome of mutational analysis, we supposed that the malignancy is not driven by somatic 
mutations of PDGFRB, but it could be involved in MPM because of its increased expression (that 
could be functionally equivalent to a constitutive activation), rather than somatic mutations. As 
regard the CALB2 depletion, from our negative finding we can hypothesize that this gene does not 
seem intimately linked in triggering the disease. Finally, the most important result of this work 
provide evidence for a possible use of MSLN siRNA alone or in combination with chemotherapy 
for the treatment of MPM.  
For the future, it could be interesting adopt the same approach that we employed to study the 
behavior of MSLN and CALB2, also in order to analyze the other genes resulted up-regulated in 
the MPM. This disease is rare, and for this reason, acquiring a large set of sample results very 
difficult. This represents a strong challenge that could allow to further validate our finding in an 
independent and larger number of specimens. 
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Appendix 1. Number of studies statistically significant with Up-regulation >1.3-fold or Down-
regulation <0.7-fold   
Gene name 
from official 
HUGO 
nomenclature 
Gene name 
as reported 
in the 
manuscript 
Rank 
Total 
number 
of 
studies 
Total 
number of 
studies with 
a 
statistically 
significant 
deregulation  
MPM 
unspecified 
MPM 
epithelioid 
MPM 
sarcomatoid 
MPM 
biphasic 
Total 
number 
of studies 
corrected 
by 
authors 
Total 
number of 
studies with 
a statistically 
significant 
deregulation, 
corrected by 
authors 
Final 
judgment 
P-value 
Reference 
(1) 
Reference 
(2) 
Reference 
(3) 
ANXA4 ANXA4 1 6 3 UUU 
   
6 3 Up-regulated 6,85E-06 PMID:12912960 PMID:14732480 PMID:15920167 
ASS1 ASS1 2 7 3 UUU 
   
7 3 Up-regulated 1,19E-05 PMID:12912960 PMID:14732480 PMID:15920167 
JUNB JUNB 3 2 2 U U U 
 
2 2 Up-regulated 4,97E-05 PMID:11251971 PMID:15136399 
 
S100A11 S100A11 3 2 2 UU 
   
2 2 Up-regulated 4,97E-05 PMID:15920167 PMID:12912960 
 
PTGS2 PTGS2 3 2 2 DD 
   
2 2 Down-regulated 4,97E-05 PMID:12912960 PMID:15920167 
 
TMEM176A HCA112 3 2 2 UU 
   
2 2 Up-regulated 4,97E-05 PMID:14732480 PMID:15920167 
 
HEG1 KIAA1237 3 2 2 UU 
   
2 2 Up-regulated 4,97E-05 PMID:14732480 PMID:15920167 
 
RCN2 RCN2 3 2 2 UU 
   
2 2 Up-regulated 4,97E-05 PMID:12912960 PMID:15920167 
 
KIF23 KIF23 3 3 3 UUU 
   
2 2 Up-regulated 4,97E-05 PMID:19753302 PMID:19380173 PMID:19662092 
PLK2 PLK2 10 3 2 UU 
   
3 2 Up-regulated 1,48E-04 PMID:11034307 PMID:15920167 
 
UBXN4 UBXN4 10 3 2 U U U 
 
3 2 Up-regulated 1,48E-04 PMID:15136399 PMID:15920167 
 
DSP DSP 10 3 2 UU 
   
3 2 Up-regulated 1,48E-04 PMID:12912960 PMID:15920167 
 
EEF2 EEF2 10 3 2 UU 
   
3 2 Up-regulated 1,48E-04 PMID:12912960 PMID:15920167 
 
FGF9 FGF9 10 3 2 UU 
   
3 2 Up-regulated 1,48E-04 PMID:14732480 PMID:15920167 
 
HELLS HELLS 10 3 2 UU 
   
3 2 Up-regulated 1,48E-04 PMID:19753302 PMID:19662092 
 
SULF1 KIAA1077 10 3 2 UU 
   
3 2 Up-regulated 1,48E-04 PMID:14732480 PMID:15920167 
 
KIF14 KIF14 10 3 2 UU 
   
3 2 Up-regulated 1,48E-04 PMID:19753302 PMID:19380173 
 
NMU NMU 10 3 2 UU 
   
3 2 Up-regulated 1,48E-04 PMID:14732480 PMID:15920167 
 
CENPF CENPF 10 4 3 UUU 
   
3 2 Up-regulated 1,48E-04 PMID:19753302 PMID:19380173 PMID:19662092 
TOP2A TOP2A 10 4 3 UUU 
   
3 2 Up-regulated 1,48E-04 PMID:19753302 PMID:19380173 PMID:19662092 
BUB1 BUB1 10 4 3 UUU 
   
3 2 Up-regulated 1,48E-04 PMID:19753302 PMID:19380173 PMID:19662092 
CDK2AP1 CDK2AP1 10 4 3 UUU 
   
3 2 Up-regulated 1,48E-04 PMID:19380173 PMID:19662092 PMID:15920167 
RAD21 RAD21 10 4 3 UUU 
   
3 2 Up-regulated 1,48E-04 PMID:19380173 PMID:19662092 PMID:15920167 
SSBP1 SSBP1 10 4 3 UUU 
   
3 2 Up-regulated 1,48E-04 PMID:19380173 PMID:19662092 PMID:15920167 
MCM2 MCM2 10 4 3 UUU 
   
3 2 Up-regulated 1,48E-04 PMID:19753302 PMID:19380173 PMID:19662092 
FGF2 FGF2 26 4 2 U U U 
 
4 2 Up-regulated 2,94E-04 PMID:15136399 PMID:11034307 
 
SMC4 SMC4 26 4 2 UU 
   
4 2 Up-regulated 2,94E-04 PMID:19662092 PMID:15920167 
 
CDC2 CDC2 26 5 3 UUU 
   
4 2 Up-regulated 2,94E-04 PMID:19753302 PMID:19380173 PMID:19662092 
ACSL1 ACSL1 26 4 2 DD 
   
4 2 Down-regulated 2,94E-04 PMID:19753302 PMID:15920167 
 
AURKA AURKA 26 5 3 UUU 
   
4 2 Up-regulated 2,94E-04 PMID:19753302 PMID:19380173 PMID:19662092 
BIRC5 BIRC5 26 5 3 UUU 
   
4 2 Up-regulated 2,94E-04 PMID:19753302 PMID:19380173 PMID:19662092 
MKI67 MKI67 26 4 2 UU 
   
4 2 Up-regulated 2,94E-04 PMID:19753302 PMID:19380173 
 
AOC3 AOC3 26 4 2 DD 
   
4 2 Down-regulated 2,94E-04 PMID:19753302 PMID:15920167 
 
PPARA PPARA 26 4 2 DD 
   
4 2 Down-regulated 2,94E-04 PMID:19753302 PMID:19662092 
 
TGFBR2 TGFBR2 26 4 2 DD 
   
4 2 Down-regulated 2,94E-04 PMID:19662092 PMID:15920167 
 
TSPAN7 TSPAN7 26 4 2 DD 
   
4 2 Down-regulated 2,94E-04 PMID:19753302 PMID:15920167 
 
CCNO CCNO 26 4 2 UU 
   
4 2 Up-regulated 2,94E-04 PMID:19380173 PMID:14732480 
 
FANCI FANCI 26 4 2 UU 
   
4 2 Up-regulated 2,94E-04 PMID:19753302 PMID:19380173 
 
RAN RAN 26 5 3 UUU 
   
4 2 Up-regulated 2,94E-04 PMID:19380173 PMID:19662092 PMID:15920167 
CCNB2 CCNB2 26 5 3 UUU 
   
4 2 Up-regulated 2,94E-04 PMID:19753302 PMID:19380173 PMID:19662092 
SMARCA4 SMARCA4 41 5 2 UU 
   
5 2 Up-regulated 4,86E-04 PMID:19753302 PMID:15920167 
 
PTMS PTMS 41 6 3 UUU 
   
5 2 Up-regulated 4,86E-04 PMID:19380173 PMID:12912960 PMID:19662092 
CHEK1 CHEK1 41 5 2 UU 
   
5 2 Up-regulated 4,86E-04 PMID:19753302 PMID:19380173 
 
CAV1 CAV1 41 5 2 DD 
   
5 2 Down-regulated 4,86E-04 PMID:19662092 PMID:15920167 
 
NR4A2 NR4A2 41 5 2 DD 
   
5 2 Down-regulated 4,86E-04 PMID:19662092 PMID:15920167 
 
PECAM1 PECAM1 41 5 2 DD 
   
5 2 Down-regulated 4,86E-04 PMID:19753302 PMID:15920167 
 
SFRP1 SFRP1 41 5 2 DD 
   
5 2 Down-regulated 4,86E-04 PMID:12912960 PMID:15920167 
 
TACC1 TACC1 41 5 2 DD 
   
5 2 Down-regulated 4,86E-04 PMID:19753302 PMID:15920167 
 
VWF VWF 41 5 2 DD 
   
5 2 Down-regulated 4,86E-04 PMID:19753302 PMID:15920167 
 
IFITM1 IFITM1 41 5 2 UU 
   
5 2 Up-regulated 4,86E-04 PMID:14732480 PMID:15920167 
 
LGALS3BP LGALS3BP 41 5 2 UU 
   
5 2 Up-regulated 4,86E-04 PMID:12912960 PMID:15920167 
 
PTGIS PTGIS 41 5 2 UU 
   
5 2 Up-regulated 4,86E-04 PMID:14732480 PMID:15920167 
 
S100A10 S100A10 41 5 2 UU 
   
5 2 Up-regulated 4,86E-04 PMID:12912960 PMID:15920167 
 
XPOT XPOT 41 5 2 UU 
   
5 2 Up-regulated 4,86E-04 PMID:19380173 PMID:15920167 
 
NME2 NME2 41 6 3 UUU 
   
5 2 Up-regulated 4,86E-04 PMID:19380173 PMID:15920167 PMID:19662092 
COL1A1 COL1A1 56 6 2 UU 
   
6 2 Up-regulated 7,24E-04 PMID:14732480 PMID:15920167 
 
CDK4 CDK4 56 6 2 UU 
   
6 2 Up-regulated 7,24E-04 PMID:15920167 PMID:20043850 
 
CCNB1 CCNB1 56 7 3 UUU 
   
6 2 Up-regulated 7,24E-04 PMID:19753302 PMID:19380173 PMID:19662092 
EGR2 EGR2 56 6 2 DD 
   
6 2 Down-regulated 7,24E-04 PMID:19662092 PMID:15920167 
 
EGR3 EGR3 56 6 2 DD 
   
6 2 Down-regulated 7,24E-04 PMID:19662092 PMID:15920167 
 
EPAS1 EPAS1 56 6 2 DD 
   
6 2 Down-regulated 7,24E-04 PMID:19753302 PMID:15920167 
 
ALDOA ALDOA 56 6 2 UU 
   
6 2 Up-regulated 7,24E-04 PMID:12912960 PMID:15920167 
 
CFB BF 56 6 2 UU 
   
6 2 Up-regulated 7,24E-04 PMID:14732480 PMID:15920167 
 
CCT2 CCT2 56 6 2 UU 
   
6 2 Up-regulated 7,24E-04 PMID:19380173 PMID:15920167 
 
CDH11 CDH11 56 6 2 UU 
   
6 2 Up-regulated 7,24E-04 PMID:14732480 PMID:15920167 
 
COL6A1 COL6A1 56 6 2 UU 
   
6 2 Up-regulated 7,24E-04 PMID:19753302 PMID:15920167 
 
CRIP1 CRIP1 56 6 2 UU 
   
6 2 Up-regulated 7,24E-04 PMID:14732480 PMID:15920167 
 
EIF4G1 EIF4G1 56 6 2 UU 
   
6 2 Up-regulated 7,24E-04 PMID:12912960 PMID:14732480 
 
FHL1 FHL1 56 6 2 UU 
   
6 2 Up-regulated 7,24E-04 PMID:14732480 PMID:15920167 
 
KIF5B KIF5B 56 6 2 UU 
   
6 2 Up-regulated 7,24E-04 PMID:19380173 PMID:15920167 
 
MSLN MSLN 56 6 2 UU 
   
6 2 Up-regulated 7,24E-04 PMID:14732480 PMID:15920167 
 
PGM1 PGM1 56 6 2 UU 
   
6 2 Up-regulated 7,24E-04 PMID:14732480 PMID:15920167 
 
PKM2 PKM2 56 6 2 UU 
   
6 2 Up-regulated 7,24E-04 PMID:19662092 PMID:15920167 
 
PSMD11 PSMD11 56 6 2 UU 
   
6 2 Up-regulated 7,24E-04 PMID:19380173 PMID:14732480 
 
VCAN VCAN 56 6 2 UU 
   
6 2 Up-regulated 7,24E-04 PMID:14732480 PMID:15920167 
 
CDK7 CDK7 56 7 3 UUU 
   
6 2 Up-regulated 7,24E-04 PMID:19380173 PMID:11034307 PMID:19662092 
PCNA PCNA 56 7 3 UUU 
   
6 2 Up-regulated 7,24E-04 PMID:19380173 PMID:11034307 PMID:19662092 
GAPDH GAPDH 56 6 2 UU 
   
6 2 Up-regulated 7,24E-04 PMID:12912960 PMID:15920167 
 
ITGA4 ITGA4 79 8 3 UUU 
   
7 2 Up-regulated 1,01E-03 PMID:12912960 PMID:11034307 PMID:14732480 
ANK2 ANK2 79 7 2 DD 
   
7 2 Down-regulated 1,01E-03 PMID:19753302 PMID:15920167 
 
COL11A1 COL11A1 79 7 2 UU 
   
7 2 Up-regulated 1,01E-03 PMID:14732480 PMID:15920167 
 
PGK1 PGK1 79 7 2 UU 
   
7 2 Up-regulated 1,01E-03 PMID:12912960 PMID:15920167 
 
TNPO2 TNPO2 79 7 2 UU 
   
7 2 Up-regulated 1,01E-03 PMID:12912960 PMID:11034307 
 
CCNH CCNH 84 8 2 U U U U 8 2 Up-regulated 1,33E-03 PMID:15136399 PMID:11034307 
 
KRT18 KRT18 84 8 2 UU 
   
8 2 Up-regulated 1,33E-03 PMID:12912960 PMID:15920167 
 
KRT5 KRT5 84 8 2 UU 
   
8 2 Up-regulated 1,33E-03 PMID:12912960 PMID:15920167 
 
SOD1 SOD1 84 8 2 UU 
   
8 2 Up-regulated 1,33E-03 PMID:12912960 PMID:11034307 
 
CLDN15 CLDN15 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
BLMH BLMH 88 2 2 UU 
   
1 1 Up-regulated 7,05E-03 PMID:11034307 PMID:14732480 
 
ITGBL1 ITGBL1 88 2 2 UU 
   
1 1 Up-regulated 7,05E-03 PMID:11034307 PMID:14732480 
 
C21orf7 c21ORF7 88 1 1 
 
D D D 1 1 Down-regulated 7,05E-03 PMID:15136399 
  
CCNF CCNF 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:12912960 
  
DSC3 DSC3 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:11251971 
  
TNC HXB 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:11251971 
  
OSTF1 OSTF1 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:12912960 
  
PDGFRA PDGFRA 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:11251971 
  
RNASEL RNASEL 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:11034307 
  
ST8SIA5 ST8SIA5 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:12912960 
  
DAP DAP 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:12912960 
  
TMSB4X AA634103 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:12912960 
  
ACOX1 ACOX1 88 1 1 
 
U U U 1 1 Up-regulated 7,05E-03 PMID:15136399 
  
 84 
 
MLLT10 AF10 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:14732480 
  
ARMCX2 ALEX2 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:14732480 
  
PRDX3 AOP1 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:14732480 
  
FAS APO-1 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:12912960 
  
ARPC1B ARC41 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:12912960 
  
RHOB ARHB 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:14732480 
  
ASPA ASPA 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:14732480 
  
CDH19 CDH19 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:14732480 
  
CNTN1 CNTN1 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:14732480 
  
COL4A1 COL4A1 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:14732480 
  
ERBB4 ERBB4 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:11251971 
  
ACSL6 FACL6 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:14732480 
  
FGF3 FGF3 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:11251971 
  
STAT3 FLJ20882 88 1 1 
 
U U 
 
1 1 Up-regulated 7,05E-03 PMID:15136399 
  
HLA-DRB3 HLA-DRB3 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:14732480 
  
HSPH1 HSP105B 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:14732480 
  
AUTS2 KIAA0442 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:14732480 
  
L1CAM L1CAM 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:11251971 
  
LAPTM5 LAPTM5 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:14732480 
  
LBP LBP 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:14732480 
  
PDF LOC64146 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:14732480 
  
NFKBIZ MAIL 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:14732480 
  
METAP1 METAP1 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:14732480 
  
NTF3 NgF2 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:11251971 
  
SERPINB2 PAI-2 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:11034307 
  
PDGFRB PDGFRB 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:11251971 
  
PGRMC1 PGRMC1 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:14732480 
  
PSMD3 PSMD3 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:14732480 
  
RHO RHO 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:12912960 
  
FIG4 SAC3 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:14732480 
  
SFRP2 SARP1 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:11251971 
  
NPTN SDFR1 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:14732480 
  
SPI1 SPI1 88 1 1 
 
U U 
 
1 1 Up-regulated 7,05E-03 PMID:15136399 
  
TOP2B TOP2B 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:14732480 
  
ZNF630 ZNF630 88 1 1 
  
U U 1 1 Up-regulated 7,05E-03 PMID:15136399 
  
MACF1 ACF7 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
ADAMTS1 ADAMTS1 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
PLIN2 ADFP 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
ALDH1B1 ALDH1B1 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
ALOX5AP ALOX5AP 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
C10orf116 APM2 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
ATP1A2 ATP1A2 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
ATP6V0E1 ATP6H 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
MALL BENE 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
CD93 C1QR1 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
C5AR1 C5R1 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
CDC5L CDC5L 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
CD52 CDW52 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
CEACAM6 CEACAM6 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
CH25H CH25H 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
CTSS CTSS 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
CD55 DAF 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
C10orf10 DEPP 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
SYNM DMN 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
RCAN1 DSCR1 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
F3 F3 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
FBLN1 FBLN1 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
ZC3HAV1 FLB6421 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
LPCAT1 FLJ12443 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
TCTN2 FLJ12975 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
C1orf115 FLJ14146 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
C1orf56 FLJ20519 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
CIDEC FLJ20871 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
C14orf139 FLJ21276 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
PHF17 FLJ22479 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
C4orf31 FLJ23191 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
GEM GEM 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
GTPBP3 GTPBG3 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
HLA-DRB4 HLA-DRB4 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
IRF8 ICSBP1 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
IGL@ IGL@ 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
IGLJ3 IGLJ3 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
LAMP3 LAMP3 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
PLAC8 LOC51316 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
LMO3 LOC55885 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
PNO1 LOC56902 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
ITIH5 MGC10848 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
C17orf91 MGC14376 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
LOH3CR2A NAG-7 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
TSPAN13 NET-6 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
NAMPT PBEF 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
PCOLCE2 PCOLCE2 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
LITAF PIG7 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
PIK3R3 PIK3R3 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
PLIN1 PLIN 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
CAMK2N1 PRO1489 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
RASSF2 RASSF2 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
C13orf15 RGC32 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
S100A8 S100A8 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
S100A9 S100A9 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
CCL15 SCYA15 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
CCL18 SCYA18 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
CXCL14 SCYB14 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
SERPINA3 SERPINA3 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
SFTPB SFTPB 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
SFTPD SFTPD 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
SORBS1 SH3D5 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
HOPX SMAP31 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
SOCS2 STATI2 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
TSPAN8 TM4SF3 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
SCGB1A1 UGB 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
LYVE1 XLKD1 88 1 1 D 
   
1 1 Down-regulated 7,05E-03 PMID:15920167 
  
ADAM10 ADAM10 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
ADNP ADNP 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
C11orf9 C11orf9 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
CPA4 CPA4 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
EID1 CRI1 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
CRIM1 CRIM1 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
MYOF FER1L3 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
ZNF532 FLJ10697 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
MAP4K4 FLJ20373 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
DDIT4 FLJ20500 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
SLC12A8 FLJ23188 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
ZFPM2 FOG2 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
HIST1H4C H4FG 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
C19orf53 HSPC023 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
TRMT112 HSPC152 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
WWC1 KIAA0869 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
MEMO1 LOC51072 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
WBP5 LOC51186 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
TMEM176B LR8 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
LRRC8D LRRC5 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
NDFIP1 MGC10924 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
TMEM106C MGC5576 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
MRPL3 MRPL3 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
NSUN5 NOL1R 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
NSUN5C NOL1R2 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
PABPC3 PABPC3 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
SERBP1 PAI-RBP1 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
PIGCP1 PIGCP1 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
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PNMA2 PNMA2 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
C19orf10 R33729_1 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
SEC61A1 SEC61A1 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
SGPL1 SGPL1 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
PRSS23 SPUVE 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
HSPA13 STCH 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
TNS3 TEM6 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
CNPY2 TMEM4 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
UBL5 UBL5 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
FBXO11 VIT1 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:15920167 
  
DTL DTL 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:19753302 
  
NDC80 NDC80 88 1 1 U 
   
1 1 Up-regulated 7,05E-03 PMID:19380173 
  
PTPRF PTPRF 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
UPK1B UPK1B 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
THBS2 THBS2 244 3 2 UU 
   
2 1 Up-regulated 1,40E-02 PMID:11034307 PMID:14732480 
 
CTSH CTSH 244 2 1 D 
   
2 1 Down-regulated 1,40E-02 PMID:11034307 
  
GDF10 GDF10 244 2 1 D 
   
2 1 Down-regulated 1,40E-02 PMID:12912960 
  
HTRA1 HTRA1 244 2 1 D 
   
2 1 Down-regulated 1,40E-02 PMID:11034307 
  
KLF9 BTEB1 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
BYSL BYSL 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
COL4A4 COL4A4 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:12912960 
  
FGL2 FGL2 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
FMOD FMOD 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
HLA-DOB HLA-DOB 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
HLA-DPB1 HLA-DPB1 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
HLA-DRB1 HLA-DRB1 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
HNRNPC HNRPC 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
IL4R IL4R 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
PSMD6 KIAA0107 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
TTC9 KIAA0227 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
KIAA0247 KIAA0247 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
SUSD5 KIAA0527 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
KIAA0528 KIAA0528 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
COBLL1 COBLL1 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
LRRC1 LRRC1 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
MAP1B MAP1B 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
UPK3B UPK3B 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
MTMR6 MTMR6 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
IL32 NK4 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
OR7E12P OR7E12P 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
RARS RARS 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:11034307 
  
RND3 RND3 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:11034307 
  
RSC1A1 RSC1A1 244 2 1 
  
U 
 
2 1 Up-regulated 1,40E-02 PMID:15136399 
  
SPRR2A SPRR2A 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
TAF15 TAF2N 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
VAMP8 VAMP8 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
ZNF277 ZNF277 244 2 1 
 
U U U 2 1 Up-regulated 1,40E-02 PMID:15136399 
  
GCLC GCLC 244 3 2 UU 
   
2 1 Up-regulated 1,40E-02 PMID:11034307 PMID:14732480 
 
ABCA8 ABCA8 244 2 1 D 
   
2 1 Down-regulated 1,40E-02 PMID:15920167 
  
AREG AREG 244 2 1 D 
   
2 1 Down-regulated 1,40E-02 PMID:15920167 
  
CD83 CD83 244 2 1 D 
   
2 1 Down-regulated 1,40E-02 PMID:15920167 
  
CPA3 CPA3 244 2 1 D 
   
2 1 Down-regulated 1,40E-02 PMID:15920167 
  
EMP2 EMP2 244 2 1 D 
   
2 1 Down-regulated 1,40E-02 PMID:15920167 
  
STOM EPB72 244 2 1 D 
   
2 1 Down-regulated 1,40E-02 PMID:15920167 
  
INPP5A INPP5A 244 2 1 D 
   
2 1 Down-regulated 1,40E-02 PMID:15920167 
  
KDR KDR 244 2 1 D 
   
2 1 Down-regulated 1,40E-02 PMID:11251971 
  
LHFP LHFP 244 2 1 D 
   
2 1 Down-regulated 1,40E-02 PMID:15920167 
  
MAN1A1 MAN1A1 244 2 1 D 
   
2 1 Down-regulated 1,40E-02 PMID:15920167 
  
MEF2C MEF2C 244 2 1 D 
   
2 1 Down-regulated 1,40E-02 PMID:15920167 
  
MEFV MEFV 244 2 1 D 
   
2 1 Down-regulated 1,40E-02 PMID:15920167 
  
OPHN1 OPHN1 244 2 1 D 
   
2 1 Down-regulated 1,40E-02 PMID:15920167 
  
PBK PBK 244 2 1 
 
D D D 2 1 Down-regulated 1,40E-02 PMID:15136399 
  
SELE SELE 244 2 1 D 
   
2 1 Down-regulated 1,40E-02 PMID:15920167 
  
TACSTD2 TACSTD2 244 2 1 D 
   
2 1 Down-regulated 1,40E-02 PMID:15920167 
  
UNG UNG 244 2 1 D 
   
2 1 Down-regulated 1,40E-02 PMID:12912960 
  
ABCE1 ABCE1 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:11034307 
  
AP3S1 AP3S1 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
ARHGAP4 ARHGAP4 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:11251971 
  
BET1 BET1 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
FAM120A C9orf10 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
COL4A5 COL4A5 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
COL5A2 COL5A2 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
KLF6 COPEB 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
CTSK CTSK 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
DCTD DCTD 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
EIF3C EIF3S8 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
PDIA4 ERP70 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
FCGR3A FCGR3A 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
FMR1 FMR1 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
GFPT2 GFPT2 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
HIST1H2BG H2BFA 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
HIST1H2BD H2BFB 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
HLA-DOA HLA-DOA 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
HLA-DPA1 HLA-DPA1 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
HSP90B1 HSP90B1 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:12912960 
  
HSPA6 HSPA6 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
IL18 IL18 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
KARS KARS 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:11034307 
  
PDZD2 KIAA0300 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
LAPTM4B LC27 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
PDLIM5 LIM 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
LUC7L3 LUC7A 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
CAPRIN1 M11S1 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
MDH2 MDH 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:12912960 
  
NEO1 NEO1 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
HYOU1 ORP150 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
C5orf13 P311 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
POLR3C POLR3C 244 2 1 
  
U 
 
2 1 Up-regulated 1,40E-02 PMID:15136399 
  
PROCR PROCR 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
PTS PTS 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
IPO7 RANBP7 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
RARRES1 RARRES1 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
RBP1 RBP1 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
RPS5 RPS5 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
SLPI SLPI 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:14732480 
  
SOX15 SOX15 244 2 1 
 
U U U 2 1 Up-regulated 1,40E-02 PMID:15136399 
  
SPOCK2 SPOCK2 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:12912960 
  
SFRS2B SRP46 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
ABI1 SSH3BP1 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
EZR VIL2 244 2 1 U 
   
2 1 Up-regulated 1,40E-02 PMID:15920167 
  
DNA2 DNA2L 244 3 2 UU 
   
2 1 Up-regulated 1,40E-02 PMID:19380173 PMID:19662092 
 
ESPL1 ESPL1 244 3 2 UU 
   
2 1 Up-regulated 1,40E-02 PMID:19380173 PMID:19662092 
 
GINS1 GINS1 244 3 2 UU 
   
2 1 Up-regulated 1,40E-02 PMID:19380173 PMID:19662092 
 
RNASEH2A RNASEH2A 244 3 2 UU 
   
2 1 Up-regulated 1,40E-02 PMID:19380173 PMID:19662092 
 
TIMELESS TIMELESS 244 3 2 UU 
   
2 1 Up-regulated 1,40E-02 PMID:19380173 PMID:19662092 
 
POLR2J POLR2J 244 2 1 D 
   
2 1 Down-regulated 1,40E-02 PMID:12912960 
  
KRT15 KRT15 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:14732480 
  
NSUN2 NSUN2 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 
  
FEN1 FEN1 348 4 2 UU 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 PMID:19662092 
 
COL11A2 COL11A2 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:12912960 
  
COL16A1 COL16A1 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:14732480 
  
CSF1R CSF1R 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:14732480 
  
IFI35 IFI35 348 3 1 
 
U U 
 
3 1 Up-regulated 2,08E-02 PMID:15136399 
  
ITGA1 ITGA1 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:14732480 
  
ITGA3 ITGA3 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:11034307 
  
PLLP PLLP 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:15920167 
  
PRKY PRKY 348 3 1 
  
U U 3 1 Up-regulated 2,08E-02 PMID:15136399 
  
COPS2 TRIP15 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:15920167 
  
ORC6L ORC6L 348 4 2 UU 
   
3 1 Up-regulated 2,08E-02 PMID:19662092 PMID:19380173 
 
NUSAP1 NUSAP1 348 4 2 UU 
   
3 1 Up-regulated 2,08E-02 PMID:19662092 PMID:19380173 
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GADD45A GADD45A 348 4 2 UU 
   
3 1 Up-regulated 2,08E-02 PMID:11034307 PMID:14732480 
 
RPS6KA5 RPS6KA5 348 3 1 D 
   
3 1 Down-regulated 2,08E-02 PMID:19753302 
  
S1PR1 S1PR1 348 3 1 D 
   
3 1 Down-regulated 2,08E-02 PMID:19753302 
  
CSF2RB CSF2RB 348 3 1 D 
   
3 1 Down-regulated 2,08E-02 PMID:19662092 
  
EMP1 EMP1 348 3 1 D 
   
3 1 Down-regulated 2,08E-02 PMID:15920167 
  
GSTM1 GSTM1 348 3 1 D 
   
3 1 Down-regulated 2,08E-02 PMID:19662092 
  
HOXA5 HOXA5 348 3 1 D 
   
3 1 Down-regulated 2,08E-02 PMID:19753302 
  
GPD1L KIAA0089 348 3 1 D 
   
3 1 Down-regulated 2,08E-02 PMID:15920167 
  
RP11-159J2.1 KIAA0603 348 3 1 D 
   
3 1 Down-regulated 2,08E-02 PMID:15920167 
  
GPR116 KIAA0758 348 3 1 D 
   
3 1 Down-regulated 2,08E-02 PMID:15920167 
  
LDLR LDLR 348 3 1 D 
   
3 1 Down-regulated 2,08E-02 PMID:15920167 
  
MGST2 MGST2 348 3 1 D 
   
3 1 Down-regulated 2,08E-02 PMID:15920167 
  
MNDA MNDA 348 3 1 D 
   
3 1 Down-regulated 2,08E-02 PMID:15920167 
  
NFIL3 NFIL3 348 3 1 D 
   
3 1 Down-regulated 2,08E-02 PMID:15920167 
  
PGAP3 PER1 348 3 1 D 
   
3 1 Down-regulated 2,08E-02 PMID:19662092 
  
PER3 PER3 348 3 1 D 
   
3 1 Down-regulated 2,08E-02 PMID:19662092 
  
PGC PGC 348 3 1 D 
   
3 1 Down-regulated 2,08E-02 PMID:15920167 
  
PGRMC2 PGRMC2 348 3 1 D 
   
3 1 Down-regulated 2,08E-02 PMID:19662092 
  
PRKAR2B PRKAR2B 348 3 1 D 
   
3 1 Down-regulated 2,08E-02 PMID:15920167 
  
RNASE4 RNASE4 348 3 1 D 
   
3 1 Down-regulated 2,08E-02 PMID:15920167 
  
SPN SPN 348 3 1 D 
   
3 1 Down-regulated 2,08E-02 PMID:15920167 
  
SYNPO2 SYNPO2 348 3 1 D 
   
3 1 Down-regulated 2,08E-02 PMID:19753302 
  
THBD THBD 348 3 1 D 
   
3 1 Down-regulated 2,08E-02 PMID:15920167 
  
AATF AATF 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 
  
ACTR3 ACTR3 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:15920167 
  
AGGF1 AGGF1 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19662092 
  
BCCIP BCCIP 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 
  
CD53 CD53 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:14732480 
  
CHD1 CHD1 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:14732480 
  
CKAP2 CKAP2 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19753302 
  
COL5A1 COL5A1 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:15920167 
  
CTSL1 CTSL 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:12912960 
  
DLGAP5 DLG7 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19753302 
  
DYNC1H1 DYNC1H1 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 
  
E2F7 E2F7 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19662092 
  
EME1 EME1 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 
  
F10 F10 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:14732480 
  
FAAH FAAH 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:14732480 
  
FANCD2 FANCD2 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 
  
FANCF FANCF 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 
  
FICD FICD 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 
  
GFPT1 GFPT1 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:15920167 
  
FAM3C GS3786 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:15920167 
  
HIST2H2AA3 H2AFO 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:15920167 
  
HLA-DMB HLA-DMB 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:14732480 
  
HMGB2 HMG2 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:15920167 
  
INHBE INHBE 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19662092 
  
CLINT1 KIAA0171 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:15920167 
  
SR140 KIAA0332 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:15920167 
  
TBC1D9 KIAA0882 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:15920167 
  
KIF18A KIF18A 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 
  
LAMA5 LAMA5 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19753302 
  
MARCKS MACS 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:15920167 
  
NCAPD3 NCAPD3 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19662092 
  
NRCAM NRCAM 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:14732480 
  
NSMCE1 NSMCE1 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 
  
P4HB P4HB 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:15920167 
  
PPL PPL 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:15920167 
  
RAB2A RAB2 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:15920167 
  
RAD18 RAD18 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 
  
RAD54L RAD54L 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 
  
RCC2 RCC2 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19662092 
  
TMED2 RNP24 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:15920167 
  
SEMA3C SEMA3C 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:15920167 
  
SHFM1 SHFM1 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 
  
SOX4 SOX4 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19753302 
  
STK36 STK36 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19753302 
  
TCF19 TCF19 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 
  
TAX1BP3 TIP-1 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:15920167 
  
TRNT1 TRNT1 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 
  
UHRF1 UHRF1 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 
  
VTN VTN 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:15920167 
  
XPO5 XPO5 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 
  
CDC23 CDC23 348 4 2 UU 
   
3 1 Up-regulated 2,08E-02 PMID:19662092 PMID:19380173 
 
RFC4 RFC4 348 4 2 UU 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 PMID:19662092 
 
RFC5 RFC5 348 4 2 UU 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 PMID:19662092 
 
CLASP1 CLASP1 348 4 2 UU 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 PMID:19662092 
 
GINS2 GINS2 348 4 2 UU 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 PMID:19662092 
 
GLI2 GLI2 348 4 2 UU 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 PMID:19662092 
 
GMNN GMNN 348 4 2 UU 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 PMID:19662092 
 
KIF2C KIF2C 348 4 2 UU 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 PMID:19662092 
 
MCM3 MCM3 348 4 2 UU 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 PMID:19662092 
 
MCM4 MCM4 348 4 2 UU 
   
3 1 Up-regulated 2,08E-02 PMID:19662092 PMID:19380173 
 
MCM6 MCM6 348 4 2 UU 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 PMID:19662092 
 
NUDC NUDC 348 4 2 UU 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 PMID:19662092 
 
PRIM2 PRIM2 348 4 2 UU 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 PMID:19662092 
 
RBM14 RBM14 348 4 2 UU 
   
3 1 Up-regulated 2,08E-02 PMID:19380173 PMID:19662092 
 
HDGF HDGF 348 3 1 U 
   
3 1 Up-regulated 2,08E-02 PMID:15920167 
  
TACC2 TACC2 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
KIAA1199 KIAA1199 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
LGALS8 LGALS8 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
ITGA2 ITGA2 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:12912960 
  
PLP2 PLP2 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
PPAPDC1B PPAPDC1B 450 3 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19380173 
  
MARS MARS 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19380173 
  
UBE2C UBE2C 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19753302 
  
BUB1B BUB1B 450 5 2 UU 
   
4 1 Up-regulated 2,76E-02 PMID:19380173 PMID:19662092 
 
GBA2 GBA2 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:12912960 
  
HLF HLF 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:19662092 
  
TXNL4A TXNL4A 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 
   
CDC27 CDC27 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:14732480 
  
FSTL3 FSTL3 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19753302 
  
KIF4A KIF4A 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19753302 
  
KRT14 KRT14 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:14732480 
  
KRT7 KRT7 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:12912960 
  
LAMC2 LAMC2 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19753302 
  
MMP14 MMP14 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19753302 
  
RPSA RPSA 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:12912960 
  
TIA1 TIA1 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
TPBG TPBG 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
TRAF4 TRAF4 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19753302 
  
UBE2V2 UBE2V2 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19380173 
  
ADH1B ADH1B 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
AGTR1 AGTR1 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:19753302 
  
ALDH1A1 ALDH1A1 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
AQP3 AQP3 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
ARHGEF3 ARHGEF3 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:19753302 
  
ATP5J ATP5J 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:19753302 
  
CCL14 CCL14 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:19753302 
  
CFD CFD  450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
CLEC3B CLEC3B 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
COX7A1 COX7A1 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
CXCL2 CXCL2 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
IL8RB CXCR2 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:19753302 
  
CYP4B1 CYP4B1 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
DARC DARC 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:19753302 
  
FBLN5 FBLN5 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
FTL FTL 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
G0S2 G0S2 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
GADD45B GADD45B 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
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GNG11 GNG11 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
GPC3 GPC3 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
GPX3 GPX3 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
H3F3B H3F3B 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
HBA1 HBA1 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
HBA2 HBA2 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
HEY1 HEY1 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
IDI1 IDI1 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
IGHM IGHM 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
IGKC IGKC 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
IL8 IL8 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
ITM2A ITM2A 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
JAM2 JAM2 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
MAFF MAFF 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
MUC1 MUC1 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
MYH11 MYH11 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
MYL4 MYL4 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
NR1D1 NR1D1 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:19662092 
  
PALMD PALMD 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
PLCL2 PLCL2 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:19753302 
  
PLXDC1 PLXDC1 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:19662092 
  
PPP2R5A PPP2R5A 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
PTGDS PTGDS 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:19753302 
  
RBP4 RBP4 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
RPL27 RPL27 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
RPL27A RPL27A 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
RPLP2 RPLP2 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
SERPINA1 SERPINA1 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
SFTPA2 SFTPA2 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
SFTPC SFTPC 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
SLC19A2 SLC19A2 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
SNX15 SNX15 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
SPARCL1 SPARCL1 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
SPON1 SPON1 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
SRPX SRPX 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
THRB THRB 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:19662092 
  
TNS1 TNS 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
TRA@ TRA@ 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
CEP55 CEP55 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19662092 
  
AASDHPPT AASDHPPT 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
ALDH1A2 ALDH1A2 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
ASPM ASPM 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19753302 
  
ATP1B1 ATP1B1 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
ATP5G2 ATP5G2 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
ATP5J2 ATP5J2 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
BACE2 BACE2 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
BAT3 BAT3 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
BBS4 BBS4 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19380173 
  
C11orf10 C11orf10 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
C4B C4B 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
CBS CBS 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19753302 
  
CBX3 CBX3 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
CCDC99 CCDC99 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19753302 
  
CCNL2 CCNL2 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19753302 
  
CDC123 CDC123 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19380173 
  
CDCA3 CDCA3 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19753302 
  
CIB1 CIB1 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19380173 
  
DYNC1I2 DYNC1I2 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19380173 
  
DYNLRB1 DYNLRB1 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19380173 
  
EZH2 EZH2 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19753302 
  
FUS FUS 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19753302 
  
GALNT7 GALNT7 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
GLS GLS 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
GNAS GNAS1 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
GPI GPI 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
GTPBP4 GTPBP4 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19380173 
  
KIF20A KIF20A 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19753302 
  
LEF1 LEF1 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19753302 
  
MAD2L1 MAD2L1 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19753302 
  
MCTS1 MCTS1 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19380173 
  
MYBL2 MYBL2 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19380173 
  
NIPBL NIPBL 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19753302 
  
NPIP NPIP 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
PCDHGC5 PCDHGC5 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
PSMA7 PSMA7 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19380173 
  
PSMD14 PSMD14 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19380173 
  
RACGAP1 RACGAP1 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19753302 
  
RAD51AP1 RAD51AP1 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19380173 
  
REC8 REC8 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
RPL36 RPL36 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
RUVBL1 RUVBL1 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19662092 
  
SDR16C5 SDR16C5 450 4 1 
 
U U U 4 1 Up-regulated 2,76E-02 PMID:15136399 
  
SERPINH1 SERPINH1 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
SMC2 SMC2 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19662092 
  
SPP1 SPP1 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
SRPK1 SRPK1 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19380173 
  
SULT1A1 SULT1A1 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
TOPBP1 TOPBP1 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
TUBB4 TUBB4 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:15920167 
  
XRCC4 XRCC4 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:19380173 
  
CDC20 CDC20 450 5 2 UU 
   
4 1 Up-regulated 2,76E-02 PMID:19380173 PMID:19662092 
 
MSH6 MSH6 450 5 2 UU 
   
4 1 Up-regulated 2,76E-02 PMID:19380173 PMID:19662092 
 
PHB PHB 450 5 2 UU 
   
4 1 Up-regulated 2,76E-02 PMID:19380173 PMID:19662092 
 
CCT6A CCT6A 450 5 2 UU 
   
4 1 Up-regulated 2,76E-02 PMID:11034307 PMID:14732480 
 
DKK3 DKK3 450 4 1 D 
   
4 1 Down-regulated 2,76E-02 PMID:15920167 
  
ACTA2 ACTA2 450 4 1 U 
   
4 1 Up-regulated 2,76E-02 PMID:12912960 
  
CDC25A CDC25A 450 5 2 UU 
   
4 1 Up-regulated 2,76E-02 PMID:19380173 PMID:19662092 
 
RBBP4 RBBP4 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:12912960 
  
RNASE1 RNASE1 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
RNF10 RNF10 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
SPINT2 SPINT2 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
ANXA11 ANXA11 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:12912960 
  
SLC9A3R1 SLC9A3R1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
DAB2 DAB2 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
DDR1 DDR1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
TRIM29 TRIM29 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
CRYAB CRYAB 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:19753302 
  
NR5A2 NR5A2 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:19662092 
  
SELL SELL 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:19753302 
  
TNF TNF 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:19662092 
  
C3AR1 C3AR1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
COL10A1 COL10A1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
DPYD DPYD 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:11034307 
  
INPPL1 INPPL1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:19753302 
  
KRT4 KRT4 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:11251971 
  
PODXL PODXL 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
TPR TPR 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:19753302 
  
BRCA2 BRCA2 589 6 2 UU 
   
5 1 Up-regulated 3,43E-02 PMID:19380173 PMID:19662092 
 
NR3C2 NR3C2 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:19662092 
  
CDC6 CDC6 589 6 2 UU 
   
5 1 Up-regulated 3,43E-02 PMID:19380173 PMID:19662092 
 
IARS IARS 589 6 2 UU 
   
5 1 Up-regulated 3,43E-02 PMID:11034307 PMID:14732480 
 
ACTG2 ACTG2 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:20043850 
  
AGER AGER 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
AKR1C1 AKR1C1 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
ANG ANG 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:19662092 
  
AP3B2 AP3B2 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:12912960 
  
ARHGDIG ARHGDIG 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:11251971 
  
ATP1B3 ATP1B3 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
BAI3 BAI3 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:12912960 
  
BCL6 BCL6 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
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BTG2 BTG2 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
C7 C7 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
CAT CAT 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
CD24 CD24 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
CES1 CES1 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
CREM CREM 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
CUL3 CUL3 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:12912960 
  
DMBT1 DMBT1 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
DMD DMD 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:19753302 
  
DYRK3 DYRK3 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:12912960 
  
EDNRB EDNRB 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
ELF3 ELF3 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
ENPP2 ENPP2 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
FBLN2 FBLN2 589 5 1 
 
D D D 5 1 Down-regulated 3,43E-02 PMID:15136399 
  
FPR1 FPR1 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
GMFG GMFG 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
HBB HBB 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
HBG2 HBG2 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
HPGD HPGD 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
IL15 IL15 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:19662092 
  
ITGB3 ITGb3 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:11251971 
  
LDB2 LDB2 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
LPL LPL 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
LTBP1 LTBP1 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
MAP2K3 MAP2K3 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
MAT2A MAT2A 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
MITF MITF 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:19753302 
  
NFIB NFIB 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
PARD6A PARD6A 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:12912960 
  
PRSS2 PRSS2 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:12912960 
  
PTGES PTGES 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:11251971 
  
RPL14 RPL14 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
RPS11 RPS11 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
SCD SCD 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:15920167 
  
TGFBR3 TGFBR3 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:19753302 
  
TLE4 TLE4 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:12912960 
  
TNFRSF10C TNFRSF10C 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:12912960 
  
ACTR1A ACTR1A 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:12912960 
  
ANXA7 ANXA7 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:12912960 
  
AP2M1 AP2M1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
APOL1 APOL 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
ARHGDIB ARHGDIB 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:11251971 
  
ATP2A2 ATP2A2 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
ATRX ATRX 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:19753302 
  
BAX BAX 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:19753302 
  
BCOR BCOR 589 5 1 
 
U 
  
5 1 Up-regulated 3,43E-02 PMID:15136399 
  
BGN BGN 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:19753302 
  
BLNK BLNK 589 5 1 
 
U U U 5 1 Up-regulated 3,43E-02 PMID:15136399 
  
BUB3 BUB3 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
CADM1 CADM1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:19380173 
  
CALB2 CALB2 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
CALD1 CALD1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
CCT7 CCT7 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:19380173 
  
CD177 CD177 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:12912960 
  
CD74 CD74 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
CDC25B CDC25B 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:11251971 
  
CDC7 CDC7 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:19380173 
  
CLIC4 CLIC4 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
CLTA CLTA 589 5 1 
  
U 
 
5 1 Up-regulated 3,43E-02 PMID:15136399 
  
COPA COPA 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
DGCR6 DGCR6 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
DTYMK DTYMK 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:19662092 
  
ENO1 ENO1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
FABP5 FABP5 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:11034307 
  
FANCA FANCA 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:19380173 
  
FGF12 FGF12 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:11251971 
  
FHL2 FHL2 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
FZD6 FZD6 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
GTF2H2 GTF2H2 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:19380173 
  
HSPA1A HSPA1A 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
HSPA8 HSPA8 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
IFI16 IFI16 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
IFITM3 IFITM3 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
IGFBP2 IGFBP2 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
IGHG3 IGHG3 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
IL1RAP IL1RAP 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:19662092 
  
ING1 ING1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:11251971 
  
JAG1 JAG1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:11251971 
  
KIFC3 KIFC3 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:19380173 
  
KPNA2 KPNA2 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
KRT19 KRT19 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
LILRB5 LILRB5 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
LMNB1 LMNB1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:19753302 
  
MAP3K14 MAP3K14 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:11251971 
  
MAPK7 MAPK7 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:11251971 
  
MAPK8 MAPK8 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:11251971 
  
MATK MATK 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:19380173 
  
MEIS2 MEIS2 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
MEST MEST 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
MID2 MID2 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:12912960 
  
MRC2 MRC2 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
MRE11A MRE11A 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:11034307 
  
MVP MVP 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:12912960 
  
NAB1 NAB1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
NCBP1 NCBP1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
NDUFB4 NDUFB4 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
NDUFC1 NDUFC1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
NMB NMB 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:12912960 
  
NONO NONO 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
NOP56 NOP56 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
OXCT1 OXCT1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:11034307 
  
PABPC1 PABPC1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
PAIP1 PAIP1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
PAK1 PAK1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:11251971 
  
PAWR PAWR 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
PAX6 PAX6 589 5 1 
 
U U U 5 1 Up-regulated 3,43E-02 PMID:15136399 
  
PDGFC PDGFC 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
PFN2 PFN2 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
PGAP2 PGAP2 589 5 1 
 
U 
  
5 1 Up-regulated 3,43E-02 PMID:15136399 
  
PPP1R12A PPP1R12A 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
PSMA4 PSMA4 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:19380173 
  
PSMB2 PSMB2 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:19380173 
  
PSMC5 PSMC5 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:19380173 
  
PSMD2 PSMD2 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:19380173 
  
PTMA PTMA 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:12912960 
  
PTTG1 PTTG1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:19662092 
  
PTTG1IP PTTG1IP 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:12912960 
  
RAD50 RAD50 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:19380173 
  
RGS16 RGS16 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
RGS5 RGS5 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
RPLP0 RPLP0 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
SAT1 SAT 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
SFRP4 SFRP4 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
SKIL SKIL 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
SLC16A1 SLC16A1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
SLC25A1 SLC25A1 589 5 1 
 
U U 
 
5 1 Up-regulated 3,43E-02 PMID:15136399 
  
SLC25A6 SLC25A6 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
SLC3A2 SLC3A2 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
SPHK1 SPHK1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
SRP72 SRP72 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:11034307 
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ST14 ST14 589 5 1 
 
U U U 5 1 Up-regulated 3,43E-02 PMID:15136399 
  
SYNE1 SYNE1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:12912960 
  
TFG TFG 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
TIMM17A TIMM17A 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:11034307 
  
TNXB TNXB 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:14732480 
  
TSPAN3 TSPAN-3 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
TXNRD1 TXNRD1 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:15920167 
  
VEGFA VEGFA 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:19662092 
  
XRCC5 XRCC5 589 5 1 U 
   
5 1 Up-regulated 3,43E-02 PMID:11251971 
  
ZNHIT1 ZNHIT1 589 5 1 
 
U U 
 
5 1 Up-regulated 3,43E-02 PMID:15136399 
  
RRM1 RRM1 589 6 2 UU 
   
5 1 Up-regulated 3,43E-02 PMID:19380173 PMID:19662092 
 
TYMS TYMS 589 6 2 UU 
   
5 1 Up-regulated 3,43E-02 PMID:19380173 PMID:19662092 
 
ZWINT ZWINT 589 6 2 UU 
   
5 1 Up-regulated 3,43E-02 PMID:19380173 PMID:19662092 
 
FOXO3 FOXO3A 589 5 1 D 
   
5 1 Down-regulated 3,43E-02 PMID:19753302 
  
FOXO1 FOXO1A 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:15920167 
  
MMP15 MMP15 766 6 1 
 
U 
  
6 1 Up-regulated 4,08E-02 PMID:15136399 
  
MTRR MTRR 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
TARS TARS 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:11034307 
  
NTRK2 NTRK2 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:19753302 
  
ARL1 ARL1 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
E2F2 E2F2 766 5 2 UU 
   
6 1 Up-regulated 4,08E-02 PMID:19380173 PMID:19662092 
 
WT1 WT1 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:19753302 
  
TIMP3 TIMP3 766 7 2 UU 
   
6 1 Up-regulated 4,08E-02 PMID:11034307 PMID:14732480 
 
CCND2 CCND2 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:11251971 
  
KRAS KRAS 766 7 2 UU 
   
6 1 Up-regulated 4,08E-02 PMID:11034307 PMID:14732480 
 
THBS1 THBS1 766 7 2 UU 
   
6 1 Up-regulated 4,08E-02 PMID:11034307 PMID:14732480 
 
TPM1 TPM1 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:19753302 
  
ABCB1 ABCB1 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:19662092 
  
APOD APOD 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:15920167 
  
BSG BSG 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:11034307 
  
BTG1 BTG1 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:19753302 
  
CASP1 CASP1 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:15920167 
  
CAV2 CAV2 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:15920167 
  
CD36 CD36 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:15920167 
  
CSRP2 CSRP2 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:15920167 
  
DCN DCN 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:15920167 
  
DLC1 DLC1 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:19662092 
  
DPT DPT 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:15920167 
  
FABP4 FABP4 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:15920167 
  
FDX1 FDX1 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:12912960 
  
HLA-DQA1 HLA-DQA1 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:15920167 
  
ICAM2 ICAM2 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:19753302 
  
IGFBP4 IGFBP4 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:11251971 
  
IL11RA IL11RA 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:19662092 
  
ITGA7 ITGA7 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:19753302 
  
LEPR LEPR 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:15920167 
  
MAOA MAOA 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:15920167 
  
MGP MGP 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:15920167 
  
NR4A3 NR4A3 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:15920167 
  
PDE4B PDE4B 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:19753302 
  
PDE4D PDE4D 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:15920167 
  
PPAP2B PPAP2B 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:15920167 
  
PTGER4 PTGER4 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:15920167 
  
RARA RARA 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:15920167 
  
RARB RARB 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:11251971 
  
RPS20 RPS20 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:15920167 
  
SOD2 SOD2 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:15920167 
  
UQCRFS1 Uqcrfs1 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:12912960 
  
NR3C1 NR3C1 766 6 2 DD 
   
6 2 Down-regulated 4,08E-02 PMID:19753302 PMID:19662092 
 
ACLY ACLY 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:11034307 
  
AHCY AHCY 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
ANXA1 ANXA1 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:11034307 
  
ANXA3 ANXA3 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
APBB2 APBB2 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:19753302 
  
APOE APOE 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
ARNTL ARNTL 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:19662092 
  
C5 C5 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
CA10 CA10 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
CALR CALR 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:12912960 
  
CALU CALU 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
CANX CANX 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
CASP10 CASP10 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:11251971 
  
CD59 CD59 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:11034307 
  
CIT CIT 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:19662092 
  
COL3A1 COL3A1 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:12912960 
  
COL6A2 COL6A2 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:12912960 
  
COMP COMP 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
COPB1 COPB 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
CSRP1 CSRP1 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
CXADR CXADR 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
DDOST DDOST 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
DFNA5 DFNA5 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
DHFR DHFR 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:19753302 
  
DIO2 DIO2 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:11034307 
  
EFEMP1 EFEMP1 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
EIF3A EIF3A 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:12912960 
  
FAP FAP 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
FKBP1A FKBP1A 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
FZD2 FZD2 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:11251971 
  
GTF2B GTF2B 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
GTF3A GTF3A 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
HINT1 HINT 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
IGFBP7 IGFBP7 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
IGSF1 IGSF1 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
IQGAP1 IQGAP1 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
IRAK1 IRAK1 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
KDELR2 KDELR2 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
KIAA0101 KIAA0101 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
KRT17 KRT17 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
LOX LOX 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
MAL MAL 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
MDK MDK 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:19753302 
  
MFAP2 MFAP2 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:12912960 
  
MMP11 MMP11 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:19753302 
  
MYC MYC 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:11034307 
  
MYLK MYLK 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
NPAS2 NPAS2 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:19662092 
  
OGT OGT 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
PLOD2 PLOD2 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
PPIB PPIB 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
PPM1G PPM1G 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
PRKCI PRKCI 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
PSAP PSAP 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
PSMC1 PSMC1 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:19380173 
  
PSMC2 PSMC2 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:19380173 
  
PSMC3 PSMC3 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:19380173 
  
PSMD1 PSMD1 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:19380173 
  
PTGS1 PTGS1 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
RAD23B RAD23B 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
RARRES2 RARRES2 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
RBMS1 RBMS1 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
RGS1 RGS1 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
SDC2 SDC2 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
SERPINF1 SERPINF1 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
SETMAR SETMAR 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:19380173 
  
SNRPD2 SNRPD2 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
SNRPF SNRPF 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
STIP1 STIP1 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:11034307 
  
TM4SF1 TM4SF1 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
TPD52L1 TPD52L1 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
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TPI1 TPI1 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
TRAF2 TRAF2 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:11251971 
  
TXNL1 TXNL1 766 6 1 
 
U U U 6 1 Up-regulated 4,08E-02 PMID:15136399 
  
UCHL1 UCHL1 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
UCP2 UCP2 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
UQCRC2 UQCRC2 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:12912960 
  
VCAM1 VCAM1 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
VLDLR VLDLR 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:15920167 
  
WASL WASL 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:19753302 
  
ZNF177 ZNF177 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
ZNF238 ZNF238 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:14732480 
  
NME1 NME1 766 7 3 UUU 
   
6 2 Up-regulated 4,08E-02 PMID:19380173 PMID:19662092 PMID:11034307 
PRKCA PRKCA 766 7 2 UU 
   
6 1 Up-regulated 4,08E-02 PMID:19380173 PMID:19662092 
 
CCNE2 CCNE2 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:19753302 
  
CDKN1A CDKN1A 766 6 1 D 
   
6 1 Down-regulated 4,08E-02 PMID:19753302 
  
ACTB ACTB 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:12912960 
  
CCNA2 CCNA2 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:19753302 
  
CCND1 CCND1 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:11251971 
  
CCND3 CCND3 766 6 1 U 
   
6 1 Up-regulated 4,08E-02 PMID:11251971 
  
FGF7 FGF7 901 7 1 D 
   
7 1 Down-regulated 4,73E-02 PMID:11251971 
  
TNFSF10 TNFSF10 901 7 1 D 
   
7 1 Down-regulated 4,73E-02 PMID:15920167 
  
EGR1 EGR1 901 7 1 D 
   
7 1 Down-regulated 4,73E-02 PMID:15920167 
  
FN1 FN1 901 7 1 D 
   
7 1 Down-regulated 4,73E-02 PMID:11034307 
  
IL6 IL6 901 7 1 D 
   
7 1 Down-regulated 4,73E-02 PMID:15920167 
  
MCL1 MCL1 901 7 1 D 
   
7 1 Down-regulated 4,73E-02 PMID:15920167 
  
SH3BP5 SH3BP5 901 7 1 D 
   
7 1 Down-regulated 4,73E-02 PMID:15920167 
  
ADSL ADSL 901 7 1 
  
U U 7 1 Up-regulated 4,73E-02 PMID:15136399 
  
AKT1 AKT1 901 7 1 U 
   
7 1 Up-regulated 4,73E-02 PMID:12912960 
  
ALDH6A1 ALDH6A1 901 7 1 U 
   
7 1 Up-regulated 4,73E-02 PMID:12912960 
  
ANXA8 ANXA8 901 7 1 U 
   
7 1 Up-regulated 4,73E-02 PMID:15920167 
  
APP APP 901 7 1 U 
   
7 1 Up-regulated 4,73E-02 PMID:19753302 
  
ARHGDIA ARHGDIA 901 7 1 U 
   
7 1 Up-regulated 4,73E-02 PMID:12912960 
  
DAP3 DAP3 901 7 1 U 
   
7 1 Up-regulated 4,73E-02 PMID:15920167 
  
EFNA1 EFNA1 901 7 1 U 
   
7 1 Up-regulated 4,73E-02 PMID:14732480 
  
EPHB2 EPHB2 901 7 1 U 
   
7 1 Up-regulated 4,73E-02 PMID:19753302 
  
FGFR3 FGFR3 901 7 1 U 
   
7 1 Up-regulated 4,73E-02 PMID:19753302 
  
ITGA6 ITGA6 901 7 1 U 
   
7 1 Up-regulated 4,73E-02 PMID:11034307 
  
KRT8 KRT8 901 7 1 U 
   
7 1 Up-regulated 4,73E-02 PMID:15920167 
  
LAMB1 LAMB1 901 7 1 U 
   
7 1 Up-regulated 4,73E-02 PMID:12912960 
  
LAMC1 LAMC1 901 7 1 U 
   
7 1 Up-regulated 4,73E-02 PMID:11034307 
  
MET MET 901 7 1 U 
   
7 1 Up-regulated 4,73E-02 PMID:15920167 
  
PSME3 PSME3 901 7 1 U 
   
7 1 Up-regulated 4,73E-02 PMID:19380173 
  
SPTAN1 SPTAN1 901 7 1 U 
   
7 1 Up-regulated 4,73E-02 PMID:15920167 
  
TGFBI TGFBI 901 7 1 U 
   
7 1 Up-regulated 4,73E-02 PMID:15920167 
  
VIM VIM 901 7 1 U 
   
7 1 Up-regulated 4,73E-02 PMID:12912960 
  
ATM ATM 901 7 1 U 
   
7 1 Up-regulated 4,73E-02 PMID:14732480 
  
TP53 TP53 901 7 1 U 
   
7 1 Up-regulated 4,73E-02 PMID:12912960 
  
FLT3 FLT3 901 7 1 U 
   
7 1 Up-regulated 4,73E-02 PMID:11251971 
  
HMMR HMMR 930 8 1 U 
   
8 1 Up-regulated 5,37E-02 PMID:19753302 
  
KRT13 KRT13 930 8 1 U 
   
8 1 Up-regulated 5,37E-02 PMID:14732480 
  
                                
  
Genes with 
too little 
evidences 
of de-
regulation 
                            
A2M A2M 
 
7 2 UD 
   
7 2 Contradictory 
 
PMID:14732480 PMID:15920167 
 
AARS AARS 
 
6 2 UD 
   
6 2 Contradictory 
 
PMID:19380173 PMID:12912960 
 
ALCAM ALCAM 
 
1 1 
 
D U U 1 1 
Inc. among 
histotypes  
PMID:15136399 
  
BCL2 BCL2 
 
7 2 UD 
   
7 2 Contradictory 
 
PMID:12912960 PMID:19662092 
 
BLVRB BLVRB 
 
4 1 
 
U U D 4 1 
Inc. among 
histotypes  
PMID:15136399 
  
CALM2 CALM2 
 
7 1 
  
U D 7 1 
Inc. among 
histotypes  
PMID:15136399 
  
CD9 CD9 
 
7 1 
 
U 
 
D 7 1 
Inc. among 
histotypes  
PMID:15136399 
  
CXCL12 CXCL12 
 
4 2 UD 
   
4 2 Contradictory 
 
PMID:14732480 PMID:15920167 
 
CYTH4 CYT4 
 
1 1 
 
U 
 
D 1 1 
Inc. among 
histotypes  
PMID:15136399 
  
FCGR3B FCGR3B 
 
5 2 UD 
   
5 2 Contradictory 
 
PMID:14732480 PMID:15920167 
 
THNSL1 FLJ22002 
 
1 1 
 
U U D 1 1 
Inc. among 
histotypes  
PMID:15136399 
  
FOS FOS 
 
7 2 UD 
   
7 2 Contradictory 
 
PMID:14732480 PMID:19662092 
 
GABRB1 GABRB1 
 
3 1 
 
U U D 3 1 
Inc. among 
histotypes  
PMID:15136399 
  
GSN GSN 
 
7 3 UDD 
   
7 3 Contradictory 
 
PMID:14732480 PMID:19662092 PMID:15920167 
HLA-DRA HLA-DRA 
 
2 2 UD 
   
2 2 Contradictory 
 
PMID:14732480 PMID:15920167 
 
ICAM1 ICAM1 
 
6 2 UD 
   
6 2 Contradictory 
 
PMID:14732480 PMID:15920167 
 
ID2 ID2 
 
6 3 UUD 
   
6 3 Contradictory 
 
PMID:19753302 PMID:14732480 PMID:15920167 
IFNAR2 IFNAR2 
 
5 1 
 
U 
 
D 5 1 
Inc. among 
histotypes  
PMID:15136399 
  
IGFBP5 IGFBP5 
 
8 2 U D D D 8 2 
Inc. among 
histotypes  
PMID:15136399 PMID:14732480 
 
LAMA4 LAMA4 
 
6 2 UD 
   
6 2 Contradictory 
 
PMID:19753302 PMID:11034307 
 
LY6E LY6E 
 
3 1 
 
U D D 3 1 
Inc. among 
histotypes  
PMID:15136399 
  
MCAM MCAM 
 
4 1 UD 
   
4 1 Contradictory 
 
PMID:15920167 
  
MIF MIF 
 
3 2 UD 
   
3 2 Contradictory 
 
PMID:11034307 PMID:15920167 
 
MRC1 MRC1 
 
3 2 UD 
   
3 2 Contradictory 
 
PMID:14732480 PMID:15920167 
 
NR1D2 NR1D2 
 
6 2 D 
 
U U 6 2 
Inc. among 
histotypes  
PMID:15136399 PMID:19662092 
 
NR4A1 NR4A1 
 
6 3 UDD 
   
6 3 Contradictory 
 
PMID:14732480 PMID:15920167 PMID:19662092 
CXXC1 PCCX1 
 
1 1 
 
U 
 
D 1 1 
Inc. among 
histotypes  
PMID:15136399 
  
PDZK1 PDZK1 
 
4 1 
 
U U D 4 1 
Inc. among 
histotypes  
PMID:15136399 
  
RB1 RB1 
 
7 3 UUD 
   
6 2 Contradictory 
 
PMID:19380173 PMID:12912960 PMID:19662092 
RGS2 RGS2 
 
5 2 UD 
   
5 2 Contradictory 
 
PMID:14732480 PMID:15920167 
 
S100A4 S100A4 
 
5 2 UD 
   
5 2 Contradictory 
 
PMID:14732480 PMID:15920167 
 
SEPP1 SEPP1 
 
6 2 UD 
   
6 2 Contradictory 
 
PMID:14732480 PMID:15920167 
 
SHC1 SHC1 
 
5 1 
  
U D 5 1 
Inc. among 
histotypes  
PMID:15136399 
  
SRGN SRGN 
 
1 1 
 
D U 
 
1 1 
Inc. among 
histotypes  
PMID:15136399 
  
TBL1X TBL1X 
 
5 1 
 
D U D 5 1 
Inc. among 
histotypes  
PMID:15136399 
  
TGFB3 TGFB3 
 
3 2 UD 
   
3 2 Contradictory 
 
PMID:11251971 PMID:14732480 
 
TSPAN15 TSPAN15 
 
2 1 
 
U D D 2 1 
Inc. among 
histotypes  
PMID:15136399 
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